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Epithelial ovarian carcinoma is a common and important cancer.
Biopsy and ascites samples can be successfully grown in the
laboratory enabling this cancer to be studied experimentally.
One major problem in this disease is that, while it is a
chemosensitive tumour, resistance to current regimens of
chemotherapy is a common development. In this project I have
established a model system for studying this problem.
Thirty ascites samples and 1 tumour biopsy have been collected
and 9 cell lines derived from them. Two cell lines PE/01 and
PE/04 derived from ascites from a patient before and after she
developed resistance to a regimen of cisplatinum, chlorambucil
and 5-fluorouraci1 have been extensively characterised for
cytology, karyotype, antigenicity, and growth characteristics in
vitro. PE/04 proved to be 3-fold more resistant to cisplatinum
in clonogenic assays but showed little change in sensitivity to
chlorambucil and 5-fluorouraci1 . The results suggest a
heterogeneous tumour in vivo with PE/04 cells not being derived
from PE/01 cells but rather co-existing with them and being then
selected by the chemotherapy. A third cell line from a later
ascites from the same patient was also derived together with
sub-lines of PE/01 and PE/04 with acquired resistance to
cisplatinum in vitro. Cross-resistance to other drugs including
platinum analogues of clinical interest and classical alkylating
agents has also been assessed. Little cross-resistance to
iproplatin (CHIP) and carboplatin (CBDCA) was observed or to
unrelated drugs like doxorubicin and vincristine. However
resistance to malonato-platinum (JM40) and the modified
alkylating agent prednimustine was seen.
Since cisplatinum is the major drug in present chemotherapy of
ovarian cancer I investigated mechanisms of resistance to this
drug in the above model and looked at a number of aspects known
to be significant in resistance to anti-neoplastic drugs. These
experiments suggest that:-
1) transport processes are not important in cisplatinum
resistance
2) glutathione metabolism plays only a minor role, if at all,
in the resistance.
3) the extent of certain types of cisplatinum induced DNA
damage is important since the number of DNA interstrand
crosslinks was correlated with drug sensitivity. Either
reduced DNA damage or increased DNA repair may be the
significant factors.
PGS/ABST/83 Use this side only
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1. Introduction
Ovarian adenocarcinoma is a very important tumour in women
and shows itself sensitive to chemotherapy. However,
development of resistance has become the major stumbling
block in its clinical management. We therefore set out to
develop a model to address this problem using human tumour
and ascites samples from patients from the Department of
Clinical Oncology practice in Edinburgh. The phenomenum
of drug resistance has attracted considerable attention
and much work has been dene by other groups during the
period of this project. Here in the introduction I shall
discuss literature up until the end of 1983 , when this
project was begun, as background, and consider
developments since then in the relevant chapters and in
the general discussion in chapter 7.
1.1 Ovarian Cancer - Present Treatment
Ovarian cancer is the 4th leading cause of cancer deaths
in women and the most important and lethal of the
gynaecological tumours. Incidence was 16.2/100,000 in
Scotland in 1976-1980 with mortality at 13.1/100,000. The
total 5 year relative survival rate was 28% and 1 year
rate only 49% (Cancer Registration Statistics, Scotland
1971-80). The incidence is highest in postmenopausal
women. The vast majority of ovarian tumours (85-90%) are
of epithelial histological type with only a minority,
primarily in younger women, being sex cord-stromal or
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germ-cell tumours (R.C. Young et al, 1982). A number of
different histological types have been identified (R.E.
Scully, 1977) with serous adenocarcinomas being the most
common type followed by undifferentiated carcinomas,
endometrial carcinomas, mucinous adenocarcinomas and clear
cell tumours (R.C. Young et al, 1982). All appear to be
derived from the same multipotentia1 coelomic epithelium.
However, histological type appears not to be an important
prognostic factor independent of other factors (R.C. Young
et al, 1982). In addition the ovary can be a ccmmcn site
of metastasis from other organs with the most common
primary site being the gastrointestinal tract (R.T. Parker
et al, 1981). The co-existence of ovarian and uterine
adenocarcinoma is also not infrequent with endometroid
ovarian carcinoma being associated with endometrium
carcinoma in one-third of cases (R.E. Scully, 1970).
Early diagnosis of ovarian cancer continues to be a
problem. The search for a suitable marker to allow
earlier diagnosis and monitoring of the course of the
disease is an active area of research (R.C. Bast et al,
1983). The most frequent presenting symptoms are
abdominal pain and extension which are usually indicative
of advanced disease (P.J. Di Saia and W.T. Creasman,
1981)-. The International Federation of Gynecology and
Obstetrics has set up a staging classification (O.H. Bears
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et al, 1978) with 4 stages which correspond to ovarian
(I), pelvic (II), peritoneal or coelomic (III), and
metastasizing disease (IV). Stage III and IV represent
the majority of patients and the ones with poorest
prognosis (J.S. Tobias and C.T. Griffiths, 1976). The
other important prognostic variables are histologic grade,
i.e. degree of differentiation (R.F. Ozols et al, 1980),
and extent of residual disease after surgery (C.T.
Griffiths , 1975 ).
Undoubtedly the cornerstone of therapy is surgery (P.E.
Schwartz, 1981) and the initial operation determines the
future management of the patient. Accurate staging can
only be achieved at this time by abdominal exploration and
histopathology. Ideally total hysterectomy, bilateral
salpingo-oophorectomy and omentectomy are required and
cytoreductive surgery to remove as much tumour as possible
is important in advanced disease (C.T. Griffiths et al,
1979). In patients with Stage la disease with well
differentiated malignancies surgery alone is sufficient
for cure (A.J. Dembo et al, 1979a) and it is presumably
sufficient in a further subset of patients with long-term
survival from surgery alone (C.M. Bagley et al, 1972).
However, further therapy is usually necessary with
chemotherapy generally being preferred to radiotherapy
(M.E. Katz et al, 1981 ) .
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The success of additional therapy after initial surgery
depends on the existence of residual disease with improved
survival in patients with residual tumour nodules of 1-
2cms diameter or less regardless of whether chemotherapy
(J.T. Wharton et al , 1980) or radiotherapy (A.J. Dembo et
al, 1979b) is used. Unfortunately out of approximately
60% of women who present with advanced disease at
diagnosis some 75% have such extensive disease that
extensive residual disease is left after surgery (R.C.
Young et al, 1982). In this group radiotherapy has been
less successful and this has led to its diminished use in
ovarian cancer.
Chemotherapy
For more than 20 years chemotherapy has relied on the
alkylating agents, particularly melphalan, as single
agents and their widespread use produced response rates of
35-65% in advanced disease (R.C. Young et al, 1974).
However, these responses were limited with median survival
of 17-20 months in those responding to chemotherapy versus
6-13 months in non-responders. A number of alkylating
agents (melphalan, chlorambucil, cyclophosphamide and
thiotepa) show similar activity. Since these response
rates were relatively high there have been few trials with
other single agents but amongst the most active other
drugs are hexamethylmelamine, doxorubicin, 5-f luorouracil ,
and cisplatinum. Cisplatinum has become the major drug in
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combination regimens (see below) and its activity in
combination with chlorambucil was soon clearly seen as
better than chlorambucil alone (G.H. Barker, et al,
1981a). Results with single agents are summarised in
Table I indicating overall response rates in some studies.
Various doses and schedules have been used by different
workers. Various combinations have also new been
reported. The first study, to show improved response rate
and improved survival over that of an alkylating agent
alone (melphalan) in a randomised controlled trial, was
that of Young and his colleagues (R.C. Young et al, 1978)
using the HexaCAF combination (hexamethylme1 amine ,
cyclophosphamide, methotrexate and 5-fluorouracil ) . This
achieved a 75% response rate versus 54% for melphalan and
gave an increased medium survival of 29 months versus 17
months. This study alsc illustrated the need to stratify
for important prognostic factors to convincingly
demonstrate improvements with combination chemotherapy.
The improvements with this regimen could not be confirmed
by two other groups (J. Carmo-Fereira et al, 1981; J.F.G.
Sturgeon et al, 1980) but were seen by a third group (J.P.
Neijt et al, 1980) although with a lower response rate.
However, further testing of this and other combinations
was rapidly overtaken by interest in combinations
including cisplatinum. The NCI group went on to study the
CHex-UP (cyclophosphamide, hexamethy Imelamine, 5-
TABLE 1
SINGLE AGENTS ACTIVE IN ADVANCED OVARIAN CANCER
No. of Response
Drug Patients rate (%) Reference
Alkylating agents
Melphalan 541 47 J.S. Tobias and
Chlorambuci1 388 51 C.T. Griffiths,
Thiotepa 337 48 1976
Cyclophosphamide 335 43
Cyclophosphamide
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fluorouracil and cisplatinum) regimen (R.C. Young et al ,
1979). Other similar multiple drug combinations (e.g.
CHAP - cyclophosphamide, hexamethylmelamine, doxorubicin
and cisplatinum and PAC - cisplatinum, doxorubicin and
cyclophosphamide) have been tried by others. The results
of various combinations are summarised in Table II.
Responses to cisplatinum containing combination
chemotherapy can be seen to be significantly higher than
responses to conventional alkylating agent therapy.
Variations between studies are often due to different
proportions of patient groups with patients with minimal
residual disease having a much better chance of achieving
a complete response. Various doses and schedules of drugs
have been employed. Although response rates have
improved, this has had a relatively minor effect on median
survival times. In some studies the difference in
survival has been minimised by cross-over from the
alkylating agent arm to the combination regimen upon
progression. Complete responses are only a proportion of
the total number of responses and more recently
pathologically proven complete response rates, as seen by
second look laparotomy are only about half the clinical
complete response rate. Responders to therapy do have
improved survival but it is the pathologically complete
responders who have a good chance of long term survival .
Thus the proportion of long term survivors is still
TABLEII






























































































































































































































































*Hexa-CAF-examethylmelamine,Cyclophosphamide,M thotrexateand5-Flu rouracil CAP,P C-yclophosphamide,Dox rubicinandCis-platinum CHex-UP-Cyclophosphamide,HexamethyImel ine,5-Flu rouracilndCis-platinum CHAD,PHAP-5-Cyclophosphamide,Hexamethylmela n ,DoxorubicinndCis-platinum
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depressingly low even in the face of aggressive
combination chemotherapy with its associated considerable
toxicity. Indeed its use has been questioned particularly
in patients with bulky residual disease (C.J. Williams et
al, 1983) because of its toxicity and minimal effect on
these patients' survival.
Clinical Resistance
As can be seen from the above, many tumours are responsive
to therapy but a subpopulation of cells is either
resistant or rapidly acquires resistance causing the
regrowth of the tumour and the subsequent short survival
times of patients.
Once a patient has relapsed after initial therapy the
response to second line therapy has been poor with
responses generally only of short duration (up to about 6
months) [R.C. Young et al, 1982]. .Most of the drugs in
current use were first shown to be active against ovarian
cancer by demonstrating this limited second line activity
after the failure of initial alkylating agent therapy, and
this subsequently led to their evaluation for initial
regimens as discussed above, but it has had little impact
when initial treatment fails. Cis-platinum is perhaps the
most active second line agent, first reported in 1976 and
showing response rates of around 30% (E. Wiltshaw et al,
1976; H.W. Bruckner et al 1978). Its use has even been
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reported in a third line capacity with some efficacy (M.S.
Piver et al, 1980 ). Hexamethylmelamine has also shown
significant activity as a second line agent with a
response rate of approximately 16% (G.A. Omura et al,
1981). Doxorubicin has less activity in this capacity
(S.M. Hubbard et al, 1978 ). Some of the combination
regimens have also been used with responses of 40-60%
being reported for some cis-platinum containing regimens
as shown in Table III. However, since these regimens
achieve higher initial remission rates than alkylating
agents they have not continued in second line use after
alkylating agent therapy. The present goal of therapy is
the achievement of pathological complete remissions with
the initial modality of treatment and it is these patients
who have a high chance of long term survival (P.E.
Schwartz et al, 1980).
Four potential methods of overcoming clinical drug
resistance are currently being pursued:-
(1) The use of high dose cis-platinum (greater than
lOOmg/m^) is being assessed and a clinically
important dose-response relationship has been
demonstrated with responses in patients previously
treated with lower dose cis-platinum having been
achieved (G.H. Barker et al, 1981b).
(2) Intraperitoneal administration of chemotherapy in an
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reaching the tumour is being used (R.B. Jones et al,
1978). Since even advanced ovarian carcinoma usually
remains confined to the abdominal cavity high local
concentrations of drugs achieved in the peritoneum
without systemic toxicity (J.L. Speyer et al, 1981)
could be very advantageous. This technique has been
tried with doxorubicin (R.F. Ozols et al, 1982), 5-
fluorouracil (J.L. Speyer et al, 1980) and cis-
platinum (R.G. Pretorius et al, 1983). With
intraperitoneal cis-platinum intravenous thiosulphate
has been used to protect against cis-platinum
toxicity and preliminary results indicate responses
are achievable in patients with extensive prior
therapy (S.B. Howell et al, 1983).
(3) In vitro assays to predict to which drug(s) a
particular patient would be responsive have been
attempted (D.S. Alberts et al, 1981). While
reasonable correlations have been achieved with the
clonogenic assay (D.D. Von Hoff et al, 1983) many
problems remain (P. Selby et al, 19 83) and
unfortunately many samples have not grown in vitro or
been resistant to the drugs tested. The assay is
still experimental and is discussed in the next
section.
(4) New drugs are being sought which might have improved
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efficacy against ovarian cancer as the lack of
sufficiently active drugs is obviously one of the
major problems. Currently cis-platinum analogues are
attracting the most interest particularly because of
their reduced nephrc-toxocity compared with cis-
platinum but with similar response rates (E. Wiltshaw
et al, 1983). However, there is some suggestion that
carboplatin (cis-diammine-1 , 1-cyclobutanedi-
carboxylate platinum II) may have some activity in
cis-platinum resistant ovariar tumours (B.D. Evans et
al, 1983).
Perhaps a fifth area of research should be mentioned
here, namely the search for techniques to allow
earlier detection of the disease since earlier stage
tumours show much better and mere durable responses
to current therapy. Unfortunately no ideal tumour
marker has yet emerged for this purpose and current
research is concentrating on possible tumour
associated antigens using monoclonal antibodies (M.
Bhattacharya et al, 1982; R.C. Bast et al, 1983).
1.2 Ovarian cancer - laboratory studies
Experimental work with tissue of human origin has lagged
well behind that from animals especially rodents. Tissue
from human ovarian tumours received relatively little
attention up until recently and in vitro growth of human
11
tumour cells was regarded as a rare and unusual event.
Indeed in 1975 Fogh and Tempe in preparing an inventory of
all published human tumour cell lines (J. Fogh et al,
1975) found only 4 human ovarian tumour lines in the
literature. However, work by Ioachim and his colleagues
(H.L. Ioachim et al, 1974) showed that at least short term
culture could often be achieved with 46 of 62 ovarian
tumour samples showing initial growth and 35 of these
being cultured for more than 30 days. Morphological,
cytological and immunological features could be analysed.
Clonogenic assays
Interest in culture of human ovarian carcinoma cells was
stimulated by the development of a tumour cloning assay in
agar by Hamburger and Salmon in which ovarian carcinoma
cells taken from ascites samples grew well compared with
other tumour types (A.W. Hamburger and S.E. Salmon, 1977).
It had been shown as long ago as 1964 that tumour cells
grew selectively in agar compared with normal cells (I.
MacPherson et al, 1964). Further work showed tumour
colony growth from both effusions and biopsies from 85% of
31 ovarian cancer patients (A.W. Hamburger et al, 1978).
At the same time a similar technique was developed by
Courtenay and her colleagues (V.D. Courtenay and J. Mills,
1978) and again ovarian tumours were among the best for
growth in the agar cultures (V.D. Courtenay et al, 1978).
These assays separate biopsies or effusions into single
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cell suspensions by either mechanical or enzymic
disaggregation and assess the cloning efficacy by the
number of colonies which grow up as clones from the single
cell suspension immobilised in agar. The major use of
these techniques has been in determining the sensitivity
of these tumour specimens to various antineoplastic drugs
with the idea of first correlating in vitro sensitivity
with the patient's clinical sensitivity and then hoping to
be able to predict clinical sensitivity and so help in the
clinicians choice of therapy (D.S. Alberts et al, 1980).
Although this goal has not yet been achieved (D.D. Von
Hoff et al, 1983) correlations with patients clinical
responses of approximately 95% for drug resistance and 60-
70% for drug sensitivity have been reported (B.I. Sikic et
al, 1981). The assay has been criticised for various
methodological problems (F.R. Mackintosh et al, 1981;
I. Bertoncello et al, 1982 ; M.V. Agrez et al, 1982;
P. Selby et al, 1983) and is being refined by various
groups. Although around 80% of ovarian tumour samples
will grow in the Hamburger/Salmon assay with ascites
samples growing more frequently than solid tumour samples
(D.D. Von Hoff et al, 1981) plating efficiencies of 0.001
to 1% only are achieved (I. Bertoncello et al, 1982) with
500,000 cells per 35mm dish being commonly plated. This
means even a low number of cell aggregates in the original
preparation can be a problem in assessing colony formation
at the end of the assay (M.V. Agez et al, 1982). Abortive
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colonies are also difficult to assess. In addition the
cell survival curves obtained have often shown unexpected
plateaus with increasing dose unlike most in vitro
experience suggesting this may be artifactual (P. Selby et
al, 1983). The in vitro/in vivo correlations have been
based on doses ' of drugs in vitro based on peak plasma
concentrations achievable in vivo (T.E. Moon et al, 1981)
with 1/1Oth peak plasma concentration often being used
(D.D. Von Hoff et al, 1983). This drug concentration used
in the assay plus the cut-off point of <30% survival for
assessing sensitivity have been thought to be somewhat
arbitrary by some authors (P. Selby et al, 1983).
Obviously improvements in this assay are necessary but the
clinical correlations have been sufficient to stimulate
continued interest. Unfortunately the majority of samples
have shown drug resistance in vitro and in the minority
showing sensitivity (approximately 20%) the correlation
with the clinical cutcome has not been as impressive (T.E.
Mcon et al, 1981; D.D. Von Hoff et al, 1983 ). Thus the
number of patients who could be helped is very limited at
this stage (T.J. Williams et al, 1983). While the
Courtenay assay has not been used as extensively it
warrants further use due to the increased plating
efficiency seen with this procedure, thought to be due to
the low oxygen concentration used (5% vs 20% in the
Hamburger/Salmon assay) and the presence of rat red blood
cells (K.M. Tveit et al, 1981).
14
This type of methodology has also been used by one group
in attempting to address the question of what constitutes
the stem cell population of a tumour (W.J. Mackillop et
al, 1983a). Obviously this population is critical to the
continued growth of a tumour and it would be important to
know if the low percentage of clonogenic cells observed in
vitro were representative of or represented this
population. While culture conditions are undoubtedly sub-
optimal the cells with self-renewal capacity seem to be a
subpopulation of the clonogenic cells (R.N. Buick et al,
1981) as assessed by secondary plating efficiency.
Cellular heterogeneity could be observed in ascites
samples and different cell populations (non-proliferative,
differentiated cells of high density versus proliferative
and clonogenic cells of lower density) could be separated
by density gradient fractionation (W.J. Mackillop et al,
1981). In a series of 7 ascites samples collected from
one patient over a 9 months period changes in the density
distribution of the cell population could be observed with
an increase in the number of clonogenic cells but
particularly an increase in the secondary colony plating
efficiency (W.J. Mackillop et al, 1983b).
Cell characterisations
Other studies with human ovarian carcinoma cells have
described the different cytological features of ovarian
carcinomas. This includes the different histological
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types and the different grades of differentiation, the
presence of various antigens and a number of studies on
chromosomal abnormalities. Ioachim concluded that ovarian
carcinomas in short-term culture preserve most of their
salient features as observed by light microscopy and
electron microscopy (H.L. Ioachim et al, 1974). The
histologic and cytologic features of the common epithelial
ovarian tumours were recently reviewed by Fenoglio (C.M.
Fenoglio, 1980). Ioachim and others also produced
heterologous antisera to ovarian carcinoma extracts (H.L.
Ioachim et al, 1975; J.J. Barlow et al, 1975). Since
these antisera require extensive absorption to remove
reactivities against normal host tissues the reactivity
has recently been compared with that of the monoclonal
antibody approach (R. Berkowitz et al, 1983). Most recent
attention has focussed on producing monoclonal antibodies
(R.C. Bast et al, 1981; M. Bhattacharya et al, 1982) in
the search for a specific marker to monitor this disease.
Various studies have looked at other antigens including
markers such as carcinoembryonic antigen (W.G. Haije,
1982) and also hormone receptors including those for
oestrogen and progesterone (A. Bergqvist et al, 1981).
Cytogenetic studies have shown a considerable number of
abnormal chromosomes of various sorts with cells ranging
from hypodiploid to tetraploi;d (C.D. Olinici et al, 1973).
Wake and colleagues have suggested a 6:14 translocation
may be consistently involved in ovarian cancer (N. Wake et
16
al , 1980). Others have found similar deletions in
chromosome 6 but alterations in chromosomes 1 and 3 have
also been quite common (J.M. Trent et al, 1981).
Ovarian cell lines
A number of human ovarian cell lines have been reported
since the mid 1970s. In the earlier reports simply
cellular morphology, growth rates and some karyotype
information were reported (J. Fogh et al, 1975; P.J.
DiSaia et al, 1975; R.S. Freedman et al, 1978; G.A. Sinna
et al , 1979) with epithelial characteristics and
aneuploidy being shown. Recent reports have given more
detailed characterization. Woods and her co-workers
compared 4 cell lines for isozyme patterns, hormone
production and hormone receptor proteins and showed
detailed karyotypes (L.K. Woods et al, 1979). Simon and
his colleagues showed a higher success rate in
establishing cell lines and investigated the effects on
growth of various hormones (W.E. Simon et al, 1979; W.E.
Simon et al, 1983). Welander used irradiated macrophage
feeder layers to assist the initial growth of 25 cell
lines beyond 5 passages (C.E. Welander et al, 1982) with
greater success for metastatic nodules than solid tumours.
Van Haaften-Day established 14 cell lines and 6 xenografts
in nude mice from samples from 10 patients and showed
changes in DNA content towards aneuploidy and a decrease
in hormone receptors in early passages in culture (C. Van
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Haaften-Day et al , 1983). Other recent attempts to
establish xenografts have shown greater success from solid
tumours than ascites (S. Kullander et al, 1978; G.G. Steel
et al, 1983 ). A group at the N.C.I, has also recently
shown interest in establishing human ovarian cell lines to
investigate drug resistance (T.C. Hamilton et al,.
1983a,b). Obviously now that growth of ovarian carcinoma
cells in vitro has been demonstrated, various groups are
using them to investigate their particular interests.
There are some cell lines without published
characterisations being used in this way, for example to
test monoclonal antibodies (R.C. Bast et al, 1981) and to
demonstrate the presence of oncogenes (A. Eva et al, 1982)
and the general area of the culture of human ovarian
cancer cells is likely to continue to expand.
1. 3 Drug resistance studies
Drug resistance is undoubtedly a major clinical problem
and various studies have attempted to understand the
patterns of resistance between different drugs and to
elucidate mechanisms of resistance. Much of this work has
been done with mouse tumours and in vitro with various
mammalian cell lines and only recently has the importance
of using human cell material been recognized.
Murine tumour studies
A very major contribution to anti-cancer drug resistance
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studies has been that of Schabel , Skipper and their
colleagues mainly using the L1210 and P388 murine
leukaemias, and various sublines selected for mutation to
drug resistance, to plot the rate of appearance of
resistance and to analyse the subsequent relative
sensitivity to the drugs. In 1972 they produced a
reference chart of cross resistance cr sensitivity amongst
27 agents of clinical interest (H.E. Skipper et al, 1972)
in which cross resistance between certain closely related
drugs was demonstrated but continued sensitivity to
unrelated drugs was mere often the case. Detailed work
with the alkylating agents has shown that cells selected
for resistance to one alkylating agent may remain fully
sensitive to some other alkylating agents and still show
some sensitivity to others (F.M. Schabel et al 1978).
Various factors have been investigated including the total
body tumcur cell burden, growth and regrowth rates of
sensitive and resistance cells, ratios of sensitive to
resistant cells, drug dose levels, intervals between
doses, duration of treatment and choice and sequence of
drugs (H.E. Skipper et al 1978). The rate of spontaneous
mutation to resistance appears to vary markedly in these
tumours for various drugs being highest for the mitotic
inhibitors like Vincristine and lowest for alkylating
agents like Cyclophosphamide. Treatment failures occur
with large tumour burdens (greater than approximately 10^
cells for single agents) due to overgrowth of drug-
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resistant tumour cells after initial responses. Changing
to a new drug when the tumour burden reaches its nadir can
result in therapeutic gain and even cure (F.M. Schabel et
al 1980). Sequential rather than combined drug protocols
seemed to give better results usually because full doses
of the drugs could be employed. The second drug or drugs
could be selected on the basis of profiles of cross-
resistance. Resistant cells which overgrow a tumour can
also sometimes show collateral sensitivity to other drugs.
Cross resistance patterns for over 100 drugs have now been
established in these models (F.M. Schabel et al 1983).
Theoretical models
The mathematical model of Norton and Simon has added to
our understanding of the effects of tumour size and growth
rate on the effectiveness of therapy (L. Norton and R.
Simon 1977) since most clinical tumours show gompertzian
growth, where growth is slowed down in large tumours,
rather than the exponential growth in some simple
experimental systems. The model suggests that resistance
can sometimes be due to the timing, dosage and duration of
the initial therapy as can be seen from tumours which
regrow after successful initial therapy but then still
respond to that therapy and the model can successfully fit
various experimental data.
However, the overgrowth of a tumour by truly drug-
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resistant cells has led to another influential
mathematical model, that of Goldie and Coldman, who
modelled the spontaneous mutation rate of a tumour to
suggest when and how fast drug resistant cells would be
generated (J.H. Goldie and A.J. Goldman 1979). The
likelihood of finding any cells with resistance to a
specific drug is related to the size of the tumour and the
mutation frequency and in this model the drug acts only as
a selecting agent rather than a mutating agent in its own
right. The model is based on that of Luria and Delbruck
who showed resistance to viral infection in bacteria arose
by random spontaneous mutations which occurred at a fixed
frequency (S.E. Luria and M. Delbruck 1943). Their
fluctuation test, which has now been applied to resistance
to chemotherapeutic agents in mammalian cells, shows that
since the mutations occur randomly the number of resistant
cells in each of a number of parallel subclonal cultures
of a certain size will fluctuate to a large extent. Thus
for a tumour of a certain size a probability value for the
number of resistant mutant cells to be expected can be
given based on the mutation rate but the resistant cell(s)
could have arisen at any time in the tumour's progression.
Therefore one prediction of the model is that chemotherapy
should be begun as early as possible but there will be a
variable response between similar sized tumours of the
same type in different patients. Secondly it suggests
that alternating non-cross-resistant chemotherapy between
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two active regimens would usually be the optimum treatment
to maximise the chance of avoiding the development of
doubly resistant cells and combination chemotherapy would
be superior to single agent treatment (J.H. Goldie et al
1982). The model also predicts that slower growing
tumours will be more resistant since there will have been
many more division cycles of the stem cells for the
population as a whole to reach any given size (J.H. Goldie
et al 1983). Basically the strategy suggested is to limit
to a minimum the time that any resistant subtype has to
grow unimpeded by therapy. Various experimental data,
particularly with mammalian cell lines in culture, support
this concept of the genetic basis of resistance, with
mutation frequencies of 10~5 to 10~7 (v. Ling 1982).
Selection of a pre-existing minor clone of cells has been
demonstrated (J.T. Isaacs et al 1981) and heterogeneity in
tumour subpopulations has been observed by many groups (T.
Tsuruo et al 1981).
Other concepts
Other concepts which may also explain some drug resistance
include the pharmacology of drugs in reaching the tumour,
including factors such as its vascularization, and also
the kinetic status of the tumour with cycling cells being
preferentially killed. A steep dose response curve is
observed for many agents and so where extra toxicity can
be avoided, for example by regional chemotherapy, then an
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increased response can be achieved by increasing the dose
(E. Frei et al 1980). The pharmacokinetics of different
anti-neoplastic drugs concerning their absorption,
distribution, metabolism including active metabolites, and
excretion (M.G. Donnelli et al 1977; E. Mihich 1980) is an
increasing area of study due to the recent use of more
sensitive and specific assay methods (C. Erichman et al
1980) particularly high pressure liquid chromatography,
and can explain apparent tumour resistance (R.L. Dedrick
et al 1975) where not enough active drug reaches the
tumour. The presence of hypoxic cells in tumours, often
due to poor vascularization (I.F. Tannock 1968) has also
been demonstrated and can protect cells from both
radiotherapy and chemotherapy (K.A. Kennedy et al 1980).
In vitro studies with multicellular spheroids have also
shown central hypoxia and also poor penetration of some
drugs such as Doxorubicin (R.E. Durand 1981). Most of the
presently available drugs are more toxic against cycling
cells (W.R. Bruce et al 1966; B. Drewinko et al 1981) and
so the presence of non-proliferating or G0 cells in a
tumour could limit its response to therapy (V.T. DeVita
1971). Many of the commonly used drugs have also been
shown to be more toxic in a particular phase of the cell
cycle in tumour cell lines in tissue culture (F. Mauro et
al 1970). This has led to a large body of data especially
with the L1210 murine leukaemia involving the scheduling
of various drugs to take account of these factors (I.
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Tannock 1978 ) but it has been much more difficult to
translate these results to scheduling in man and kinetic
data on human tumours are much more limited (I. Tannock
1978; B.T. Hill 1978 ) .
1.3.1 Biochemical mechanisms of resistance
Most of the above concepts have been elucidated in animal
tumour models or cell lines in vitro. The studies of the
mechanisms by which truly resistant tumour cells avoid
drug toxicity has largely been determined in murine or
Chinese hamster cell lines. The mechanisms so far
identified cover the whole ambit of cellular activities
including defective drug transport either influx or
efflux, defective metabolism to active species, increased
drug inactivation, altered pools of competing normal
metabolites and enzymes, altered target proteins and
increased quantity of target protein via gene
amplification, and altered DNA repair.
Methotrexate resistance
Methotrexate is the most studied drug regarding its
mechanism of action and acquired resistance to it. It
acts as an inhibitor of the enzyme dihydrofolate reductase
required in the de novo synthesis of thymidine and
purines. Resistance at almost every step of its
metabolism has been shown. In the 1960s defective
transport (D. Kessel et al 1965) and increased levels of
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the target enzyme dihydrofolate reductase (J.L. Biedler et
al 1963) were observed. Later altered dihydrofolate
reductases with decreased affinity for drug (W.F. Flintoff
et al 1976) were recognised and more recently reduced
metabolism of methotrexate to its polyglutamate forms
(K.H. Cowan et al 1983) or the efficiency of purine
salvage pathways (G.P. Browman et al 1981) have been
indicated. It has been suggested that the transport and
increase in target enzyme mechanisms are the most
important (F.M. Sirotnak et al 1981), although more than
one of the above mechanisms can be found together (D.A.
Haber et al 1981). Detailed analyses have shown different
types of transport defect including both a reduced Vmax
and increased Km for carrier mediated methotrexate influx
(B.T. Hill et al 1979; F.M. Sirotnak et al 1981). The
increase in the amount of target enzyme can occur by
increased synthesis and delayed turnover (R.C. Jackson et
al 1973) but the major mechanism has been shown to be via
gene amplification (R.T. Schimke et al 1978) with stable
resistance being associated with specific expansions of
the chromosome known as homogeneously staining regions,
and unstable resistance with extra-chromosomal elements
called double minute chromosomes (R.J. Kaufman et al
1981). The mechanism of gene amplification is thought to
be by extra rounds of DNA replication and may represent an
important general mechanism for altering gene activity (A.
Varshavsky 1981). Recent DNA-mediated genetic transfer
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techniques have allowed the transfer of DNA coding for the
dihydrofolate reductase gene thus confering methotrexate
resistance on the recipient cell (K. 0'Hare et al, 1981).
Efforts have also turned towards the synthesis of
different folate antagonists to circumvent methotrexate
resistance either at the membrane (T. Ohncshi et al 1982)
or enzyme (S. Dedhar et al, 1983) level. In the clinical
setting high dose methotrexate with leucovorin rescue has
been used (J.R. Bertino 1977).
Pleiotropic resistance
The importance of gene amplification has also been
suggested in the so-called pleictropic resistance
phenctype (J.L. Biedler et al 1983). This phenotype is
best characterised in Chinese hamster cell lines and cross
resistance to various drugs principally the
anthracyc1ines, vinca alkaloids, colchicine and
actinomycin D is observed (N.T. Bech-Hansen et al 1976).
This cross resistance appears to be due to reduced drug
transport with membrane permeability being implicated (V.
Ling et al 1973 ) and the presence of an approximately
170,000 MW cell surface glycoprotein (R.L. Juliano et al
1976) being closely correlated with drug resistance.
Expression of this glycoprotein was co-transferred with
drug resistance by DNA-mediated gene transfer from the
resistant mutants (P.G. Debenham et al 1982). In mouse-
leukaemia models increased drug efflux has been suggested
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to be the critical factor (M. Inaba et al 1981) and the
blocking of this process by calcium channel blockers and
calmodulin inhibitors has increased sensitivity again (T.
Tsuruc 1983). This phenotype has attracted considerable
attention since the cross-resistance is acquired even when
different drugs are used to select resistance and so it
could affect many combination chemotherapy regimens (V.
Ling et al 1983).
Other agents
Other agents have shown different mechanisms of
resistance. For antimetabolites like 5-fluorouraci1 and
cytosine arabinoside, which act through the appropriate
nucleoside metabolism pathways, the activities of various
enzynes and levels of normal metabolites in these pathways
are often the critical factors, making fcr a complex
picture of affected metabolism (B. Ardalan et al 1980).
For the alkylating agents drug inactivation and DNA repair
can play a role. The cellular toxicity of the
phenylalanine mustards has been recently reviewed by
Vistica looking at the above factors and also emphasising
some of the pitfalls in experimental methodologies such as
media compcsition in tissue culture which can affect the
results (D.T. Vistica 1983). Most work has been done with
melphalan, which is actively transported into cells by
amino acid carrier systems particularly that fcr leucine
(A. Begleiter et al 1979) and resistance at this transport
27
level has been demonstrated in L1210 cells (W.R. Redwood
et al 1980 ). Some of the other alkylating agents are
apparently carrier independent (J.E. Byfield et al 1981).
Intracellular sulphydryl compounds capable of
participating in alkylating agent inactivation have also
been shown to play a role. Melphalan resistance has been
related to levels of glutathione, the principal non¬
protein thiol in cells (K. Suzukake et al 1983) and
reversal to drug sensitivity correlated with glutathione
depletion (K. Suzukake et al 1982). Glutathione may also
be important with other alkylating agents (H.L. Gurtoo et
al 1981). The low molecular weight cytoplasmic
metallothionein proteins which are rich in sulphydryl
groups can also contribute to resistance and have been
implicated in chlorambucil resistance in one study (L.
Endresen et al 1983).
Since the DNA of the cell appears to be the target of many
cytotoxic drugs the various types of DNA repair have been
an important area of research. For the bifunctional
agents resistance to melphalan (P.G. Parsons et al 1981;
L. A. Zwelling et al 1981), busulphan (P. Bedford et al
1982), cis-platinum (L.A. Zwelling et al 1981) and the
nitrosourea CCNU (L.C. Erickson et al 1978) has been
reported with reduced DNA crosslinking although different
sorts of DNA lesions may be important in each case.
Differences in the initial formation of crosslinks seemed
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to be important as well as the subsequent temporal repair
of them. These results have been criticised by others who
found that, while their sensitive cell lines showed
increased cross-linking at a particular dose of cis-
platinum, at an equitoxic dose the resistant lines showed
more cross-links apparently simply indicative of the
higher drug concentrations present (M.C. Strandberg et al
1982) implying that either the critical DNA lesion was not
measured or there are other causes for the resistance as
well. Particular repair pathways will be important for
particular drugs, as has been shown with base excision
monoadduct repair for nitrosoureas where the so-called Mer
phenotype was important to resistance (L.C. Erickson et al
1980). The nuclear matrix itself within the cell may also
be important (K.D. Tew et al 1983). It seems likely that
in many cases, particularly at low levels of resistance,
more than one mechanism of resistance will be acting in
concert (A. Begleiter et al 1983) to give the end result
of survival against cytotoxic insult and more studies are
needed where the different possibilities are investigated
together.
1. 4 Cisplatinum studies
Cisplatinum has rapidly become an important anti-cancer
drug since its introduction into clinical trials in the
early 1970s with activity against a number of human
cancers (A.W. Prestayko et al (eds) 1980). Its biological
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activity was first noticed by Rosenberg and his colleagues
in 1965 when they showed inhibition of cell division and
abnormal filamentous growth in E. coli by electrolysis
products from a platinum electrode (B. Rosenberg et al
1965). When the compound was identified as cisplatinum,
(formerly known and synthesised in the 19th century as
Peyrone 's chloride), its antitumour activity was soon
shown in murine sarcoma 180 and L1210 leukaemia (B.
Rosenberg et al 1969) and phase I trials began in humans
in 1971. Its major toxicities include nephrotoxicity now
largely controlled by hydration and mannitol diuresis
(I.H. Krakoff 1979), gastrointestinal toxicity, some
myelosuppression and neurotoxicity (D.D. Von Hoff et al
1979 ) .
The chemistry of cisplatinum has been recently reviewed
(S.J. Lippard 1982). It can undergo a hydrolysis reaction
with displacement of the chloride groups in a stepwise
manner with water molecules. These aquated complexes
appear to be the active species and can react with
nucleophiles such as DNA and proteins (N.P. Johnson et al
1980). Pharmacokinetic studies which have mainly only
measured the platinum, by atomic absoption spectroscopy,
have had to take account of reactions in the plasma
especially the binding to protein and so figures for total
platinum and ultrafilterable (i.e. not protein bound)
platinum are usually quoted (J.J. Gullo et al 1980). Both
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total and u1trafi1terable platinum have a rapid initial
clearance with half-lives less than a half-hour but total
platinum has a much slower secondary phase of clearance
(half-life 2-5 days). The initial rapid loss of platinum
is mainly by excretion in the urine with 60-70% of the
total platinum recovered there during the first 4 hours
(C.L. Litterst et al 1976). Cisplatinum appears to bind
to most plasma proteins (J.J. Gullo et al 1980) but also
react with other low molecular weight plasma species (A.J.
Repta et al 1980). However 60 to 80% of the
ultrafilterable platinum is parent drug (K.J. Himmelstein
et al 1981) and work to identify the other metabolites is
only in preliminary stages (P.T. Daley-Yates et al 1983).
Generally it would appear that the chloride concentration
in the plasma (100mM) is high enough to leave the
equilibrium of the aquation reaction far to the left but
when the drug enters the cell and meets a much reduced
chloride ion concentration (5mm) the equilibrium is pushed
to the right and the more active aquated complexes are
formed and can then react intracellularly (A.F. Le Roy et
al 1979) as shown in Figure 1. However others have argued
that reactions not dependent on initial aquation can occur
in the plasma (A.J. Repta et al , 1980 ).
There is general agreement that the major target of
cisplatinum for its toxicity and anti-tumour-activity is
DNA (J.J. Roberts et al 1979). DNA synthesis is inhibited
Figure 1. Aquation of Cis-Platinum
Plasma - [CI©] - 103 mM Cell - [CI©] -4mM
C\, -,NH3
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before and at lower drug concentrations than other cell
activities like RNA and protein synthesis (H.C. Harder et
al 1970). Subcellular fractionation studies have shown
amounts of platinum species are greatest in the cytoplasm
(R.P. Sharma et al 1983 ) but on a per gram of protein
basis considerable amounts concentrate in the nucleus
(D.D. Choie et al 1980). Using electron microscopy to see
the platinum one study has shown platinum concentration in
the nucleus (M.U.A. Khan et al 1978). At LD37 toxic doses
to HeLa cells more platinum is bound to DNA than RNA or
protein on a mole per mole basis (although similar amounts
on a mole per gram basis, suggesting the DNA is the most
sensitive cell target). Only one protein in every 1500
would have undergone reaction at this dose, theoretically
the dose just required to kill one cell (J.J. Roberts et
al 1979). The precise DNA lesions which are critical to
toxicity are still uncertain but bifunctional attack seems
to be important. Suggested lesions are shown in Figure 2.
DNA interstrand crosslinks have been correlated with both
toxicity and resistance (L.A. Zwelling et al 1981).
Others have criticised this work and suggested that, while
the extent of interstrand crosslinking was related to the
concentration of drug applied, a more cytotoxic lesion
must exist (M.C. Strandberg et al 1982) wiih intrastrand
crosslinks being the most likely possibility (S.J. Lippard
1982). The presence of interstrand crosslinks can be
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studied by the technique of alkaline elution but the
chemical nature of the reaction products of cisplatinum
with DNA are only now being elucidated with the N7 of
guanine proving the most reactive centre (J.P. Macquet et
al 1983). Intrastrand crosslinks between neighbouring
guanines in DNA in vitro have been identified (A.M.J.
Fichtinger-Schepman et al 1982). Antibodies to
cisplatinum-DNA abducts have recently been prepared and
they may provide a way of studying adducts such as
intrastrand crosslinks more closely (S.J. Lippard et al
1983). Others have used the radiolabelled analogue cis-
dichloro(ethylenediamine)platinum (II) to start looking at
these adducts (A. Eastman 1983) and shown the intrastrand
crosslink to be quantitatively the most important lesion
with calf thymus DNA. By contrast interstrand crosslinks
only represent about 1% of the platinum DNA reactions
(J.J. Roberts et al 1982) but may be a critical lesion.
Over 1000 cisplatinum analogues have been synthesised and
studied and the structure-activity relationships obtained
(K.R. Harrap 1983) have suggested the likely cytotoxic
lesions briefly discussed above. Other lesions such as
DNA mono-adducts or DNA-protein crosslinks are thought to
be less important since they can be formed by much less
toxic analogues such as trans-platinum with similar
efficiency to cisplatinum (L.A. Zwelling et al 1979a). As
discussed by Harrap, studies on structure-activity
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relationships have revealed that for antitumour activity
the complexes should be neutral and have the leaving
groups necessary for bifunctional reactivity in the cis
rather than the trans orientation of the square planar
complex. The two leaving groups such as the chlorides in
cisplatinum have an effect on the reactivity of the
molecule, while the two inert ligands usually amine
derivatives seem to have more effect on the anti tumour
selectivity and systemic toxicity (J-P. Kacquet et al,
1983a). Various analogues have been designed with
increased activity or solubility or decreased
nephrotoxicity etc. in mind. Certain platinum (IV)
complexes are also active. The chemistry of this platinum
group of antitumour agents can be seen to be similar to
the classical bifunctional alkylating agents with whom
they are often broadly categorised (F.M. Schabel et al
1978) but the reactivity and selectivity show important
differences. For example cisplatinum induces many less
DNA interstrand crosslinks than sulphur mustards per DNA
reaction (J.J. Roberts et al 1979).
Cisplatinum is as toxic (if net more so) to stationary
phase as to proliferating cells in tissue culture and
longer exposures are more toxic than short exposures of
the same dose (J-P. Bergerat et al 1979), suggesting it is
toxic at all phases of the cell cycle. However, toxicity
is greater towards G]_ phase cells and DNA repair
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processes have been invoked to explain this (J.J. Roberts
et al 1980). For example interstrand crosslinks appear to
be generated in a two step process with the- second step
taking several hours (L.A. Zwelling et al 1979b) so that
their formation will be competing with repair processes
even on the mono-adducts where quenching of otherwise
reactive adducts could reduce toxicity (K. Micetich et al
1983). DNA repair pathways are best understood in
bacteria and various E. coli repair deficient mutants have
been shown to be more sensitive to cisplatinum (R. Alazard
et al 1982). This sensitivity is due in part to deficient
excision repair but other pathways such as postreplication
repair would seem to be important as well (J.J. Roberts et
al 1979). Increased sensitivity has also been shown in a
human excision-repair deficient xeroderma pigmentation
cell line (H.N.A. Fraval et al 1978). Cisplatinum is also
mutagenic to Chinese hamster cells presumably due to DNA
lesions and misfunction of repair processes (L.A. Zwelling
et al 1979c).
Resistance of cells to the effects of cisplatinum can be
attributed to the DNA repair process discussed above.
Mono-adduct quenching has been suggested as a possibility
(K. Micetich et al 1983). However, other cellular
processes could also inhibit the DNA lesions being formed.
Transport processes into the cell have not been directly
implicated as cisplatinum as a neutral complex, is thought
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to pass through the cell membrane by passive diffusion.
However, resistance to melphalan in an L1210 sub-line
cross-resistant to cisplatinum has been associated with
changes in transport mechanisms (W.R. Redwood et al 1980).
It is perhaps important to distinguish between cisplatinum
resistance associated with cross-resistance to the
classical bifunctional alkylating agents such as melphalan
and resistance not showing this association (A. Eastman et
al 1981). For example Schabel and his colleagues using
both L1210 and P388 cells and resistant sublines have
shown that sublines selected for resistance against
malphalan showed cross-resistance to cisplatinum but
sublines selected for resistance against cisplatinum did
not show cross-resistance to melphalan (F.M. Schabel et al
1983). Thus the selecting agent is probably important for
the mechanism of resistance observed. Levels of SH-
compcunds, particularly glutathione, have been implicated
in resistance to melphalan with deactivation of the
reactive agent (K. Suzukake et al 1983) and appear to play
some role in the metabolism of cisplatinum.
Diethyldithiocarbamate, a sulphydryl group reagent, can
inhibit cisplatinum induced nephrotoxicity (R.F. Borch et
al 1979). Alterations in renal levels of glutathione and
glutathione dependent enzymes can be observed after
cisplatinum treatment (C.L. Litterst et al 1982) although
this may not be due to a direct interaction of cisplatinum
with SH-compounds (J. Levi et al 1980). In rat liver and
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kidney appprcximately 50% of the platinum in the cytoplasm
of the cell was in the form of low molecular weight
species (C1000MW) with about 25% bound to high molecular
weight proteins (>20,000 MW) and 25% bound to small
proteins of 6000-12000 molecular weight thought to be
metallothionein-like proteins (R.P. Sharma et al 1983).
Indeed in 2 cell lines selected for resistance against
cadmium, cross resistance was observed against cisplatinum
and resistance was ccrrelated with an increase in the
cysteiny1-rich metallothionein proteins which bind cadmium
and platinum (A. Bakka et al 1981). These cells are also
resistant to chlorambucil (L. Endressen et al 1983).
Clearly mechanisms of resistance can occur at several
levels depending on the selecting agent, the cell system
and the random chances of mutations, and variable cross-
resistance has been observed even within this class of
square-planar platinum complexes (J.H. Burchenal et al
1978). These variations will also have an effect on
interactions in combined drug or radiation therapy and
various studies have looked for modification of
cisplatinum effects with other agents, for example with
ionizing radiation (E.B. Douple et al 1980).
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1.5 Rationale for this project
The background to this project reviewed above indicates
the clinical importance of ovarian cancer. Although
responses to chemotherapy have improved considerably, a
high proportion of patients relapse and subsequent
treatment is unsuccessful. Thus while epithelial ovarian
carcinoma is a chemosensitive tumour the development of
drug resistance is a major problem leading to shortlived
survival and current therapy needs to be further improved.
Ovarian cancer cell lines can be grown in vitro from
clinical samples and so in this project I decided to use
clinical samples and derived cell lines as a model for
studying drug resistance. Emphasis has been placed on
resistance to cisplatinum since it is thought to be the
key component of the best current combination
chemotherapy.
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2. Characterization of ovarian adenocarcinoma cell lines
2.1 Material already available in the Department
When I arrived in the Medical Oncology Unit in January
1984 some progress had already been made towards a model
for drug resistance in ovarian cancer. Ten ascites
samples from 7 patients had been collected and 3 cell
lines established. Eight of the ascites were from
patients with proven ovarian carcinoma, including 3
ascites from 1 patient with a poorly differentiated
adenocarcinoma. Cell lines designated PE/01 and PE/04
(PE/0 indicating peritoneal effusion from an ovarian
carcinoma and numbered as collected) had been established
from the first two ascites from this patient collected in
February and December 1982 respectively. Two ascites
samples collected 6 months apart were from one patient
with a metastatic adenocarcinoma thought to be ovarian. A
cell line designated PE/Al had been established from the
first ascites. Samples from all the ascites were
available frozen in liquid nitrogen.
Most work had concentrated on characterisation of the 2
cell lines PE/01 and PE/04. The details of the
patient's history and treatment and the times when the
ascites were taken are shown in Figure 3. Although the
PE/01 ascites was taken upon relapse after a long
remission subsequent to initial treatment of the patient,
Figure 3
PATIENT WITH ADVANCED OVARIAN CANCER
CASE HISTORY
Advanced disease with ascites (April 1980)
J, Surgery
Treatment - Cisplatinum, chlorambucil, 5-FU^a^
Response
(Disease free at 2nd look laparotomy Jan 1981)
^ Relapse with ascites (Feb 1982) cell line PE01
^ Treatment - Cisplatinum, Chlorambucil, 5-Fu(k)
Response
Relapse (Nov 1982)
J, Treatment - High dose Cisplatinum^ c ^
No response Further ascites (Dec 1982) -->cell line PE04
^ Further ascites (Feb 1983 ) -->>cell line PE06
1
Death (Feb 1983)
(a) 7 courses May-Dec 1980
Cisplatinum 30mg/m2 and 5-fluorouracil 500mg/m2, I.V.
days 1 and 8.
Chlorambucil 0.lmg/kg x 14 days (but often reduced
due to low white blood cell count).
(b) 6 courses March-Aug 1982
Same schedule as in a)
c) Nov 1982




a further response was apparent until the relapse when the
PE/04 ascites was obtained. The ascites and the derived
cell lines thus seemed a good initial model for studying
drug resistance in human ovarian carcinoma cells.
Cytological characterisation of these 2 ascites, together
with the original surgical specimen from the patient's
operation in April 1980, had been carried out by Dr.
Margaret Mclntyre, Consultant Pathologist in the
Department of Pathology, Western General Hospital. The
cytology of the initial cultures of PE/01 before a cell-
line was established and of very early passages of the
PE/04 cell line had also been analysed with Papanicolaou
staining. Cultures of cuboidal type cells, with
fibroblastic cells in the initial cultures, were observed
with some vacuolated cells and some "signet-ring" cells
characteristic of ovarian ascites. Mucin production was
noticed in a few cells by staining by the periodic acid-
Schiff reaction (P.A.S.) with diastase.
Initial karyotyping was done by Dr. Karin Buckton of the
MRC Clinical and Population Cytogenetics Unit. Both cell
lines were hypodiploid with a modal chromosome number of
41 but a considerable range. Abnormal chromosomes in
common were 3,9,13 and 22 but PE/04 had a chromosome 8 and
17 not identifiable in PE/01. Chromosome spreads were
prepared at passages 5,9,22 and 42 for PE/01 and 7,15,17
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and 23 for PE/04 with similar results on different
passages.
A clonogenic assay using the Courtenay procedure (V.D.
Courtenay and J. Mills 1978) had been established and
preliminary experiments on sensitivity to cisplatinum,
chlorambucil and 5-fluorouraci1 done since these were the
drugs with which the patient had been treated. These
experiments suggested a difference between the cell lines
in sensitivity to cisplatinum although problems had been
experienced especially in testing PE/01 due to its low and
apparently variable plating efficiency. Attempts to
establish a xenograft from the PE/01 cell line had failed
although on two occasions some growth was observed but the
nodules then regressed.
2.2 Characterisation of cell lines PE/01 and PE/04
Some characterisation on these cell lines, as indicated
above had already been done. It was necessary to complete
the cytology and cytogenetics and improve the cell growth
in agar so that reliable results could be obtained in the
Courtenay assay. Experiments to assess the growth of the
cell lines under a variety of conditions in vitro were
also required and other cellular features including cell
volume, DNA content, antigenic determinants, hormone




The cell line designated PE/01 took approximately 6 months
to become established, possibly due to its sensitivity to
trypsin and several samples were analysed during this
period by various stains including May-Grunwald Giemsa,
Toluidine Blue, and the special stains Sudan black for
lipid, Southgate mucicarmine for mucins, and Alcian blue
for acid mucopolysaccharides. However, most preparations
were stained using the Papanicolaou technique for
morphological detail or by the periodic acid - Schiff
(P.A.S.) reaction for mucopolysaccharides and mucins with
and without diastase which removes glycogen. These
initial cultures showed characteristic epithelial cuboidal
and some multinucleate cells together with more elongated
fibroblasts which gradually died out. Some "signet-ring"
cells were observed (with the nucleus pushed into a
crescent on one side by a large vacuole) as well as other
vacuolated cells. Some but not all the cuboidal and
vacuolated cells were positive with P.A.S. - diastase
indicating mucin in the cytoplasm. In the cuboidal cells
the large oval nuclei were normally central with prominent
and irregular nucleoli and often multiple nucleoli. No
changes were observed with passaging of the cells and
cells at passage 78 showed a similar profile. The number
of vacuolated cells seemed to vary with the culture
conditions with more observed in confluent cultures.
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Ascites preparations showed more "signet-ring" and
vacuolated cells than the cultured cells. Their cytology
was unaffected after freezing in liquid nitrogen.
The cells in cultures of PE/04 showed similar cytological
features to PE/01. Cuboidal and vacuolated cells at
passages 2-4 showed the features noted above. PE/04 grew
out in culture much more rapidly than PE/01 with
cytological analysis in both cell lines being done by Dr.
Mclntyre approximately 3 months after cultures were
initiated. No differences were observed between parallel
cultures of PE/04 which had arisen from different wells
and been kept separate. Part of the initial PE/04
cultures also grew in suspension in clusters of closely
packed cells. Cytology of suspension cultures at passage
1 showed similar features to those above although in this
sample the P.A.S. positivity was removed by diastase. The
monolayer cultures at later passage (passage 48) showed
similar features to the early passage cells and again no
changes were observed with passaging.
Some typical examples of the cytology of the ascites and
cell lines are shown in Figures 4 and 5.
Electron microscopy
Both cell lines were also observed at the ultrastructural
level. Initial experiments involved harvesting cultures
Figure 4 Cytology of Ascites
(Papanicolaou stained)
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4a. Original ascites, April 1980 (mag. x900)
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4b. PE/01 ascites, Feb 1982 (mag. xl400)
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by trypsinization to a cell pellet. For transmission E.M.
cells were fixed in 2.5% glutaraldehyde in 0.1M cacodylate
buffer pH7.3, post fixed in 1% osmium tetroxide,
dehydrated through increasing ethanol solutions, embedded
in araldite, sectioned on a LKB V ultratome, stained with
uranyl acetate plus lead citrate and viewed on a Philips
EM300. To look at cell surface features by scanning E.M.
cells were fixed and post fixed in the same way,
dehydrated through acetone, critical point dried from
liquid CO2 (Balzer Union), gold coated on a sputter coater
(Polaron E5001) and viewed on a Cambridge Stereoscan 180.
In later experiments cells were grown on plastic
coverslips in Leighton Tubes (Costar) and fixed in situ.
Processing was similar to above with the coverslip being
peeled away from the cells after embedding in araldite (G.
Seman et al 1975) to then allow horizontal and vertical
sections to be cut through the cell monolayer for
transmission E.M.
Cells from both lines show large sometimes convoluted
nuclei with prominent nucleoli and dark nuclear
margination. The cell surface shows many microvilli under
scanning E.M. and under transmission E.M. these could also
be seen. Sometimes the cells were extremely indented at
one end with microvilli concentrated there. Some
desmosomes between cells were observed. Some cells had
many organelles and vacuoles while others had relatively
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featureless cytoplasm. Also mitotic cells could be seen.
Many pale rounded inclusions in some cells appeared to be
lipid droplets or mucinous secretions. The in situ
sections show quite dilated intercellular spaces and some
possibly non-cellular inclusions. The monolayers show
some overlapping of adjacent cells and occasional multi-
layering. These features were similar in both cell lines
and consistent with the light microscopy cytology.
Examples of these features are shown in the E.M.
photographs in Figures 6 to 10.
2.2.2 Cytogenetics
Chromosome preparations were obtained by a routine air-
drying procedure by Ms. Sandra Lawrie and analysed for
chromosome number per cell. They were stained for Q-
banding with spermadine bis-acridine by the technique of
Van de Sande (J.H. Van de Sande et al 1979) and analysed
by Dr. Karin Buckton of the M.R.C. Clinical and Population
Cytogenetics Unit. The PE/01 cell line was analysed at
passages 5,9,22 and 42 and PE/04 at passages 7,15,17 and
23. Although the populations were karyotypical ly
heterogenous a number of consistent abnormalities were
identified. Both cell lines were hypodiploid with a modal
chromosome number of 41 . This compared with a normal 46
chromosome karyotype prepared from the patient's
peripheral blood leucocytes. This blood sample was taken
in January 1983 not long before the patient died and after
Figure 6 Scanning Electron Microscopy
-
3um scale bar
PE/01 passage 79 (trypsinised cells)
PE/04 passage 48 (trypsinised cells)
Figure 7 Transmission Electron Microscopy
PE/01 passage 79, trypsinised cells
(mag. x5100 approx)
•/ • -
Figure 8 Transmission Electron Microscopy
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Figure 9 Transmission Electron Microscopy









Figure 10 Transmission Electron Microscopy
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the PE/04 ascites had been tapped.
It is perhaps best to quote the results from Dr. Buckton's
analysis and her conclusions on the significance:
"Chromosome preparations stained for Q-banding with
spermadine bis-acridine by the technique of Van de
Sande et al (1979) were examined from the peripheral
blood leucocytes and cultures grown from ascites
material taken from a patient with ovarian carcinoma
before and after she acquired drug resistance. The
cells from the peripheral blood showed a normal 46,XX
karyotype, whereas the ascites cultured cells were
hypodiploid, the chromosome numbers varied between 39
to 42. Examples of the chromosome complement before
resistance (PE/01) and after (PE/04) with 41
chromosomes are illustrated (Figure llb,c). Figure
11a is a fluorescent karyotype made from a normal
peripheral blood cell. The cultured ascites cells in
addition to being hypodiploid, contained many
abnormal chromosomes. In Figures lib and 11c the
chromosomes that are considered to be normal are
marked with a white square. PE/01 has only 20 such
chromosomes; none of the cells from this culture
contained a normal $8 or fyll chromosome nor any
material that could be considered as coming from
either of these chromosomes, although this cannot be
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excluded because there are so many rearranged
chromosomes. PE/01 had 12 consistent abnormalities
which were:- both 's inv ( 3 ) (p-q+) , 5p-, 9p+, 1 lp+,
both ^13's 13q- and 13q+, 22q+ and 4 chromosomes of
unknown origin. The number and appearance of the
other abnormal chromosomes varied. The polymorphic
Q-bands on chromosomes ^3 and the acrocentics allowed
us to distinguish the origin of some of the abnormal
chromosomes. From Figure 11a it can be seen that in
the normal cells the metacentric $'3 had different
polymorphic Q-bands, one was intense and the other
brilliant (Paris Conference 1971). Both $3 in the
tumour were non metacentric, the one with the
brilliant Q-band was almost acrocentric, both
rearrangements could have been pericentric inversions
(inv(3)(p-q+) but with the breakpoints at different
positions. The acrocentric pair <j£l3 were also very
distinct; one had a brilliant short arm (pi1), almost
no stalk (pl2), and a pale satellite (pl3), it is
this chromosome that appears to have an interstitial
deletion of the long arm (13q—) in the tumour. The
other normal 13 has a brilliant pll, long pl2 and
intense pi 3. These features were not seen in the
tumour. The other chromosome that was thought to be
^13 material was a long acrocentric that had pale
short arms with few features. This chromosome may
have been misclassif ied, but will be called 13q+.
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Both the j^'22 have intense satellites in the normal
cells; only one of these is seen in the tumour and it
has additional material on the long arm (22q+).
There were 4 other consistent abnormalities: 2 marker
chromosomes with very similar appearance - two
prominent bands on the distal long arm, but the
pericentric chromatin was very pale, uniformly
staining, reminiscent of homogeneous staining regions
(HSR), these regions were not C-band positive. Also
two chromosomes that appeared to be isochromosomes
being metacentric with a very similar banding pattern
each side of the centromere; one was half the size of
the other.
In contrast, PE/04 had an apparently normal member of
each chromosome pair including a chromosome ^8 and
^17, but excepting an X and Jj)13 chromosome. However,
the 13q- chromosome now has material translocated to
the brilliant pll, which could make this chromosome
complete although rearranged. Of the consistent
abnormalities seen in PE/01, the following are seen
in PE/04:- inv(3)(p-q+) with the brilliant Q-band,
5p-, 9p+, llp+, 13q+, 22q+, one of the marker
chromosomes with an HSR and in many cells the smaller
of the two isochromosomes was seen. PE/04 had
acquired a ring chromosome, which was approximately
the size of a D group chromosome, also other
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rearranged chromosomes.
The "normal" $22 in both PE/01 and PE/04 has lost the
intense satellites. Deletion of satellites or the
whole of an acrocentric short arm is often found as a
constitutional "abnormality" in normal individuals,
therefore this chromosome material is considered non
essential for normal development. Short arm material
from other of the acrocentrics in the tumour cells
may have been deleted also. In PE/04, neither the
$14 nor $15 seem to have the same short arm features
as those seen in the normal cells. Despite the loss
of the short arm material the $22, $14 and $15 are
considered normal.
The chromosome abnormalities found in the tumour
cells of other patients, with ovarian carcinoma have
also been bizarre and inevitably some of the
rearranged chromosomes in these tumours have involved
the same chromosomes as in the tumour cells from the
present case (S. Kakati et al 1975, R.S. Freedman et
al 1978, M.F. Van der Riet-Fox et al 1979, L.K. Woods
et al 1979, J.M. Trent et al 1981, T.C. Hamilton et
al 1983, S.M. Hill et al 1984). However, we did not
find the (6;14) translocation which it is suggested
may characterise this carcinoma (Human Gene Mapping
7: 1984).
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No double minutes were found in these cells. The
appearance of two marker chromosomes in PE/01 was
consistent with them carrying HSR. HSR's are usually
associated with the acquisition of drug resistance
(for review see P.E. Barker 1982), therefore it is
somewhat surprising that the number of HSR's was
reduced in PE/04. PE/04 appears to contain more
"normal" chromosomes than the earlier culture of
ascites cultured cells. Since both cell lines have
several rearranged chromosomes in common and had very
heterogeneous cell populations, it could be argued
that the two cell lines probably arose from a common
ancestor, both diverged and co-existed in the body,
but that PE/01 was more susceptable to the drug
treatment and was overgrown by PE/04. It is very
unlikely that PE/04 evolved from PE/01, as it would
be almost impossible to regain a normal $8 and $17
having once lost them."
2.2.3 Growth in vitro
My first priority was to assess how well the cell lines we
had would grow under experimental conditions and what
manipulations could be done without damaging the cells.
When I began work the then current passages of the cell
lines PE/01 and PE/04 were passage 63 and 32 respectively.
In April 1984 it was decided not to continue passaging
these 2 lines indefinitely and a cell bank in liquid
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nitrogen at their current passages was built up. Cells
were then routinely cultured for 5 passages before a fresh
sample was taken from liquid nitrogen. Thus all later
experiments were done with passages 77-82 for PE/01 and
passages 46-51 for PE/04 unless otherwise stated.
Trypsin sensitivity
PE/01 was thought to be sensitive to trypsin since initial
cultures had appeared to be severely retarded after
trypsinisation. They grew better if the cells were
passaged by being scraped off in versene (0.02% EDTA) with
a rubber policeman after a wash in Dulbecco 's phosphate
buffered saline without calcium and magnesium (PBS).
However in my experiments on PE/01 at passage 63, cells
grew equally well after scraping in versene or after
detachment by half strength or normal strength (0.2%)
trypsin in versene. Solutions of collagenase/dispase (0.1
U/ml. collagenase, 0.8 U/ml dispase in PBS, Boehringer
Corp. Ltd) also proved to be suitable. Viability of
detached cells was 98-100% by nigrosin staining. Clearly
later passages of PE/01 were not sensitive to trypsin but
it is not known precisely when this change occurred,
possibly as PE/01 became better adapted to growth in vitro
during its period in culture. The PE/04 cell line never
showed any sensitivity to trypsin.
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Confluent cultures
Confluent cultures were observed at passages 63 and 79 for
PE/01 and 32 and 48 for PE/04 . Both PE/01 and PE/04
showed contact inhibition at confluence although some
multi-layering was discernable so that cultures were more
than a monolayer thick in parts. Also cells as well as
cell debris were found floating in the medium and this
increased under nutritional deprivation. When the medium
was not replenished many cells detached from the adherent
monolayer of confluent PE/01 cultures into the medium but
PE/04 maintained a healthy looking monolayer for much
longer before many cells started detaching. Thus PE/04
seemed to be more robust than PE/01 when stressed by poor
culture conditions.
Sub-clones
Single cell suspensions of PE/01 and PE/04 at passages 66
and 35 respectively were plated out at low density in agar
as described in chaper 3 for the Courtenay assays.
Colonies grown up from these single cells could then be
plucked from the agar using a sterile drawn out pasteur
pipette manipulated by hand under a microscope at low
magnification and the single colony transferred to a well
in a microtitre or 24 well plate. Cells then grew out
from the agar plug and became established growing on the
plastic surface with liquid medium. Each well of the
plate could be checked under the microscope to see that
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only 1 colony had been transferred to it. One clone of
each of the 2 cell lines was derived in this way. These
cells were then grown up, and passaged into dishes and
then flasks until enough cells could be obtained for
storing in liquid nitrogen. Unfortunately the PE/01 clone
was lost through contamination during this process but a
PE/04 clone was obtained and stored for future use. In
any case it was apparent that this cloning technique could
be successfully applied with these cell lines. Much later
in the course of this project 6 clones of PE/01 from
passage 78 and 10 clones of PE/04 from passage 47 were
derived by Ms. Sandra Lawrie using this technique.
A different "limiting-dilution" technique for cloning cell
lines was also attempted. Here cells from both cell lines
(at passages 78 and 47 for PE/01 and PE/04 respectively)
were diluted to a concentration of 10 cells/ml in a single
cell suspension and 0.1ml aliquots plated out in the wells
of a microtitre plate. These wells were then checked
later in the day to score those wells which actually had 1
cell in them and these wells observed over the succeeding
weeks. Only about 30% of wells actually had 1 cell in
them while about 50% of wells had no cells. No colonies
grew up from 60 wells plated for PE/01. For PE/04
colonies grew in a number of wells but subsequently died.
However continued growth in 2 wells and subsequent
expansion of these 2 populations led to the derivation of
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2 PE/04 clones by this method. One clone grew from a well
which had 2 cells in it (one on each side of the well) but
cell division and growth into a colony was observed from
only one of them. Thus this technique was not very
successful with these cell lines and the clones obtained
may not be very representative of the population from
which they came owing to their severe selection. This
technique was not pursued further and agar cloning was the
preferred method.
Perhaps it should also be noted here that two PE/01 cell
lines were originally derived, one of which was not
cultured past passage 5. However both were thought to be
clonal or near clonal in origin since they developed from
single colonies in a tissue culture well. On the other
hand eleven parallel PE/04 adherent cell lines and two
suspension culture cell lines were originally derived of
which only one adherent cell line has been cultured past
passage 9. These lines were thought to be polyclonal due
to the number of epithelial cell colonies which grew in
the initial tissue culture wells.
Colony forming efficiency - plastic
The plating efficiency of the two cell lines was assessed
at different cell concentrations and plating densities in
various dishes and media. The usual medium was RPMI 1640
containing 10% (v/v) foetal calf serum with added insulin
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(2.5ug/ml) and buffered with up to 12.5mM 3-[N-
morpholino]propanesulfonic acid (MOPS). The antibiotics
streptomycin (lOOug/ml) and penicillin (100 IU/ml) were
routinely added. Cells were cultured in a high humidity
incubator with a 5% C02/air gas phase at 37°C.
In 24 well plates (Nunc, Gibco Ltd) with a 1.9cm3 plating
surface area, colony forming efficiency (CFE) was 0.8% for
PE/01 (passage 63) compared with 5.7% for PE/04 (passage
32) when 103 cells were plated out in 1ml medium. When
only 500 cells were plated no PE/01 colonies formed but
CFE was still 4.2% for PE/04. At 5 x 103 cells or greater
too many colonies to count were observed for both cell
lines. The colony forming efficiency for PE/04 was
obviously greater than for PE/01 at low plating densities
and at least for PE/01 the efficiency improved with the
number of cells plated. In 50mm diameter dishes with
approximately 20.8cm3 plating surface area PE/04 again
showed a superior CFE at low plating density to PE/01 and
here the increase in CFE with increasing cell number
plated could be clearly seen (Table 4). In addition the
CFE in the 20.8cm3 dishes was lower than that in the
1.9cm3 wells on a cells plated/cm3 basis (103 cells/well
and 1.1 x 10^ cells/dish both being approximately 500
cells/cm3 of plating surface).
Six well plates (Linbro, Flow Laboratories) with 35mm
TABLE 4
COLONY FORMING EFFICIENCY OF PE/01 AND PE/04
IN 5 OMM DISHES
Cell no. plated Colonies formed
(in 3mls) PE/01 (CFE) PE/04 (CFE)
103 Too many colonies to count
3.3 x 104 426 est. (1.3) 1632 est. (4.9)
1.1 x 104 12 (0.1) 128 (1.2)
3.7 x 103 2 (0.05) 13 (0.35)
CFE = % colony forming efficiency
(est = estimate. With large numbers of colonies some
colony overlap occurs making colony counting more
difficult).
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wells (surface area 9.6cm^) were found most suitable for
the drug assay reported in Chapter 3. Initial work (PE/01
passage 66 and PE/04 passage 36) showed improved CFE by
the addition of sodium pyruvate (ImM) but no significant
increase with nicotinamide (200uM) as shown in Table 5.
Medium RPMI 1640 contains no pyruvate and only 8uM
nicotinamide although some contribution can be expected
from the foetal calf serum. Pyruvate is well recognised
as a growth factor in vitro especially at low cell
densities (K.A.O. Ellem et al 1983) and nicotinamide has
also been shown to improve colony forming efficiencies at
the concentration used here (P.G. Parsons et al 1983).
Thereafter ImM sodium pyruvate was routinely added to the
medium when plating cells at low density. Plating cells
at densities to give 100-200 colonies in the 35mm wells
was used extensively for drug assays in Chapter 3.
Plating cell s in 2mls of medium gave a more even spread of
cells across the well (medium swirls around less in
carrying plates to the incubator before the cells attach)
but using 3mls of medium gave slightly better colony
growth (3.4% CFE versus 2.4% CFE on passage 78 PE/01 cells
in one experiment). A good compromise was found to be
plating cells out in 2mls and then adding another 1ml of
medium the next day with medium changes every 2-3 days
thereafter. Using this system over the following 2 years
in some 50 assays colony forming efficiences were 3.9
+2.3% for PE/01 (passage 77-82) from approximately 4-6 x
TABLE 5
EFFECT OF ADDITIVES ON COLONY FORMING EFFICIENCY
Colonies formed
Additive PE/01 (CFE) PE/04 (CFE)
None 0.0 256, 233 (2.4)
Sodium pyruvate (ImM) 51, 40 (0.45) 798, 768 est (7
Nicotinamide (0.2mM) 0,0 271, 439 (3.5)
(lO^ cells plated in 2mls medium/9.6cm2 well)
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lO^ cells plated and 8.1 +3.8% for PE/04 (passages 46-51)
from approximately 2 x 10^ cells plated. The CFE for
PE/01 shown in Table 5 was below our general experience
and may simply be attributable to poorer technique in a
first experiment. Slightly higher CFE in the central
wells of plates was also sometimes noted as well as
variations between plates from different suppliers. Later
during this project a new incubator was acquired which
allowed us to vary the oxygen tension. PE/01 and PE/04
cells grown at low density in 5% O2, 5% CO2 and 90% N2
instead of 5% CO2 in air both showed a 2-3 fold increase
in colony forming efficiency.
Colony forming efficiency-agar
Colony growth was also observed from PE/01 and PE/04 cells
suspended in 0.3% soft agar under the conditions of the
Courtenay assay (V.D. Courtenay and J. Mills 1978 - Hams
F-12 medium with 10% foetal calf serum and August rat red
blood cells in 5% 02, 5% CO2 and 90% N2) • This assay had
been previously set up in this laboratory by Ms. Sandra
Lawrie and after my arrival we decided to pursue it to
obtain drug sensitivity data comparable to other groups.
The colony forming efficiencies are reported here and more
detail regarding this assay is shown in Chapter 3. Colony
forming efficiency improved with passage number . PE/04
again had higher CFEs than PE/01 and gave more consistent
resuIts.
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At early passages (passages 1-10) PE/04 gave CFE of 1-5%
but PE/01 gave CFE of only 0.01-1%. At late passage this
had improved to 3.9 + 2.5% for PE/01 and 18.3 + 10.4% for
PE/04 (passages 77-82 and 46-51 respectively). These
changes are illustrated by the experiment shown in Table 6
when we went back to early passage cells to compare drug
sensitivities. Colony forming efficiencies shown are the
average of 5 replicates.
Doubling time
5 x 10-3 cells per well were plated out in 24 well plates
(Nunc, Gibco Ltd), let grow for 4 days, then quadruplicate
wells harvested and counted using a Coulter counter at the
same time each day for the succeeding 9 days during which
time exponential growth was observed. The doubling time
calculated was 53 hours for PE/01 and 59 hours for PE/04.
Less detailed previous experiments on earlier passages had
indicated doubling times of 68 hours for PE/04 at passage
33, 44 hours for PE/01 at passage 66 and approximately 120
hours for PE/01 at passage 7. These results might suggest
an increased growth rate with passaging but not much
change at later passages.
2.2.4 Cell volume
Cell volume measurements were done using an electronic
particle size analyser (Coulter Counter Model Zg with
Coulter Channelyzer and X-Y recorder, Coulter Electronics
TABLE 6
COLONY FORMING EFFICIENCY OF PE/01 AND PE/04




in agar CFE Passage no.
Cell no.
in agar CFE
2 2 x 104 0.16 2 103 1.9
5 x 104 0.31 2 X 103 2.5
105 0.33 5 X 103 2.2
11 2 x 104 0.35 11 103 1.4
5 x 104 0 . 34 2 X 103 2.5
105 0.40 5 X 103 2.2
79 103 3.1 49 5 X 102 11.3
2 x 103 10.3 103 10.1
4 x 103 11.2 2 X 103 12.4
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Ltd). Latex beads at 12.9um and 14.2um diameter were used
as calibration standards and a linear response of the
recorder with particle volume was observed. Both cell
lines showed a distribution of cell sizes equivalent to a
normal distribution with a standard deviation of
approximately + 400um3 in volume although there was a
small tail to the higher size range. The means of this
distribution were calculated and averaged from 5
experiments giving a volume of 1230 +_ 190 (SEM) and 950 +
lOOum^ for PE/01 and PE/04 respectively. This is
equivalent to diameters (assuming spherical cells) of 13.2
+ 0.7 (SEM) and 12.1 + 0. 4um for PE/01 and PE/04. While
these figures are not significantly different (p>0.10) and
each cell line showed a spread of cell sizes, the average
volume of PE/04 was only 77% of PE/01.
2.2.5 DNA content
Relative DNA content was measured by flow microfluorimetry
using normal human lymphocytes as a standard. Cells were
harvested by trypsinisation, spun down and resuspended and
stained in buffer containing 50ug/ml propidium iodide
either by the method cf Fried using hypotonic sodium
citrate (0.1% sodium citrate, 0.1% triton X-100, J. Fried
et al, 1978) or by the method of Taylor simply using 1%
triton X-100 in PBS (I.W. Taylor, 1980). Lymphocytes from
peripheral blood were resuspended and stained in the same
manner, after lysis of erythrocytes with 0.168M NH4CI, and
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mixed with the ovarian carcinoma cells. Approximately 10^
cells were analysed on a FACS IV fluorescence activated
cell sorter (Becton Dickinson) in the MRC Clinical and
Population Cytogenetics Unit operated by Harris Morrison.
Both cell lines PE/01 and PE/04 showed a single peak at
slightly greater DNA content than the lymphocytes. This
peak was 1.1X diploid in the hypotonic sodium citrate
method and 1.3X diploid in the triton X-100 method with no
difference between the 2 cell lines. From DNA profiles
using the triton X-100 method without a lymphocyte marker,
approximately 75% of PE/01 cells and 65% of PE/04 cells
were in the phase of the cell cycle in logarithmic
cultures.
2.2.6 Antigenic determinants
PE/01 and PE/04 cultures grown in 75cm2 flasks (Nunc,
Gibco Ltd) were harvested in versene using a cell scraper
(Costar) and without any enzyme treatment. The cells were
suspended in medium containing foetal calf serum, a drop
of human blood added (to add some red blood cells as a
control) and the suspension spun down to a cell pellet.
Cell smears on clean microscope slides were produced from
this cell pellet and frozen at -20°C. The slides were
sent in dry ice to Dr. Lynda Bobrow, Department of
Histopathology, University College Hospital in London who
had a strong collaboration with the I.C.R.F. laboratories.
Slides were prepared in this way after discussions with
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her and her results with various monoclonal antibodies are
shown in Table 7. PE/04 but not PE/01 showed expression
of placental alkaline phosphatase, which has been
associated with malignant ovarian tumours (J.O. Davies et
al 1985). Conversely vimentin was expressed in PE/01 but
not in PE/04.
2.2.7 Hormone receptors
Oestrogen and progestogen receptors were kindly assayed by
Dr. Tony Hawkins of the Department of Clinical Surgery of
the University of Edinburgh using a biochemical assay used
for assaying breast cancer biopsies (R.A. Hawkins et al
1981). Seven 75cm2 flasks of each cell line were grown to
confluence and then changed to fresh medium, containing
serum stripped of steroids to exclude endogenous
oestradiol , for 6 days as recommended by Hamilton (T.C.
Hamilton et al 1983b). Serum was stripped of steroids by
the method of Stanley using dextran-coated charcoal (E.R.
Stanley et al 1977). Cells were harvested to a cell
pellet and conveyed to Dr. Hawkins' laboratory at 4°C.
The results showed 169 fmol oestrogen receptor sites/mg
soluble protein for PE/01 and 219 fmol receptor sites/mg
soluble protein for PE/04. When the experiment was
repeated, this time after 10 days culture in steroid
stripped medium the results were similar with slightly
lower levels of 121 and 187 fmol oestrogen receptor
sites/mg soluble protein for PE/01 and PE/04 respectively.
5.2=monoclonalwhi hrecognises lowMWcytokeratinsviz8,18+19 LP34=monoclonalwhi hrec gnises cytokeratinepitopes,wh chhav notbeenfullycharacterised. (=verystrongexpressionin squamouscarcino a). AuA^=mabagainstmembrane glycoprotein(nfully characterised)presentinm y epithelia. Vimentin=abagai stth intermediatef la np esei mesenchymalc lls.Itishowever, knowntbeexpressedisom epithelialcellsincultureand inbodyfluids. H317mabagainstplacentalalkali e phosphatase(Reaganenzymetype ). H17E2mabagainstplacental alkalinephosphatase.(N nReag n type)
TABLE7
PE01
+++cytoplasmicgranular staininginmorethan75% cells. +++cytoplasmicfilamentous networkimorethan75% cells.
PE04
+++cytoplasmicgranula staininginmorethan75 eel1s. +++cytoplasmic filamentousnetworki morethan75%cells.
+++membranestainingin+me branestain g morethan75%cells.morethan75%cells. 25-50%cells. +++cytoplasmicstaining. 25-50%cells+++ lessthan1%ofcellshowM rethan50cells+++. palecytoplasmicstaining.





Progestogen receptor sites were also assayed in this
experiment but could not be detected.
2.2.8 Mer phenotype
A cryotube of cells from each cell line frozen in liquid
nitrogen was sent in dry ice to Dr. Tomas Lindahl at
I.C.R.F. in London. They were then grown by him and
assayed for the O^-methylguanine-DNA methyltransferase
protein. Both were shown to be mer+ cell lines with 2.77
and 3.29 units methyltransferase/mg protein for PE/01 at
passage 83 and PE/04 at passage 55 respectively.
2.3 Other ovarian cancer samples and cell lines
2.3.1 Cell lines related to PE/01 and PE/04
PE/06
As shown in Figure 3 above, a third ascites was obtained
from the same patient a week before she died. Many less
cells were obtained from this ascites than from the two
from which were derived the cell lines PE/01 and PE/04.
The cells from the ascites were therefore initially stored
in liquid nitrogen and not cultured for over 2 years until
the latter part of 1985 when a cell line designated PE/06
was successfully derived. Sub-lines were derived
separately from the ascites by culturing with either 5% O2
or 20% O2 in the gas phase (5% O2, 5% CO2/ 90% N2, high
humidity versus 5% CO2, air, high humidity). At 20% O2 a
62
suspension culture was also established. Cytology at
passage 2 was similar to that of PE/01 and PE/04. Initial
experiments (passages 2 and 4) have shown that the PE/06
subline derived in 5% O2 had considerably higher colony
forming efficiency (in 5% O2) than the subline derived in
20% O2 (in 20% O2) in 6 well plates. Other experiments
relating to drug sensitivity are reported in later
chapters.
PE/01 - Ci sPt-E
Late passage PE/01 cells (passage 78) were cultured in
75cm2 flasks in the presence of low concentrations of cis-
platinum starting at 25nM and increasing the dose when the
cells appeared unaffected by the preceeding one. The
culture medium was replaced every 3 days and fresh cis-
platinum added at that time. This resulted in a
reasonably close but intermittent dose schedule since the
half life of cis-platinum toxic species in medium will
only be some hours (A.J. Repta et al 1980). Dose
increments were 25nM, 50nM, lOOnM, 500nM and luM. A dose
of 500nM was quickly reached after 6 weeks culture.
However it was two-and-a-half months before the dose could
be increased to luM (at passage 89) and passaging was
continued at this dose until passage 107. Cells at
different dose levels and passages were stored in liquid
nitrogen. This cell line was then passaged for a further
4 months until passage 124 without cis-platinum to see if
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it retained its resistance to the drug. No attempt was
made to incubate the cells in concentrations of
cisplatinum higher than luM. Plated at low density in 6
well plates the colony forming efficiency of 9.9 +5.7%
(passage 102-122) was superior to PE/01 and the colonies
formed were tighter and more distinct. In 75cm2 flasks
the line appeared to grow faster than PE/01 although the
doubling time has not been formally checked. Measured at
passage 110 the line still showed the same DNA content (by
flow microf luorimetry) as PE/01 with only one G]_ peak
observed and approximately 65% of cells in the G]_ phase of
logarithmic cultures. At this time the line also still
showed a Mer+ phenotype with 1.64 units 0^-methylguanine-
DNA methyItransferase/mg protein. This was slightly lower
than the parent PE/01 line (2.77 units) but further work
would be needed to test its significance. The cell volume
at a mean of 1200 +_ 200um^ or cell diameter of 13.1 +
0.7um was the same as PE/01. Drug sensitivity of the cell
line is reported in Chapter 3.
PE/04 - Cis-PtR
At the same time as PE/01, late passage PE/04 (passage 48)
was cultured with cis-platinum as reported above for PE/01
Cis-PtR. While a 500nM cis-platinum dose was reached in
the same time higher resistance was more difficult to
develop in PE/04 than in PE/01. PE/04 was much slower to
become tolerant of the 500nM dose. After 5 months a luM
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dose was attempted (at passage 57) but under these
conditions the cells grew poorly. A second attempt from
an ampoule of cells (passage 57) stored in liquid nitrogen
was also unsuccessful. However a third attempt from
another ampoule proved more successful. After one passage
without drug, 500nM cis-platinum was introduced at passage
59, and lum cis-platinum 7 weeks later at passage 65 and a
subline which tolerated this dose eventually produced. At
passage 75 further passaging was continued in the absence
of drug to see if resistance was maintained.
2.3.2 Other tumour samples and derived cell lines
During this project it became apparent that while
interesting conclusions could arise from the PE/01 and
PE/04 model and its related samples and sub-lines from the
one patient, it would be important to increase the
generality of any such conclusions by testing samples from
other patients either untreated or undergoing various
therapies. I was particularly interested in samples from
patients prior to chemotherapy since not only would these
provide a benchmark for drug sensitivity in vitro, but
there would also be the possibility of obtaining future
samples subsequent to therapy allowing valuable
comparisons to be made. Since ascites fluid needs to be
removed for the comfort and well-being of the patient
concerned liaison with the Oncology ward staff of the
Department enabled these samples to be collected. Many
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such ascites samples were initially stored in liquid
nitrogen after initial centrifugation, washing and removal
of red blood cells and then the most interesting samples
cultured at a later date since this is a time consuming
process in the laboratory. The efforts towards deriving
cell lines was continued. This cell culture work was a
combined effort by various members of the laboratory.
Factors such as keeping a varied cell population in
initial cultures, high cell density and when to passage
cells into larger culture dishes, the use of conditioned
medium from other cell lines or the addition of sterile
filtered ascites fluid, partial or complete replenishment
with fresh medium, differential trypsinisation,
recognition of different cell types and in general how
well a cell culture is looking are all a matter of
experience and everyone in the laboratory contributed to
this. I worked with some of the ascites and also cultured
cells from the only solid tissue biopsy we received as no
one else in the laboratory had experience in culturing
cells from solid biopsies rather than from effusions. The
samples we received and their culture are summarised in
Table 8. Twenty-seven ovarian carcinoma ascites and 3
ascites from patients with adenocarcinomas presumed to be
ovarian have now been received and we have attempted to
culture 17 of these and 11 cell lines have been derived.
Two of these cell lines were not epithelial cells and
curiously turned out to be EBNA positive lymphoblastoid
TABLE 8










PE/01 18.2.82 Feb. 82 Yes CisPt, Chb,
5-FU*
PE/0 2 27.10.82 Oct. 82 No PredM






March 83 Yes As PE/01, and
further courses
of same treatment









PE/0 7 22.3.83 - - Chb, CisPt,
Spirolactone
PE/0 8 5.9.83 - - Chb








PE/011 13.6.84 June 84 No Thiotepa
PE/012 23.10.84 Oct. 84 No Chb
PE/013 6.11.84 Nov. 84 Lympo- Untreated
blastoid
1 ine











PE/015 29.5.85 May 8 5 No Untreated
PE/016 30.5.85 May 8 5 Yes Radiotherapy
TABLE 8 (contd)










(same patient as PE/017)
PE/021 5.9.85
PE/022 11.9.85
PE/023 22.10.85 Oct. 85 Yes
(same patient as PE/014)
PE/024 26.11.85
PE/025 3.12.85





PE/Al 13.9.82 Sept. 82 Yes
PE/A2 14.3.83 June 85 Yes
(same patient as PE/Al)























* CisPt - cisplatinum, Chb - chlorambucil, 5-FU, 5-
fluorouracil, PredM - prednimustine, HMM -
hexamethylmelamine, CTX - cyclophosphamide
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cell lines. PE/014 and PE/023 were derived from the same
patient before and after treatment although the patient
showed no response to her chemotherapy. The cell lines
PE/Al and PE/A2 were similarly derived from ascites before
and after treatment although this patient's cancer was an
adenocarcinoma presumed but not positively identified to
be ovarian. The cell line T/014 which I derived showed
similar cytological characteristics and growth patterns in
vitro to PE/014 derived from ascites from the same patient
at the same time. It was established by mechanical
disaggregation of the biopsy and removal of the fatty
tissue, culture in RPMI 1640 plus 10% foetal calf serum
and with differential trypsinisation to prevent fibroblast
overgrowth of the initial epithelial colonies. In dense
cultures T/014 and PE/014 showed a marked tendency to form
domes above the growth surface which grew into rounded
cysts. Four parallel cell lines and a cell line which
grew as cell clusters in suspension were derived from the
T/014 solid biopsy. Characterisation of various antigenic
phenotypes of these samples and cell lines has been done
by Dr. Francis Hay and Dr. Simon Langdon. Only 2 of the
patients from whom an ascites sample was obtained before
treatment (PE/015 and PE/026) are still alive. Examples
of cell lines PE/01, PE/04, PE/014 and PE/016 in culture
on plastic are shown in figures 12 and 13.
Figure 12 Ovarian Carcinoma cells in Tissue Culture
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2 . 4 Discuss ion
These characterisations are consistent with the published
literature on ovarian carcinoma cell lines as referred to
in chapter 1. Recent studies (A.P. Wilson 1984; I.
Bertoncello et al 1985; R.N. Buick et al 1985; J. Benard
et al 1985) have shown similar cytological and
u11rastructura 1 features and similar results in
establishing and growing ovarian carcinoma cells in vitro.
'PE/01 and PE/04 appear cytologically similar to each other
and to the 2 ascites from which they were derived and do
not show any separate morphologically distinct
subpopulations . The different types of cells observed
would appear to derive from each other depending on
culture conditions in a similar way to that observed by
Whitehead for a breast adenocarcinoma cell line (R.H.
Whitehead et al 1983). More of the differentiated type
cells were observed in initial cultures than in later
passages when growth was more rapid. Features at the
uItrastructura1 level were consistent with the light
microscopy and with other uItrastructural studies of
epithelial ovarian tumours (C.M. Fenoglio, 1980).
The cytogenetic analysis for PE/01 and PE/04 gives some
indication of the relationship between the 2 cell lines
and their possible evolution. The cell lines have several
rearranged chromosomes in common and some distinct
differences particularly normal chromosomes 8 and 17 in
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PE/04 but not PE/01, suggestive of a common ancestor with
subsequent divergence but not lineal descent from PE/01 to
PE/04. The DNA content of both cell lines was slightly
greater than that of a normal human cell suggesting that
within the hypodiploid karyotype are rearrangements
incorporating additional DNA. Only one near diploid peak
of DNA was observed by flow microf luorimetry in late
passage cells of PE/01, PE/04 and the resistant subline
PE/01 CisPtR suggesting there had not been the changes
towards higher aneuploidy during culturing observed by
others (C. van Haaften-Day et al 1983). If the cell lines
are representative of the ascites from which they were
derived this analysis would support the notion of a pre¬
existing drug resistant sub-population (represented by
PE/04) which is simply selected by treatment. Buick and
his colleagues have described antigenic, growth and
karyotypic variations in 5 cell lines. Two of these cell
lines were from the one patient from two ascites 9 months
apart that were karyotypically similar. The first cell
line was karyotypically different but remained stable in
culture while the second line represented a karyotypically
minor population in the ascites but showed marked changes
in culture (J.M. Trent et al 1985). Horowitz has shown
selection for particular cells (carcinoembryonic antigen
positive) in primary culture (A.T. Horowitz et al 1985).
Both Benard and Wilson have studied features at different
culture passages without noticing significant
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morphological or cytogenetic changes, although Wilson
noted some changes in chemosensitivity. Bertoncello
noticed varying CFE amongst clones from the same and
different tumours and some variation within the basic
karyotype of a family of clones. Clearly conclusions
about a patient's tumour drawn from an analysis of derived
cell lines can only be tentative but the results for PE/01
and PE/04 suggest a heterogeneous tumour.
PE/04 is a little more robust in culture than PE/01 with
more prolific primary cultures and a higher colony forming
efficiency at low cell density at all passages but cell
doubling time and bulk culture in flasks were similar. It
is difficult to know why the CFE for late passage PE/04
but not PE/0 1 should be higher in soft agar than on
plastic growth surfaces. Presumably more work to optimise
the growth conditions in either case could improve the
CFE. Perhaps the low oxygen tension is a factor or it may
be that PE/04 is more prone to growth in suspension than
PE/01 as evidenced by the establishment of a suspension
culture cell line from its ascites in addition to the
monolayer cell line used above.
The PE/01 CisPtR resistant subline was derived with
comparative ease. Whether the difficulty in producing the
PE/04 Cis-PtR resistant subline was simply due to
laboratory mistakes (e.g. wrong dilution of the cis-
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platinum) or caused by some innate property of the PE/04
cell line is not completely clear. However it is tempting
to suggest that PE/04, being already more resistant to
cis-platinum than PE/01 (see chapter 3), found it more
difficult to produce further resistance. Certainly the
mechanisms of resistance of the various lines will prove
interesting. With both cell lines were stopped at luM
cis-platinum since the LD50s of the parent lines were
0.08uM and 0.2uM cis-platinum for PE/01 and PE/04
respectively (data in chapter 3) and thus sub-lines which
grew in luM cis-platinum must be significantly resistant.
Other features of PE/01 and PE/04 such as their
antigenicity were fully consistent with cells from an
epithelial ovarian adenocarcinoma. The most interesting
antigens were those showing differences between the 2 cell
lines (placental alkaline phosphatase and vimentin) and
these differences could potentially be useful in
distinguishing the lines from each other in experiments
where they were mixed together. Later work by Dr. Francis
Hay and Dr. Simon Langdon has extended the range of
antibodies tested on these lines and other ovarian ascites
samples and cell lines in this laboratory. One difference
in their work was a low level of antibody staining with
vimentin in both PE/01 and PE/04, although vimentin
content can change with culture conditions (N.D. Connell
et al, 1983).
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The oestrogen receptor levels in PE/01 and PE/04 are very
high compared with those usually observed in ovarian
carcinomas (M. Lantta 1984 ; J.S. Lazo et al 1984) or in
the only other ovarian cell line reported (T.C. Hamilton
et al 1983b). The relative proportions of oestrogen and
progestogen receptors reported were variable but included
oestrogen receptor positive/progestogen receptor negative
tumours. It has also been shown that oestrogen
(specifically excluded in the protocol here) can induce
the production of progesterone receptors (P.G.
Satyaswaroop et al 1983 ; T.C. Hamilton et al, 1984b) and
it may be that hormone influences are important in the
PE/01 and PE/04 cell lines.
In cell lines derived from other human tumours other
authors have noted stable characteristics of cell lines
over long periods in culture (W. Tilgen et al 1983 ) and
also that consistent features of the parent tumour are
present (K.M. Tveit 1981a). Various morphological
features in cell lines from different carcinomas are also
common to the cell lines described here and include not
only the characteristic shape of epithelial cells but also
cells full of lipid as in breast cancer cells (P.S.
Rudland et al 1985) or the formation of domes and cysts as
in colon adenocarcinoma (S.C. Kirkland 1985). Further
characterisation of the various ascites samples and cell
lines of ovarian carcinomas is continuing in this
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laboratory. This project concentrated on PE/01 and PE/04
and these 2 cell lines were compared for more specific
features related to drug metabolism and sensitivity as
described in the succeeding chapters.
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3. PE/Q1,PE/O 4 AND RELATED CELL LINES - SENSITIVITY TO
ANTINEOPLASTIC DRUGS
In this chapter data on drug sensitivity testing in the
cell lines PE/01, PE/04, PE/01 CisPtR and preliminary data
for PE/04 CisPtR and PE/06 are described. Unless
otherwise indicated assays have been done at the later
passages, 77-82 for PE/01 and 46-51 for PE/04. Initial
work concentrated on the drugs used clinically viz
cisplatinum, 5-fluorouracil and chlorambucil. Later wcrk
tested ether drugs for cross-resistance.
Two different assays have been used. When I joined the
Unit a Courtenay assay (see below) had been set up but
difficulty was being experienced in obtaining consistent
results due to various technical problems with the assay.
Since the data were preliminary and it was imperative to
be sure what differences in drug sensitivity there were
between PE/01 and PE/04 and how large these differences
might be, I set about establishing a new assay which might
be less troublesome, but still reliably measure clonogenic
cell survival. With cell lines it is not necessary to use
agar to inhibit the growth of the fibroblasts found in
primary samples. Colony forming efficiency is also
usually higher. Therefore assays where cells are plated
directly cnto a plastic growth surface are commonly used
with cell lines (E.T. Hill, 1983) and I had previous
experience with such an assay (P.G. Parsons et al, 1982).
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The ovarian cell lines here all formed discrete colonies
on plastic which could be counted by microscope and so the
clonogenic assay on plastic (see below) later became the
routine drug sensitivity assay in this laboratory. The




The protocol of Courtenay (V.D. Courtenay and J. Mills,
1978; V.D. Courtenay et al, 1978) was followed in detail.
This assay was preferred to that of Hamburger and Salmon
(A. W. Hamburger and S.E. Salmon, 1977 ) since it shows
higher colony forming efficiences (K.M. Tveit et al,
1981) .
Cells in logarithmic growth were harvested by
trypsinisation, resuspended in Hams F12 medium + 10%
foetal calf serum (Gibco),"' and a single cell suspension
obtained by vigorous pipetting or passing through a 19
gauge needle. Cell counts, clumping and viability were
assessed by counting nigrosin (Sigma) stained cells in a
haemocy tome ter. Cells were suspended at 5x the final
concentration required (5 x 10^ and 10^ cells final
concentration for PE/01 and PE/04 respectively). Red
blood cells were obtained from anaesthetised August rats
by cardiac puncture with a heparinised syringe, the buffy
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coat removed by centrifugation, the cells washed in
phosphate buffered saline and made up to the original
volume in Hams F12 medium + 10% foetal calf serum. 5%
agar (Agar Noble, Difco Laboratories) in water was
prepared by autoclaving, cooled to 44°C and diluted to
0.5% with medium prewarmed to 37°C. 3.6mls of this agar
was added to a mixture of 1.2mls of the 5x cell
suspension, 0.6mls of a 1 in 8 dilution of the August rat
red blood cells (less than 3 weeks old stored at 4°C) and
0.6mls of drug in medium at lOx final concentration. 1ml
aliquots were pipetted into 5 replicate tubes (Falcon
2051) and the tubes placed in crushed ice to set the agar.
Each tube was then gassed for 20 seconds with the sterile
filtered gas mixture (5% O2, 5% CO2, 90% N2), placed
upright in a plastic box and then the box gassed, sealed
and placed in an incubator at 37°C. Later in this project
when an incubator with this gas mixture was obtained
(Hereaus, model B5060 EK/O2) this gassing step could be
omitted. After a week 1ml of medium was added to the
tubes and again thereafter at weekly intervals, the tubes
being regassed on each occasion. When colony size was
greater than approximately 50 cells, usually 21 days, the
agar plug was removed onto a petri dish lid. The grided
bottom of the petri dish was used to flatten out the agar
and assist visual counting of colonies at 40x
magnification using a Leitz Diavert inverted microscope.
Clonogenic survival was measured as the percentage of
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control after counting colony numbers in drug treated and
control untreated tubes. Any variation from this
procedure is discussed with the particular experiment
involved.
3.1.2 Clonogenic assay on plastic
Cells were plated out in 6 well plates (Linbro, Flow
Laboratories) in 2mls medium (RPMI 1640 plus 10% foetal
calf serum with added insulin (2.5ug/ml), sodium pyruvate
(ImM), antibiotics streptomycin (lOOug/ml) and penicillin
(100 IU/ml) and buffered with up to 12.5mM MOPS) at a cell
density to give approximately 100-200 colonies per well
(PE/01 2-3 x 103/ml, PE/04 103ml, PE/01 CisPtR 0.5-3 x
103/ml) taking care to have a single cell suspension.
Incubation was at 37°C in a 5% COg, high humidity
incubator (Vindon Scientific Ltd). The next day 1ml extra
medium was added. The medium was changed on the third day
and drugs were added in fresh medium to wells in
triplicate. The cells had attached to the plastic growth
surface but not divided at this stage. Three days later
the medium with drug was removed and replaced with fresh
medium which was changed every 2 to 3 days thereafter.
Colonies of 50 cells or more were counted (by eye at 40x
magnification) 10 to 12 days after addition of the drug
and then pulsed with luCi/ml [ methyl-3H ]-thymidine
(Amersham) for 3-5 hours before being harvested by
trypsinisation and washed on to glass fibre filters (GF/A,
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Whatman) with 5% trichloroacetic acid. These filters were
then dried and counted on a Packard Tri-Carb 4000 liquid
scintillation counter with Unisclve E (Koch-Light Ltd) as
the scintillant. Counts were expressed as a percentage of
control untreated wells and dose response curves drawn on
semi-log plots.
Counting colonies by eye and by a []-thymidine pulse at
the same time to measure dose response shewed good
agreement (see results below). The []-thymidine pulse
and measurement of label incorporated into TCA
precipitable material (i.e. DNA) should be a relative
measure of the number of growing cells per well and hence
the colony number when dene when cells have had time to
fully recover after drug treatment. In later experiments
only 1 well per triplicate (usually the central wells of a
6 well plate) was counted visually to check that the
radiolabe11ing method did not give artifactual results in
any particular experiment.
Early experiments used Sterilin 6 well plates (Sterilin,
U.K.) but some variation in CFE between wells and the
occasional well where cells did not attach led us to check
plates of other suppliers. Nunc 6 well plates (Nunc,
Gibco Ltd) gave poorer CFE perhaps due to the greater
depth of the wells in the plates. Both Linbro plates
(Linbro, Flow Laboratories) and Falcon plates (Becton
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Dickinson and Cc.) gave gocd results. Most experiments
were done using the Linbro 6 well plates.
3.1.3 Antineoplastic drugs used
Mcst drugs were obtained from the same sources as used by
the clinical staff in the Department and made up as per
the manufacturers instructions before diluting in medium.
Cisplatinum was from Farmitalia Carlo Erba Ltd (with
sodium chloride and mannitol) and the powder was
reconstituted with water to a concentration of 5mM.
Aliquots of this stock were kept frozen at -20°C. 5-
fluorouracil was from Roche Prcducts Ltd. in saline at
25mg/ml. Chlorambucil and melphalan were from Sigma
Chemical Co. Ltd. and were dissolved in dimethylsulphoxide
(lOmM) or in 0. IN HC1 (lOmg/ml) respectively immediately
before use. Some melphalan (as "Alkeran") was also
obtained from the Wellcome Foundation. The platinum
analogues CBDCA and CHIP were a kind gift from Dr. M.
Jones and Professor K.R. Harrap of the Institute of Cancer
Research, Sutton and were dissolved in saline (Dulbeccc's
phosphate buffered saline) at 5mM concentration and
aliquots frozen as a stock solution. JM40 was from
Bristol-Myers Pharmaceuticals as a solution at 5mg/ml and
was also diluted in saline to 5mM and aliquots frozen.
Doxorubicin was from Farmitalia Carlo Erba Ltd
( "adriamycin" with lactose) and was dissolved in water at
1 OmM and aliquots of this stock solution frozen.
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Vincristine (as "cncovin" with lactose) from Eli Lilly and
Co. Ltd. was dissolved in saline to ImM and aliquots
frozen. Mitozantrcne was from Lederle Laboratories as a
2mg/ir l solution ( "Novantrone" ) . Prednimustine, a gift
from Aktiebclaget Leo, (Helsingborg, Sweden) was dissolved
at lOmM in DMSO and used immediately. Experiments using
X-rays were done using a Siemens Stabilipan 2 X-ray set
with a Farmer dosimeter type 2570 (Nuclear Enterprises
Ltd) at a dose rate of approximately 35 rads/minute.
3 . 2 Results of assessment of assay conditions
3.2.1 Courtenay assay
It was decided to continue with this assay for two
reasons. Firstly the preliminary data was suggestive of
seme differences in drug sensitivity between the twe cell
lines PE/01 and PE/04 and it was clearly important to
obtain firm data to follow this up. Also this data could
then be compared with that of other authors since agar
clonogenic assays have come to be regarded as the bench
mark for ether drug sensitivity assays and are widely used
(P.P. Dendy et al, 1983). Secondly as this project
develcped it was hoped to check back to the drug
sensitivity of ascites samples where an agar assay would
be necessary to exclude fibroblast growth and Courtenay
had shewn good growth of tumour cells from ovarian ascites
(V.D. Courtenay et al, 1978).
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Before I joined the Unit experiments using PE/01 at from
10^ up to 10^ cells per ml showed CFE varying from 0-8.4%
with the highest CFE obtained at 10^ cells/ml giving
thousands of colonies. 10^ cells/ml gave high CFE on 3
occasions (7.0, 1.5 and 8.4% CFE respectively) but only
0.1% CFE on a 4th occasion. At passage numbers between 9
and 45 using between 1 and 5 x 104 cells/ml CFE was 0.11 +
0.08% (mean + standard deviation of 6 experiments) giving
too few colonies for accurate dose response data. This
variation cculd possibly be due to variation in the growth
potential of PE/01 at various times, or to different
batches of foetal calf serum or rat red bleed cells. In
addition seme problems with contamination had been
experienced thought to be due to contaminated rat red
blood cell preparations.
After I joined the Unit a concerted effort was made to
clear up these problems. Colony forming efficiency of
different passages was checked in one experiment (at the
same time in the same medium) as shown in Table 9 and
appeared to be improved at late passage in both cell lines
(See also Table 6 in chapter 2 which shows data cn
different passages of these cell lines from an experiment
done much later in this project when the assay appeared to
be working better). Over all the experiments on the late
passage cells using 10^ up to 5 x 10^ cells/ml (PE/01
usually 5 x 10^ cells/ml and PE/04 usually 10^ cells/ml)
TABLE 9
COLONY FORMING EFFICIENCY IN AGAR AT DIFFERENT PASSAGES
PE/01 PE/04
ce11 nc. eel 1 no.
in agar CFE in agar CFE
Fassage medium (% ) Passage medium (%)




105 0 .007 5 X 0.75
30 103 0 .02 2 6 5 X 102 7 . 4
1C4 0.018 103 6 . 3
105 0 . 0 8 7 5 X 103 4 . 4
78 103 0 . 6 48 103 8.9
104 1.2 5 X 103 11.4
105 3.3
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CFE were 3.9 _+ 2.5% and 18.3 + 10.4% fcr PE/01 and PE/04
respectively (see alsc my ccmments on CFE in chapter 2).
To overcome the contamination problem we tested the use of
rat red blcod cell lysate which could be filter sterilised
instead of whole red blood cells, as a cell lysate had
also been used in the original work using erythrocytes to
enhance colcny growth (I. Bertoncello et al, 1977) and has
been used by others in agar clonogenic assays (J.W.
Sheridan et al, 1981). However this appeared to give
reduced colony forming efficiency with our cell lines and
the use of whole rat red blood cells was continued with
extra care taken to obtain the blcod sterilely (shave
thorax of rat, spray with methylated spirits, only one
attempt to withdraw blood, and the procedure done in a
laminar floow hood). Courtenay has reported that lysis of
the rat red blcod cells occurs after about 5 days in the
agar culture and this timing is important to the protocol,
with August rat red blcod cells giving superior results to
either cell lysate or cells from Wistar or Marshall rats
which did not lyse in the first week of the agar culture
(V.D. Courtenay and J. Mills, 1978).
Cell density appeared not to affect the results as similar
drug survival curves were obtained with as low as 20 or as
high as 4000 colonies in controls. However experiments
with very low or very high colony numbers like this were
usually excluded from the drug sensitivity analysis since
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the accuracy of the percentage survival figures obtained
from such experiments is always more doubtful. In most
experiments I aimed for approximately 200 colonies in
controls. Meyskens has described the importance of cell
number plated in the Hamburger/Salmon assay and its
effects on drug sensitivity assays (F.L. Meyskens et al,
1983). This may be less important in the Courtenay assay
where the medium, is replenished during the assay. For
PE/04 colony forming efficiency (CFE) was fairly constant
down to low cell density but there was a drop off in CFE
at low cell numbers with PE/01 but this did not affect the
drug survival assay results which are reported as
percentage of control.
3.2.2 Clonogenic assay on plastic
Initial experiments to check colony forming efficiency and
growth in 35mm wells of 6 well plates are described in
chapter 2. Two other parameters were important. Firstly
the []-thymidine incorporation procedure, designed to
reduce time spent in manual counting at a microscope,
needed to correlate well with the colony counts by eye.
It might also reduce the time of the assay. Secondly any
possible effects cf cell density needed tc be determined
since it was apparent that at low cell density the colony
forming efficiency could increase with cell number.
Three sets of 6 well plates of each cell line were set up,
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1 plated at high cell density (6 x 10^ cells and 3 x 10^
cells/well for PE/01 and PE/04 respectively) and 2 at lew
cell density (10^ cells and 3 x 10-3 cells for PE/01 and
PE/04 respectively). Various doses of cisplatinum were
added on day 3 and left on for 2 days before being reir.eved
and replaced with fresh medium. Six days after the drug
treatment the control wells of the high cell density
plates started to become crowded with cells and these
plates were pulsed with []-thymidine while still in
logarithmic phase together with 1 set of the low cell
density plates. When colonies of 50 cells or more had
grown up in the other set of low cell density plates
(after 15 days) the colonies were counted by eye and then
pulsed with []-thymidine. The results are shown in
Figures 14 and 15. The colony counts and [ ]-thymidine
pulse after 15 days correlate well. The correlation of
the [ 3H ]-thymid ine pulse after 6 days with the 15 day
results was not as good particularly at the high drug
doses but little difference between the low cell and high
cell density plates at this time could be observed. This
tendency towards resistance at shorter times appeared even
greater in 2 preliminary experiments pulsed at 4, 5 and 7
days and I therefore kept the assay with the [3H]-
thymidine pulse done at the time when colonies would
normally be counted visually. In all later experiments
the correlation at this time between colony counting and
[3h]-thymidine pulse was very good.
Figure 14 Timing of L%1 -thymidine pulse in Clonogenic Assay
PE/01
Colony count at 15 days • •
-pulse at 15 days 0 O
\%l-pulse at 6 days S———41
[%1-pulse at 6 days □ "0
(cells at high cell density)
% Survival
Dose Low cell density High cell density
(uM) Colony count [?h1 pulse L3H^\ pulse [%1 pulse
15 days 15 days 6 days 6 days
0.06 72.1 + 20.2(a> 83.3 t 26.5 51.2 t 17.4 126.5 ± 20.7
0.1 30.2 t 13.6 30.3 t 13.1 29.6 t 9.7 79.4 ± 11.4
0.2 19.8 ± 6.2 16.8 + 5A 33.7 ± 10.3 40.3 t 6.4
0.6 0(b) ?l.l(c) 9.0 ± 2.6 8.8 t 2.2
1.5 0 ?i.o(c) 3.4 t 1.1 1.7 t 0.2
(a) standard error of the mean from triplicates
(b) no colonies in all 3 wells. If there was 1 colony per 3 wells
then %survival would be 0.4% which therefore represents the
limit of sensitivity of the assay
(c) 155-191 cpm against background thought to be 100 cpm
ie may be simply a background reading since background was
calculated from a well with j-thymidine but without cells
ever being in the well.
CisPlatinum conc. (uM)
Figure 15 Timing of L3Hl-thymidine pulse in Clonogenic Assay
PE/04
Colony count at 15 days • •
Ph] -pulse at 15 days 0— *0
^%~]-pulse at 6 days W1 ®
i?H~\-pulse at 6 days D— O
(cells at high cell density)
% Survival
Dose Low cell density High cell density
(uM) Colony count pulse [3H~\ pulse [_3h"\ pulse
15 days 15 days 6 days 6 days
0.06 96.6 + 29.9(a) -(b> 63.0 ± 14.9 112.9 + 11.4
0.1 50.0 t 23.4 31.4 ± 20.3 130.3 ± 41.5 102.2 t 9.5
0.2 51.0 t 19.1 36.6 ± 19.4 56.7 ± 19.9 68.3 + 6.8
0.6 14.6 t 7.6 14.3 t 9.6 11.7 ± 3.5 31.8 + 4.0
1.5 0(°) ?1.2(d) 3.8 t 0.8 2.5 t q.5
(a) standard error of the mean from triplicates
(b) cells lost during harvesting
(c) as in figure 14, limit of sensitivity approximately 0.4%
(d) 140-169 cpm against background thought to be 100 cpm
ie may be simply a background reading
0.1 0.5 1.0 1.5
(JisPiatmum conc. (uM)
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Cell density did not apparently affect the drug assay
results. In the normal assay where I aimed for 100-200
colonies in untreated wells, a number of assays by chance
gave greater or less than these colony numbers. These
were not discarded unless there were too many colonies to
count or too few to give an indication of dose response.
Different assays gave the same result across a 10-fold
range in colony numbers per well in control wells (i.e.
approximately 50-500 control colonies counted).
Apparently after the cells have attached as single cells
to the growth surface a subsequent reduction in their
density does not affect their colony forming efficiency.
3.3 In vitro sensitivity of drugs used clinically
3.3.1 Cisplatinum
Courtenay assay
Combined results from 2 experiments for PE/01 and 6
experiments for PE/04 are shown in Figure 16. Other
experiments with PE/01 were consistent with these results
but showed fewer than 30 colonies in control tubes or in
one instance greater than 4000 colcnies in controls.
PE/01 is approximately 3 times more sensitive to
cisplatinum then PE/04. No variation with passage number
was observed.
Clonogenic assay on plastic
Combined results from 8 experiments for PE/01 and 5
Figure 16 CisPlatinum Sensitivity - Courtenay assay
PE/01 * *
PE/04 •
Experiments at passage 53 and 79 for PE/01 and
7,19,26,33,49 and 50 for PE/04.
Dosd % Survival^3)
(uM) PE/01 PE/04
0.0l(c) 87.5 t 7.2(l)(b) 80.1 ± 12.9(4)
0.02 74.4 t 6.6(1) 85.4 1 7.7 (2)
0.1 46.1 1 3.2(2) 76.2 + 10.7(6)
0.5 7.4 t 5.8(2) 21.8+ 8.3 (5)
1.0 0.391 0.06(1) 7.9 1 4.2 (4)
2.0 0.021 0.02(2) 0.381 0.24(5)
(a) % survival indicates colony number in drug treated tubes as a
percentage of colony number in control tubes.
(b) Standard error of the mean is shown. Number of experiments from
which the mean and standard error were calculated is shown in
brackets. Where the mean from one experiment is shown the
standard error is calculated from 5 replicates.
(c) Dose of cisplatinum was left on for the duration of the assay
Cisplatinum conc. (uM)
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experiments for PE/04 are shown in Figure 17. Also shown
are the combined results from 6 experiments with the PE/01
CisPtR line. Figure 18 shows there was no difference
between PE/01 CisFtR at passage 109, (4 experiments),
grown in luM cisplatinum before testing, and at passages
120-122 (2 experiments), grown without cisplatinum for
approximately 3 months since passage 108. PE/01 is
approximately 3 times more sensitive to cisplatinum than
PE/04, as in the Courtenay assay above, and the PE/01
CisPtR 1 ine is some 25-fold more resistant than its parent
1 ine.
Some experiments were also done using 1 hour or 6 hour
exposures of cisplatinum since a decrease in toxicity with
these shorter exposure times has been observed with this
drug (H.T. Rupniak et al , 1983a). One experiment with 1
and 6 hour exposures in the Courtenay assay did show-
increased resistance with these shcrter exposures.
However the extra manipulations involved could lead to
increased variability due to extra dilutions and the
additional procedure of holding cells in suspension,
whereas various exposure times are simply achieved in the
plastic assay as the drug can be easily removed from the
cells attached to the growth surface of a culture well.
Therefore ether assays were done by this latter method.
Figure 19 shows results from 4 experiments for a 1 hour
exposure to cisplatinum. The difference in sensitivity of




PE/01 CisPtR 0 ' ■O
(Dose of Cisplatinura left on for 3 days)
Dose % Survival
(uM) PE/01 PE/04 PE/01 CisPtR
0.02 78.6 t 6.1 (5)(a)
(77.2)(b)
0.06 67.5 t 10.8(6) 60.7 ± 1.9(2)
(65.4) (116.8)
0.1 39.2 ± 11.2(7) 56.7 t 9.0(4)
(50.0) (70.3)
0.2 17.8 + 5.8 (7) 55.3 + 8.1(4)
(16.7) (55.1)
0.6 2.4 t 1.0 (7) 18.8 + 4.6(4) 99.5 + 11.4(5)
(0.9) (14.1) (132.6)
1.0 - 6.2 t 1.1(3) 93.1 t 10.8(6)
(2.4) (104.1)
1.5 - 1.1 t 0.2(2)
(0)
2.0 - - 31.6 ± 2.9 (5)
(58.0)
4.0 - - 5.0 + 1.6 (5)
(6.0)
6.0 - - 0.6 t 0.4 (5)
(0.7)
(a) results using the Hj-thymidine method for calculating
survival after drug exposure are shown. The number of
experiments from which mean + standard error were calculated
is shown in brackets.
(b) calculated mean from results where colonies were counted
visually is shown in brackets (usually only 1 well per
triplicate counted).
Cis-Platinum conc. (uM)
Figure 18 PE/01 CisPtR - passaged without drug in medium
CisPlatinum Sensitivity
PE/01 CisPtR passage 109 x K
PE/01 CisPtR passages 120-122 •—






o.6 97.8 + 16.1
(111.1)
(3) 102.0 + 22.5 (2)




















(a) notes as in figure 17
Cisplatinum cone (uM)





0.2 98.7 ± 21.5 (4)
(99.4)
0.6 77.0 + 21.9 (4) 86.5 + 6.3 (3)
(76.3) (98.4)
1.5 43.0 1 24.0 (2) 64.1 + 7.9 (3)
(35.8) (62.5)
3.0 18.5 t 10.8 (2) 54.9 ± 16.2(2)
(22.0) (56.1)
6.0 2.9 + 2.5 (2) 27.0 ± 14.7(2)
(5.3) (24.0)
10.0 - 8.1 t 5.0 (2)
(10.3)
(a) notes as in figure 17
I 1 I <—
1.5 3 6 10
Cisplatinum conc. (uM)
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PE/01 and PE/04 remained the same. Some variation between
experiments was observed but within any one experiment
done at the same time with the same batch of drug the
ratio of PE/04 to PE/01 sensitivity remained constant.
This variation between experiments (as also noted by B.T.
Hill et al, 1984) may have been due to the speed in which
the drug diluted into medium was added to the cell
cultures, particularly in a large experiment where 1 hour,
6 hour and 3 day exposures on both cell lines were
attempted together. That experiment is shown in Figure 20
where the effect of increasing exposure time can be
observed. For PE/01 the survivals were 119.6%, 47.6% and
7.5% for 1 hour, 6 hour and 3 day exposures of 0. 6uM
cisplatinum compared with 44.1%, 5.4% and 0.1% in a
smaller experiment. The result for PE/04 at 1.5uM
cisplatinum was 79.2%, 41.4%, 0.4% compared with 37.6%,
0.3% and 0% in a small expcriment.
The possible effects of cisplatinum decomposition on the
cell survival experiments have not been pursued further in
this project and in all experiments cisplatinum solutions
were made up from frozen stock solutions in saline at
-2G°C and used immediately.
3.3.2 Chlorambuci1
Courtenay assay
Combined results from 5 experiments with each cell line
Figure 20 CisPlatinum Sensitivity - Time schedule of dose
PE/01 • 3 day dose, ■ 6 hour dose, ♦ 1 hour dose
PE/04 O 3 day dose, a 6 hour dose, ^ 1 hour dose
Cisplatinum Dose (uM)
0.02 0.06 0.1 0.2 0.6 1.5
PE/01
1 hour dose 125.4 112.4 78.6 151.5 119.6 -
6 hour dose 135.7 137.0 71.7 94.6 47.6 -
3 day dose 154.0 278.6? 120.4 96.3 7.5 -
PE/04
1 hour dose - 105.3 141.9 100.8 90.1 79.2
6 hour dose - 90.5 70.7 62.5 67.7 41.4
3 day dose - 88.9 136.1 84.9 32.6 0.4
(Survival was calculated by the L Hi-thymidine pulse method.
Visual colony counts for the highest 2 doses for each cell line
were in good agreement.)
I » 1
0.1 0.5 1.0 1.5
Cisplatinum conc. (uM)
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are shown in Figure 21. While in each experiment the dose
response curve for survival of PE/04 was higher than PE/01
any difference can be seen to be minimal at approximately
1.3-fold. Four experiments on the 2 lines were done at
the same time and a paired t-test on the slopes of the
dose response lines showed no significant difference
although on the LD50S the difference was significant at
the 5% level. The LD50S were approximately 1.5uM and 2uM
for PE/01 and PE/04 respectively.
Clonogenic assay on plastic
It was immediately apparent that PE/04 was more resistant
to chlorambucil than PE/01 in this assay unlike the
results in the Courtenay assay above. The combined
results of 3 experiments for PE/01 and 4 experiments for
PE/04 are shown in Figure 22. Also shown are the results
from 7 experiments with the PE/01 CisPtR line. A 3-fold
difference in sensitivity was observed with LD50S of 0.83
and 2.8uM chlorambucil for PE/01 and PE/04 respectively.
PE/01 CisPtR was only 4 times more resistant than its
parent line, similar to the sensitivity of PE/04.
Later in this project when a 5% Og incubator was
available, this assay was repeated in 5% Cg to mimic the
gas conditions in the Courtenay assay and a reduced
difference between the 2 cell lines PE/01 and PE/04 was
observed. Results from 1 experiment where duplicate





0.1 44.4 ± 8.5 (l)Cb) 112.9 + 37.2 (2)
0.2 76.7 + 14.1(2) 65.0 + 0.3 (2)
0.5 49.2 + 10.5(l)(b) 82.1 + 16.9 (2)
0.7 67.6 t 13.3(2) 70.4 + 3.0 (2)
1.0 70.3 t 12.2(3) 92.4 + 8.6 (2)
2.0 37.5 t 6.3 (3) 47.6 + 6.4 (4)
5.0 10.7 t 4.1 (5) 19.0 + 5.5 (5)
8.0 0.2 + 0.2 (1) 1.0 + 0.5 (1)
20.0 +
i
COo•o CNCOo•© 1.1 + 0.8 (1)
(a) notes as in figure 16
(b) from experiment with only 25 colonies in control tubes but









PE/01 CisPtR 0 Q
Dose % Survival
(uM) PE/Ol(a) PE/04(a> PE/01 CisPtR(b)
0.3 87.4 + 16.1(3) 99.5 ± 13.6(3) 102.4 ± 14.5(2)
(75.4) (111.6) (99.5)
0.4 - 87.9 (1)
0.8 51.9 t 11.0(2) 93.2 t 5.5 (3) 96.2 ± 4.5 (2)
(38.1) (93.7) (99.9)
1.0 46.6 (1) 87.5 (1) 110.0 + 6.2 (3)
(107.4)
1.5 21.7 ± 6.4 (2) 88.0 ± 16.3(2) 83.1 + 6.7 (2)
(16.1) (105.5) (79.4)
2.0 15.6 (1) 73.8 t 40.5(2) 90.2 1 6.9 (4)
(70.2)
3.0 2.9 t 2.3 (2) 45.5 ± 13.7(2) 55.7 ± 6.6 (7)
(3.6) (50.8) (51.6)
5.0 0.24 (1) 13.6 + 9.7 (2) 32.9 ± 8.5 (4)
(33.4)
6.0 0 (2) 8.7 t 2.3 (2)
(0.96) (9.7)
8.0 - - 7.1 t 2-3 (7)
(8.4)
10.0 0 (1) 0.8 (1)
15.0 - - 0 (1)
(a) results shown are those using the visual colony count since the
^.3jf|-thymidine pulse method was not used in some of the earlier
experiments. The number of experiments is shown in brackets with
the bracket underneath showing the result using the [.^H^-thymidine
method.
(b) results using the visual colony count method are shown and graphed
to compare with PE/01 and PE/04 although allwells of triplicates
were not always counted. Results using the C^Hl-thymidine pulse
method are shown underneath in brackets.
Chlorambucil conc. (uM)
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plates were incubated in 5%CC>2/air or 5%C>2/5%CC>2/90%N2 are
shown in Figure 23. The combined results of 2 experiments
at 5%C>2 are shown in Figure 24. The difference between
the 2 cell lines was only about 1.5 fold with LD5 Qs °f
2.8uM and 4.3uM for PE/01 and PE/04 respectively.
3.3.3 5-fluorouracil
Courtenay assay
The results using 5-fluorouracil were quite variable
between experiments with no cell survival at O.luM for
both cell lines in one experiment and little toxicity up
to 2uM in another. One experiment between these extremes
where a dose response was obtained is shown in Figure 25.
However in any one experiment when both cell lines were
assayed at the same time no difference in sensitivity
between them was observed (in 4 experiments). LD50S were
luM or lower in all but one experiment.
Clonogenic assay on plastic
Variability between experiments was again noticeable
although not to such an extreme extent as that observed
above. No significant difference between the two cell
lines was noticed when they were tested together (4
experiments - if anything PE/04 was slightly more
sensitive in 2 experiments and slightly less sensitive in
1 experiment). LD50 values were approximately 6uM for
PE/01 and 4uM for PE/04 (taking the average from 4
Figure 23 Chlorambucil Sensitivity at 5% vs 20% Oxygen tension
PE/01 % 20% 02, *5% 02
PE/04 o 20% 02, D 5% 02
Results from 1 experiment. Each point is the mean of triplicates.
Standard error bars omitted for clarity.
Chlorambucil conc. (uM)












93.6 + 12.4 99.7 ± 3.7
(89.4) (99.9)
86.5 ± 1.8 90.9 j; 3.6
(82.4) (86.1)
81.7 t 9.7 82.0 t 1.3
(74.3) 63.7)
46.8 t 5.4 69.8 + 9.1
(44.8) (56.9)
7.5 + 2.2 33.9 + 2.1
(5.6) (28.9)
(a) results combined from 2 experiments,








Figure 25 5-fluorouracil Sensitivity - Courtenay assay
PE/01 * *
PE/04 « %
5-fluorouracil dose left on for duration of the assay.
The results of one experiment are shown since variations
between experiments were observed. Mean and standard error
of 5 replicates are shown.
k
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experiments for PE/01 and 5 experiments for PE/04). The
LD50 figure in different experiments varied between 2uM
and 12uM and can also vary depending on the method of
estimation. One fairly representative experiment is shown
in Figure 26.
3.3.4 Drug sensitivity of early passage PE/01 and PE/04
cultures
As shown above (Figure 16) no variation in sensitivity to
cisplatinum with passage in culture was observed for PE/04
with the Courtenay assay. Recently this assay has been
further used to check sensitivity at low passage numbers
in PE/01 and PE/04 to all 3 of the clinically used drugs.
1-3 x 10^ and 5 x 10^ cells were needed for PE/01 and
PE/04 respectively due to the lower colony forming
efficiency at early passages. Essentially the same
results as at higher passages have been obtained at
passages 6 and 12 for PE/01 and passages 2 and 11 for
PE/04 in initial experiments and this work is continuing
in this laboratory. One initial experiment with
cisplatinum has also been attempted so far with the PE/04
ascites previously frozen in liquid nitrogen with
comparable results to the cell line.
3.4 Cross-resistance to other drugs (PE/01, PE/04 and
PE/01 CisPtR lines)
Other drugs were tested in the cell lines PE/01, PE/04 and




(dose of 5-fluorouracil left on for 3 days)
The results of one experiment are shown since variations
between experiments were observed. Mean and standard of
triplicates in this experiment are shown.
5-fluorouracil conc. (uM)
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PE/01 CisPtR to see what patterns of cross-resistance or
collateral sensitivity might be present. The relative
sensitivities of the lines could give important clues to
what mechanisms of resistance might be operating. The
platinum analogues CBDCA, CHIP and JM-40 were tested to
compare with cisplatinum. Another classical alkylating
agent, melphalan, was tested to compare with chlorambucil
and also with cisplatinum since resistance to melphalan
and cisplatinum in vitro has cften been associated (T.C.
Hamilton et al, 1985). Doxorubicin and vincristine were
tested as representatives of other major classes of
antineoplastic drugs and the sensitivity to x-irradiation
was also tested. The newer drugs mitozantrone ,A anthracene
dione, and prednimustine, a modified alkylating agent
composed of chlorambucil and prednisolone moieties, were
tested since others in the Department were interested in
the activity of these new clinical drugs. The clonogenic
assay on plastic was used for all these experiments.
The results for the various drugs are shown in Figures 27-
35 and a summary of LD50 values is shown in Table 10
together with the relative fold resistance compared with
PE/01. While the LD50 values are a concise way of looking
at differences the dose response curves give a better idea
as to the significance of these differences across the
dose range. Differences in the LD50 value can be due to
an initial shoulder on the curve, a change in the slope or
Figure 27 CHIP Sensitivity
PE/01 X K
PE/04 ♦ •
PE/01 CisPtR D O
(3 day exposure in clonogenic assay on plastic)
Dose % Survival(a)

























1.8 (2) 112.9 (1)
(95.2)









4.5 (3) 98.9 + 15.5(4)
(91.6)
1.5 - 2.6 +
(3.3)
0.7 (2) —




0.7 (3) 100.3 (1)
(81.3)
2.5 - - 53.7 + 2.1 (3)
(61.3)
4.0 - - 72.9 (1)
(49.8)
5.0 - - 16.1 + 3.7 (3)
(15.7)
6.0 - - 40.6 (1)
(10.1)
7.5 - - 3.0 + 1.0 (3)
(2.2)
0.0 - - 0.38+ 0.08(2)
(0.07)
t) notes as in figure 17.
Only points with results
are shown on the graph.









Figure 28 CBDCA Sensitivity
PE/01 x *
- PE/04 • •
PE/01 CisPtR Q Q
Dose % Survival
(uM) PE/01 PE/04 PE/01 CisPtR
0.1 87.7 (1) 130.6 (1)
(106.0) (91.2)
0.5 93.0 + 8.0 (3) 82.2 ± 7.6 (3)
(73.6) (81.8)
1.0 51.7 t 20.0(3) 93.5 + 7.7 (3) 110.5 ± 11.2(2)
(30.3) (67.0)
2.0 12.4 ± 4.0 (3) 54.1 + 11.1(2) 94.1 + 9.8 (2)
(12.9) (46.3) (116.0)
3.0 6.9 + 5-8 (3) 29.5 t 9.9 (2)
(2.5) (19.2)
4.0 - - 103.0 t 15.6(5)
(118.1)
5.0 0.5 t 0.2 (4) 2.9 ± 0.9 (3) 73.9 ± 4.5 (3)
(0.8) (5.3) (59.0)
6.0 - - 64.5 t 6.6 (3)
(81.3)
7.5 - - 46.9 t 0.6 (2)
(36.0)
10.0 0 (1) 0 (1) 33.5 + 6.0 (3)
(0) (0) (42.3)
15.0 - - 9.3 t 3.5 (3)
(5.2)
20.0 - - 2.0 + 1.1 (3)
(1.4)
25.0 - - 0.4 (1)
(0)
Notes as in figure 17.
 









1.0 20.2 ± 8.4(4) 68.0 + 8.6 (4) 110.0 + 11.1(2)
(93.6)
2.0 8.9 ± 2.8(2) 48.1 + 4.2 (2) 106.7 + 11.2(2)
(90.3)
4.0 - - 71.3 t 15.3(2)
(71.9)
5.0 1.0 + 0.8(2) 11.4 + 1.7 (4) 75.3 ± 14.6(2)
(78.7)
6.0 - - 79.1 + 2.8 (3)
(59.1)
7.5 - - 60.1 ± 3.2 (3)
(65.1)
9.0 - - 38.3 (1)
(33.8)
10.0 0 (1) 1.1 (1) 43.7 ± 5.8 (3)
(0) (0.35) (42.8)
15.0 - - 12.1 (1)
(7.9)
25.0 - - 2.9 t 1.1 (3)
(2.0)







60.0 + 4.2(4) 92.8 ± 12.2(2)
(88.8) (96.8)
51.3 ± 2.9(2) 93.8 + 8.6 (2)
(79.2) (84.8)








Notes as in figure 17.
 
Figure 30 Melphalan Sensitivity
PE/01 * X
PE/04 •
PE/01 CisPtR 0 0
Dose % Survival
(uM) PE/01 PE/04
0.1 87.9 + 47.0(2)
(85.4)
0.3 49.9 t 22.5(3)
(58.4)
0.6 26.4 + 13.3(3) 81.6 + 16.4(3)
(26.4) (90.9)
0.8 29.0 t 15.7(3) 85.7 + 16.9(3)
(22.4) (79.0)
1.0 11.5 + 3.9 (3) 71.2 + 14.8(3)
(8.7) (59.9)
2.0 0.5 (1) 26.8 t 8.1 (3)
(0) (28.8)
4.0 - 7.8 + 4.9 (3)
(7.3)
6.0

















Figure 31 Doxorubicin Sensitivity
PE/01 X K
PE/04 • •
PE/01 CisPtR H a
Dose % Survival
(nM) PE/01 PE/04 PE/01 CisPtR
5.0 79.8 t 13.6(3) 82.4 + 24.1(3)
(88.7) (79.7)
6.0 - - 136.2 t 1.5 (2)
(86.8)
7.5 32.8 ± 10.1(2) 85.3 t 33.7(2)
(49.0) (71.5)
10.0 36.4 + 13.5(3) 76.5 + 21.1(3) 62.7 ± 15.7(5)
(37.6) (90.4) (67.5)
15.0 - - 40.0 t 14.8(4)
(59.1)
20.0 19.1 (1) 33.2 (1) 19.5 ± 4.0 (4)
(4.7) (42.1) (35.8)
25.0 1.9 t 0.6 (2) 35.5 + 8.2 (2)
(2.8) (31.4)
30.0 - - 10.8 t 5.3 (5)
(13.0)
40.0 - - 1.7 t 0.8 (3)
(2.4)
50.0 0 (2) 5.7 + 1.7 (3)
(0) (5.2)
60.0 - - 0.9 t 0.9 (2)
(0)
Notes as in figure 17.
Doxorubicin conc. (nM)





1.0 86.A ± 13.1(3) 90.6 ± 10.8(5)
(88.8) (100.6)
2.0 10A,6 ± 29.9(3) 98.7 + 19.3(5)
(81.3) (99.7)
5.0 23.9 t 10.2(3) 57.0 ± 13.3(5)
(27.3) (39.1)
7.0 8.5 t 4.9 (3) 36.3 j; 11.5(5)
(6.6) (20.7)
10.0 3.0 t 1.2 (3) 9.6 t 2.6 (5)
(l.A) (A.9)
Notes as in figure 17.
Vincristine conc. (nM)



























0.2 (3) 6.0 +
(1.5)
0.3 (3)
Notes as in figure 17.
Mitozantrone conc.(nM)
Figure 34 Prednimustine Sensitivity
PE/01 -X K
PE/04 •- -•
PE/01 CisPtR n 0
Dose % Survival
PE/04 PE/01 CisPtR(uM) PE/01
0.2 49.9 t 17.2(3)
(38.8)
0.5 37.8 + 12.5(4)
(39.8)
0.8 24.3 + 8.8 (3)
(27.5)
1.0 13.4 + 4.2 (4)
(18.3)






Notes as in figure 17.
95.1 (1) 78.1 (1)
(158.8)
77.9 + 15.1(3) 63.9 t 7.7 (3)
(110.4) (56.4)
59.4 + 11.2(3) 56.8 ± 17.0(3)
(70.0) (55.3)
28.0 + 3.6 (4) 41.4 + 9.1 (4)
(33.4) (43.1)
14.3 t 2.4 (3) 14.5 + 3.3 (3)
(11.6) (14.3)
15.9 (1) 16.4 (1)
(7.1) (14.8)






Figure 35 X-ray Sensitivity
PE/01 X *
PE/04 •
PE/01 CisPtR ® 0
Dose % Survival
(rads) PE/01 PE/04 PE/01 CisPtR
50 81.5 + 5.8 (3) 76.2 + 2.7 (2) 73.7 + 8.5 (3)
(86.3) (84.9) (84.7)
100 39.9 ± 5.1 (3) 50.7 ± 0.6 (2) 61.3 + 5.7 (3)
(46.9) (73.6) (81.0)
200 11.2 + 3.2 (3) 24.1 + 6.0 (2) 44.3 + 8.7 (3)
(16.4) (14.4) (51.9)
500 0.56± 0.15(2) 0.67+ 0.11(2) 6.3 + 1.1 (3)
(0.07) (0.3) (10.2)
800 0.076±0.002(2) 0.07+ 0.07(2) 0.74+ 0.20(3)
(0) (0) (1.5)
Notes as in figure 17.
X-rays (rads)
TABLE 10
LD50 VALUES FOP VARIOUS DFUGs(a)
PE/01 PE/0 4 PE/01 CisPtR
Cisplatinum 0 .0 82uM 0.23uM ( 3x) (b) 1 . 6uM (25x)
CHIP 0.54uM 0.6 7uM 2. 7uM (5x)
CBDCA 1 . OuM 2 . luM (2.1x) 7 . 5uM (7.5x)
JM40 0 . 2 2uK 2 .OuM (9x) 8 . 8uM (4 Ox)
Chlorambucil 0.83uM 2 . 8uM (3.3x) 3 . 3uM (4x)
Melphalan 0.31uM 1. 3uM (4.2x) 2. 3uM (7.4x)
5-fluorouracil 6uM 4uM -
Doxorubicin 7 . OnM 1 8nM (2.5x) ] 3nM (2x)
Vincristine 3 . 5nM 5 . 6nM (1.6x)
Mitczantrone 1. OnM 2 . OnM (2x) —
Prednimustine 0.25uM 2 . 2uM ( 9x) 2 . 4uM ( 9x)
X-rays 8 4 rad 100 rad (1. 2x) 160 rad (1 .9x)
on plastic,
over PE/01 shown
3 day exposure in clonogenic assay
approximate increase in resistance
in brackets.
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a combination of both. All the dose response curves were
of the exponential or threshold-exponential type.
The PE/04 cell line was equally sensitive or more
resistant than PE/01 to all the drugs tested. With the
platinum analogues little difference between PE/01 and
PE/04 in sensitivity to CHIP was observed, seme small
difference seen towards CBDCA (approximately 2-fold) but a
larger difference shown towards JM40 (approximately 9-
fold). This pattern of sensitivity was also reflected in
the PE/01 CisPtR cell line where resistance to cisplatinum
was accompanied by high resistance to JM40 but
considerably less resistance tc CBDCA and even less to
CHIP. All 3 analogues used here were toxic only at higher
concentrations than cisplatinum itself. The sensitivity
to melphalan showed a similar pattern to that for
chlorambucil and PE/01 CisPtR showed only some partial
cross-resistance to melphalan. Experiments with melphalan
have not been repeated at 5%C>2 in the gas phase as yet.
Interestingly prednimustine showed a rather higher level
of cross-resistance, showing a large difference between
PE/01 and PE/04.
Very little cross-resistance was observed in PE/04 to the
other unrelated drugs doxorubicin, vincristine and
mitozantrone even though these drugs were toxic at
nanomolar concentrations. PE/01 CisPtR was also only
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marginally cross-resistant to doxorubicin. PE/01 and
PE/04 had a similar sensitivity to x-rays with PE/04
CisPtR showing some small increase in resistance relative
to its parent cell line.
3.5 PE/04 CisPtR and PE/06 cell lines
These 2 cell lines which have been derived more recently
(see chapter 2) have both been tested against cisplatinum
in the clonogenic assay on plastic.
PE/04 CisPtR
The results from 1 experiment testing the sensitivity of
the cell line to cisplatinum are shown in Figure 36
together with the sensitivity of PE/04 tested at the same
time. In this assay PE/04 CisPtR (passage 73) was tested
after passaging until then in luM cisplatinum. Subsequent
passaging in the absence of the drug (from passage 75) is
continuing to see if the resistance will be maintained.
At passage 73 PE/04 CisPtR was some 4.4 fold resistant to
cisplatinum compared with PE/04 and its resistance was at
a very similar level to that of PE/01 CisPtR, perhaps not
surprisingly since both were selected in luM cisplatinum.
PE/06
PE/06 (line derived in 20% O2) at passages 7 and 9 was
tested against cisplatinum and showed a dose response as
shown in Figure 37 with an LD50 of approximately 0.3uM,
similar to PE/04. Although further experiments are
needed, this would confirm the difference in sensitivity
Figure 36 PE/04 CisPtR sub-line - Cisplatinum Sensitivity
PE/04 » «
PE/04 CisPtR * *
Both cell lines tested at the same time in the clonogenic assay
on plastic. Bars represent standard error of the mean of
triplicates in the one experiment. Dose left on for 3 days.
Cisplatinum conc. (uM)
Figure 37 PE/06 - Cisplatinum Sensitivity
Sensitivity in clonogenic assay on plastic. Dose left
on for 3 days.
Mean and standard error from 2 experiments.
Cisplatinum conc.(uM)
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between the cell lines from ascites taken after the
patient's treatment (PE/04 and PE/06) and the cell line
derived from ascites taken upon relapse just before the
courses of chemotherapy (PE/01).
3 . 6 Discussion
PE/04 shows a marked resistance to cisplatinum compared
with PE/01 in both the assays used. Resistance to
chlorambucil occurred in only one assay and could be
altered by changing the oxygen tension. Its significance
is thus much more open to question and its relevance to
the phenotypic properties of PE/04 is unclear since
undoubtedly cisplatinum resistance with cross-resistance
to classical bifunctional alkylating agents must be
considered separately to cisplatinum resistance without
such cross resistance (A. East man et al, 1981). The
PE/01 CisPtR line shows cisplatinum resistance without
much cross resistance to the alkylating agents
chlorambucil and melphalan so it will be interesting to
see what specific biochemical changes from the PE/01
phenotype, compared with the changes in PE/04, have
occurred in it. PE/04 showed high resistance to
prednimustine although PE/01 CisPtR showed no greater
resistance. The toxicity of prednimustine is apparently
due to its slow hydrolysis to chlorambucil thus prolonging
the availability of the toxic chlorambucil species (B.
Hartley-Asp et al, 1986). From the LD50 values it may be
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that PE/O1 is more sensitive to prednimustine than
chlorambucil rather than PE/04 more resistant, perhaps due
to the prolonged availability of chlorambucil derived from
the prednimustine. Cross resistance to other drugs like
doxorubicin and vincristine involved in the pleiotropic
resistance phenotype (J.H. Gerlacli et al, 1986) appears to
be minimal.
Various assay conditions have been shown to affect drug
sensitivity measurements although the evidence from
different groups can be contradictory (B.T. Hill, 1983).
Provided the conditions of drug exposure are the same,
other aspects of the assay method may not change the
apparent drug sensitivity very much (B.T. Hill et al,
1983). The metabolic state of the cells when treated -
either in suspension after trypsinisation or after
attachment to a growth surface - has been shown to be
important (P.R. Twentyman, 1979) and other factors such as
anchorage dependence (T.C. Stephens et al, 1980), oxygen
tension (V. Gupta et al, 1982) and the addition of rat red
blood cells (L. Endresen et al, 1985 ) have all affected
drug sensitivity determinations in some systems. The
effects of cell density or cell transfer after drug
exposure can be significant and affect the sensitivity to
some drugs more than others (P.J. Hepburn et al, 1986).
In the experiments shown here the drug sensitivity to
chlorambucil has not altered very much in terms of the
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concentration of drug required but the relative
sensitivity of 2 closely related cell lines has changed
from being obviously different to minimally if at all
different. More experiments with low oxygen tension will
clearly be interesting especially with melphalan to
compare with chlorambucil and PE/01 CisPtR to compare with
PE/01 and PE/04. Whether the amount of cross-resistance
observed with melphalan or prednimustine would be reduced
at 5%©2 in a similar manner to chlorambucil needs to be
determined.
It would appear that 5-fluorouracil is less toxic in the
clonogenic assay on plastic than in the Courtenay assay.
Possibly the increased time of drug exposure in the
Courtenay assay (21 days versus 3 days) could result in
this increased toxicity since the length of exposure time
is known to be important (A.F. Sobrero et al, 1983), or it
may simply be a result of the different conditions of the
two assays. The variation is presumably caused by
variation in nucleoside concentrations in different
batches of serum (or red blood cell preparations). Hams
F-12 medium used in the Courtenay assay already contains
3uM thymidine, which is thought to be a principal
modulator of 5-fluorouracil metabolism (B. Ardalan et al,
1980) but RPMI 1640 medium used in the clonogenic assay on
plastic contains no nucleosides.
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No changes in drug sensitivity with passaging the cell
lines in vitro have been observed." In recent work with
the Courtenay assay we specifically returned to as early
passages as possible to check this aspect. While some
authors have noted changes in drug sensitivity with
passaging (A.P. Wilson, 1984; F. Holzel et al, 1985)
others have shown remarkably little change in drug
sensitivity with passaging (K.M. Tveit et al, 1981b) even
when other changes in the cell line have occurred (P.G.
Parsons et al, 1982) or over very long periods in culture
(J.R.W. Masters et al, 1986). An additional reason for
returning to early passage cells was as a link in checking
any changes back to the ascites itself. Problems with
cell clumping have been reported by many authors with agar
clonogenic assays (S. Rockwell, 1985) and this has been a
problem with our ascites preparations. Various methods of
disaggregation especially using different enzymes such as
collagenase, dispase and DNAase are presently under
investigation. A collagenase/DNAase mixture appears to be
effective with PE/04 ascites.
A number of authors have attempted assays with
radiolabelled compounds particularly []-thymidine (Group
for Sensitivity testing of tumors, 1981) and [3H]-leucine
(S. Merry et al, 1984). The validity of these various
assays has been recently reviewed (R.I. Freshney et al,
1983; L.M. Weisenthal, 1981). Correlations with
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clonogenic assays have been observed (G.E. Johnson et al,
1983) although sometimes with considerable scatter (N.
Tanigawa et al, 1982) and appear better in assays over
several days allowing recovery after drug treatment than
in short term assays conducted over a few hours (A.P.
Wilson et al , 1984; K. Zirvi et al, 1986). Short term
assays may only show a qualitative comparison (H.T.
Rupniak et al, 1983) although clinical correlations have
been observed (B.T. Hill, 1983a). Others have shown
spurious resistance with radiolabel incorporation assays
at shorter times with sensitivity increased once a
recovery period was allowed (D. Morgan et al, 1983; C.
Roobol et al, 1984). Radiolabel1ing at the time of colony
counting in a clonogenic assay seemed to give good
correlations (P.G. Parsons et al, 1979 ; C. Roobol et al,
1984) as observed in this project.
The amount of variation in drug sensitivity which is
regarded as biologically significant is also an important
question. Many studies have used cell lines with
resistance acquired in vitro to very high levels over 100-
fold (V. Ling, 1982). However in the clinical setting it
is clear that resistance of 3-4 fold would often be enough
for a tumour to survive therapy (E. Frei et al, 1980) and
high dose cisplatinum therapy has shown responses in
patients with ovarian cancer who failed standard dose
therapy (R.F. Ozols et al, 1985). Thus changes in drug
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sensitivity of the order of magnitude shown with the cell
lines here would be important clinically. Similar levels
of in vitro acquired resistance are thought to be
significant (T.C. Hamilton et al, 1984a). High stable
levels of resistance (above about 10-fold resistant) have
been difficult to produce in vitro to agents such as BCNU,
nitrogen mustard (HN2) and cisplatinum (E. Frei et al,
1985), and melphalan (P.G. Parsons et al, 1978). A
similar degree of variation (5-fold) in sensitivity to
cisplatinum has been observed in clonal human glioma cell
lines from a single untreated tumour (W-K.A. Yung et al,
1982) which serves to emphasise the importance of tumour
heterogeneity as far as drug sensitivity is concerned (T.
Tsuruo et al, 1981) particularly in vivo and this
phenomenon has been observed in primary ovarian cancer
samples (J. Siracky, 1979). Although heterogeneity makes
predictions on the response of a primary tumour in vivo
from results in vitro on a cell line derived from it
difficult, such correlations have been observed with
ovarian tumours and cell lines (22 cases, M. Albrecht et
al , 1985). The preliminary data with PE/06 giving a
similar response as PE/04 to cisplatinum (and resistant
compared with PE/01) would support the idea of a change
induced by the chemotherapy in the patient.
The LD50 values reported here (Table 10) for PE/01 and
PE/04 are at the lower end of the range for cisplatinum
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toxicity values (approximately 0.03-3uM for a 24 hour to
continuous dose) reported in the literature for ovarian
(F. Holzel et al , 1985 ; R.N. Buick et al, 1985 ; L.M. Van
Putten et al, 1986) and other human cell lines (B.T. Hill
et al , 1984 ) and below that reported for normal human bone
marrow cells (0.9uM, G.E. Umbach et al, 1985) or the
concentration commonly used in the Hamburger/Salmon
clonogenic assay for ovarian cells (0.7uM) at l/10th the
achievable peak plasman level (D.D. Von Hoff et al, 1983;
D.S. Alberts et al, 1980a). However a 1 hour treatment is
often used in the Hamburger/Salmon assay and the LD50
values for a 1 hour cisplatinum treatment on PE/01 and
PE/04 (approximately 1.luM and 3.3uM) are a little above
this value of 0. 7uM although still well in the range
(0.7uM-10uM) reported in the literature for ovarian cell
lines (G. Clamon et al, 1985; J. Benard et al, 1985; A.C.
Jones et al, 1984 ; L.M. Van Putten et al, 1986) or other
human cell lines (L. Endresen et al, 1985).
Various authors have shown increased cytotoxicity of
cisplatinum against human cells in tissue culture with the
time of incubation (J.P. Bergerat et al, 1979; H.T.
Rupniak et al , 1983a; H. Hisazumi et al, 1983 ; E. Cadman
et al, 1984 ; A.F. Sobrero et al, 1985) suggesting that
toxic species are present at least for several hours.
Bergerat suggested a simple concentration x time
computation would indicate the effective dose and that
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little cytotoxic activity is lost in tissue culture medium
containing 10% foetal calf serum over 24 hours. However
when LD50 doses at various incubation times from the other
references are computed as a concentration x time value,
the 1-4 hour values are generally less than the 24 hour
values suggesting decomposition to non-cytotoxic species
in this time. Recent data by Hill (B.T. Hill et al, 1985)
has reported that the difference between a 1 hour and 24
hour equitoxic dose depends on the cells being tested and
can vary from 6 to 50 fold.
Cisplatinum reacts with serum proteins to produce non-
cytotoxic species (K. Takahashi et al, 1985) and so will
decompose in the culture medium used here (see also the
discussion on cisplatinum in chapter 1). Although
cisplatinum has a half-life of some one-and-a-half hours
in human plasma in vitro (A.J. Repta et al, 1980) it is
unclear how much of this decomposition is to non-cytctoxic
species. Holdener reported substantially reduced
cytotoxicity against bone marrow cells in vitro after pre¬
incubation of cisplatinum in human plasma for 4 hours and
even less cytotoxicity after 24 hours pre-incubation (E.E.
Holdener et al, 1983). Decomposition also occurs in
plasma ultrafiltrates in vitro at similar rates despite
the presence of high chloride concentrations (lOOmM) which
inhibit decomposition in simple buffers (A.J. Repta et al,
1980) and at least 7 low molecular weight platinum
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containing species have been observed (P.T. Daley-Yates et
al, 1984). These species are formed in different
proportions in vitro from in vivo experiments with plasma.
In rat plasma in vitro 85% of the platinum is protein
bound after 24 hours (t^/2 for protein binding 57
minutes), parent cisplatinum is present in only trace
amounts and the major u1trafi1terable species (44%) was
tentatively identified as the cisplatinum hydrolysis
product (P.T. Daley-Yates et al, 1984). In tissue culture
medium containing 10% foetal calf serum similar
decomposition and reaction with proteins would be expected
although perhaps at a reduced rate to that in 100% serum
or plasma. RPMI-1640 medium contains lOOmM chloride ion
concentration similar to that in plasma but concentrations
of other low molecular weight species will be different.
Platinum binding to bovine serum albumin (0.69gm/100mls)
in saline occurs at similar rates to protein binding in
plasma (A.F. Leroy et al, 1979) and albumin is the major
protein in foetal calf serum (2.6gm/100mls of the total
4.5gm/100mls protein present; Gibco Quality Control
Information).
The toxicity of chlorambucil reported here is at the low
end of the range (2.4-13.5uM) reported for melanoma cell
lines (P.G. Parsons et al, 1979) but similar to that for
normal human fibroblasts (P.G. Parsons et al, 1979) and
greater than that commonly used in the Hamburger/Salmon
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assay (0.3uM). For 5-fluorouraci1 the values are similar
to other human cell lines (range l-23uM B.T. Hill et al,
1984; F. Holzel et al, 1985) and normal bone marrow cells
(2.8uM, G.E. Umbach et al, 1985) and concentrations used
in the Hamburger/Salmon assay (6uM). The exposure time
has been shown to be important for the activity of many
antineoplastic drugs in vitro (Y. Matsushima et al, 1985)
particularly for antimetabolites but apart from
cisplatinum was not further pursued in this project.
All three of the platinum analogues were less toxic than
cisplatinum. This has been the common experience of other
authors both in vitro (A.C. Jones et al, 1984; B. Drewinko
et al, 1985 ) and in vivo (E. Boven et al, 1985 ). Jones
observed approximately 10-fold less toxicity with CBDCA
than cisplatinum and Boven noted maximally toxic doses to
xenograft bearing nude mice at 5mg/kg for cisplatinum,
60mg/kg for CBDCA and 40mg/kg for CHIP and JM40. In the
clinical setting this may not be critical since higher
doses can be given. In phase I-II studies doses have been
up to 350mg/m2 for CHIP (V.H.C. Bramwell et al, 1985),
550mg/m2 for CBDCA (R.A. Joss et al, 1984) and 1200mg/m2
for JM40 (B. Winograd et al, 1986). In refractory ovarian
cancer 'Ozols and his colleagues have used 40mg/m2 qd x 5
cisplatinum versus 400mg/m2 qd x 2 CBDCA (R.F. Ozols et
al, 1985a). The lack of cross resistance of CHIP and to a
lesser extent CBDCA is the most interesting fact in the
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present study and needs to be pursued since both these
drugs are of clinical interest in ovarian cancer. To date
CBDCA has received most clinical interest and its current
status and prospects have been extensively reviewed
recently (S.K. Carter et al , 1985). It has shown similar
activity to cisplatinum in ovarian cancer with a response
rate of approximately 20-25% in patients pretreated with
cisplatinum (E. Wiltshaw, 1985; R. Canetta et al, 1985).
CHIP has shown some responses in ovarian cancer patients
pretreated with alkylating agents (V.H.C. Bramwell et al,
1985). The potential for differential activity of the
analogues, quite apart from their differential toxicity to
normal tissue (P. Lelieveld et al, 1984), needs to be
further explored. Earlier studies have explored the
structure-activity relationships of many analogues in
rodent tumours (K.R. Harrap, 1983). Different analogues
have shown varying degrees of cross-resistance to L1210
cells resistant to the parent drug cisplatinum (no cross-
resistance up to 83-fold cross-resistance in a 50-fold
cisplatinum resistant sub-line, J.H. Burchenal et al,
1979). Bis-(isopropylamine)dichloroplatinum a Pt(II)
analogue similar in structure to the Pt(IV) analogue CHIP
showed only a limited 7-fold resistance. In vivo studies
with cisplatinum resistant L1210 cells have suggested
cross-resistance between all three of the analogues used
here and cisplatinum (W.C. Rose et al, 1984). However the
clinical data (R. Canetta et al , 1985) and the data
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presented here do not support the conclusion cf complete
cross-resistance and suggest further investigations with
human tumours are warranted.
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4. Mechanisms of resistance to Cisplatinum - Cellular
Uptake studies
The transport of cisplatinum into cells has generally been
thought to be by passive diffusion of the unreacted
neutral complex (B. Rosenberg, 1985), based on the work of
Gale with tritiated cis-dichloro(dipyridine)platinum II
(G.R. Gale et al, 1 9 73) where amongst, other
characteristics consistent with passive diffusion, binding
to Ehrlich tumour cells was virtually unimpeded at 0°C.
Thus most work concerned with mechanisms of resistance has
concentrated on intracellular events (see chapters 5 and
6). However, resistance at the membrane level has been
shown to be an important mechanism with other drugs (G.A.
Curt et al, 1984 ; G.J. Goldenberg et al, 1984) and I
thought it worthwhile to check this aspect with
cisplatinum particularly if cross-resistance to other
alkylating agents like melphalan was important and as a
matter of completeness in looking at the possible
mechanisms of resistance a cell could display. Resistance
to melphalan in a L1210 cell line, which was also cross-
resistant to cisplatinum (F.M. Schabel et al, 1978) has
been associated with changes in a transport mechanism for
melphalan (W.R. Redwood et al, 1980). However, Eastman
has also reported a L1210 sub-line specifically resistant
to cisplatinum without such cross-resistance (A. Eastman
et al, 1981). Melphalan is known to enter cells by
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carrier mediated transport particularly via the carrier
system for the amino acid leucine (A. Begleiter et al,
1979 ) and resistance with a defect in this mechanism has
been shown in Chinese hamster cells (A.H. Dantzig et al,
1984). There is an extensive literature regarding the
transport of alkylating agents (G.J. Goldenberg et al,
1984). In addition Byfield has classified alkylating
agents (using the term in its broadest sense) into those
with carrier dependent or carrier independent transport
(J.E. Byfield et al, 1981) on the basis of water soluble
alkylating agents being more toxic to phytohaemagglutinin
stimulated human lymphocytes than resting lymphocytes
while lipid soluble agents were not. This division held
for a wide variety of agents including melphalan,
cisplatinum, nitrosoureas and mitomycin C and also
extended to x-rays. He suggested cisplatinum was carrier-
dependent and probably transported into cells by an amino
acid transport mechanism as amino acids protected. the
lymphocytes. Some support for this claim has come from
the report of Scanlon who showed inhibition of sodium-
dependent amino acid transport in L1210 cells by
cisplatinum (K.J. Scanlon et al, 1983). However when this
project began there was no direct evidence for any
association of transport effects with sensitivity to
cisplatinum or in acquisition of resistance to it. Some
evidence has been put forward since then as discussed at
the end of the chapter.
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The quantitation of the amount of cisplatinum in a
particular system has generally relied on atomic
absorption spectroscopy to measure the platinum after
separation of different platinum containing species where
appropriate and these procedures have been used in most
pharmacokinetic studies (C.L. Litterst et al, 1976; J.B.
Vermorken et al , 1984). Some studies have used
radioactive isotopes of platinum either 193mpt or 195mp-t-
incorporated in cisplatinum (R.C. Manaka et al, 1980).
These studies have been limited by the short half-lives of
these isotopes (4.3 and 4.1 days respectively). Only
relatively few studies have looked at uptake into cells in
vitro (J. Uozumi et al, 1984 ) and I chose to try and
measure the amount of platinum taken up into cells by
atomic absorption spectroscopy (AAS). Later in this
project I was able to use some 195mp-t- cisplatinum
available through Dr. Philip Bedford at I.C.R.F. in London
to confirm the AAS work. No attempt was made to measure
actual transport processes but rather I measured total
cellular platinum at various time points starting at 1
hour after cisplatinum was added to the incubation.
Some preliminary experiments using scanning electron
microscopy with x-ray microanalysis to detect electron-
dense platinum taken up by cells were attempted. Two
papers have reported nucleolar localization of platinum by
this method but at high cisplatinum concentrations (200uM
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cisplatinum on HeLa cells, M.U.A. Khan et al, 1978; 1.6mM
cisplatinum on human fibroblasts, J.P. Berry et al, 1983).
Others have used this technique to localize platinum in
liver and kidney after cisplatinum administration to rats
(T. Makita et al, 1985). However in another report
platinum could not be detected in HeLa cells after
exposure to 3-30uM cisplatinum in vitro (F.N. Ghadially et
al, 1981). I could detect 0.4nmoles cisplatinum dried
down on to a carbon stub but platinum could not be
detected in rat gut samples after in vivo cisplatinum
treatment (S.G. Allan, unpublished results) and the
technique was not pursued further. The results at very
high cisplatinum concentrations are of doubtful biological
significance and others have suggested that atomic
absorption spectroscopy is much more sensitive when the
element being analysed is highly dispersed in the nucleus
or cell (C.F. Shaw et al, 1981) as is most likely the case
after cisplatinum treatment (R.P. Sharma et al, 1983).
4.1 Methods
4.1.1 Atomic Absorption Spectroscopy
Initial contact with Dr. A. Rowley in the Department of
Chemistry, University of Edinburgh quickly showed that
flame atomic absorption spectroscopy was unsuitable due to
interference by sodium chloride present in biological
samples. Non-flame atomic absorption spectroscopy has
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been successful (R.P. Sharma et al, 1983a) and preliminary
work was done using a graphite furnace spectrometer in the
Department of Applied Chemical Sciences at Napier College,
Edinburgh (with the help of Ms. D. Jeffrey Smith). Since
obtaining time on this machine was difficult further work
was done at the Department of Clinical Biochemistry, Royal
Infirmary, Glasgow (with technical advice there from Dr.
D. Halls). Advice on the technique and sample preparation
was also obtained from the Department of Applied
Chemistry, Strathclyde University, Glasgow (Dr. D.
Littlejohn and Professor J. Ottaway).
Approximately 10^ PE/01 and PE/04 cells grown in 75cm^
flasks (Nunc, Gibco Ltd) were exposed to various
concentrations of cisplatinum and incubated in a high
humidity 5% CO2 incubator at 37°C for times ranging up to
24 hours. The cells were then harvested by
trypsinisation. Flasks were taken from the incubator,
cooled quickly (3 minutes in a -2o°C refrigerator), and
rapidly washed (less than 10 seconds) twice with ice-cold
PBS before trypsin (2.5mls) was added. When cells had
detached, 5mls of RPMI-1640 (without serum) was added and
the cells in this medium were counted and transferred to
soda glass tubes (Samco) and dried down at 80°C. The
dried down residue was digested overnight in 2mls
concentrated nitric acid heated to 80°C and after cooling
50uls of 30% hydrogen peroxide solution added to aid
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dissolution of any remaining residue (similar procedure to
R.P. Sharma et al, 1983a). This solution was then
analysed for platinum by atomic absorption spectroscopy.
This harvesting and digestion procedure was designed to
minimise any loss of unbound platinum from the cells by
washing the medium at low temperatures and collecting all
the trypsin solution not just a cell pellet after
centrifugation. This washing procedure should leave 2.5ng
platinum equivalent or less due to cisplatinum left from
the medium from a lOuM cisplatinum incubation.
Platinum was analysed on a Perkin Elmer 2280 atomic
absorption spectrometer with pyrolytic coated graphite
tube furnaces and a HGA 500 programmer. The instrument
parameters used are shown in Table 11 and were modified
from those of J. Haron (PhD thesis, University of
Strathclyde, 1982). An autosampler was used to inject
20ul aliquots into the graphite furnace. Digested samples
in nitric acid were diluted 1:1 with water, which
contained a standard addition of cisplatinum (usually
0,40,80 and 120ng/ml cisplatinum), in the autosampler cup
before the analysis and 2 to 3 aliquots were injected and
analysed to confirm the reading obtained. Values in fgm
platinum equivalent/cell were calculated from the sample
reading and 3 different standard additions of cisplatinum.
Preliminary experiments showed decreases in the atomic
TABLE 11
INSTRUMENT PARAMETERS FOR PLATINUM
ATOMIC ABSORPTION SPECTROSCOPY
Furnace Programme Ramp Hold Temperature
Drying stage 1 sec 10 sec 100°C
5 sec 20 sec 180°C
Ashing stage 5 sec 40 sec 1500°C
Atomisation stage 0 sec 10 sec 2700°C
Cleaning stage 0 sec 3 sec 2700°C
Internal gas flow during atomisation lOml/min
Wavelength 265.9nm
Lamp current 30.0
Background corrector ON, Autozero 2 seconds before
atomisation stage.
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absorption signal with increased nitric acid concentration
and increased cell number in the sample. For these
reasons measuring the signal with a standard additions
procedure was preferred to simply using a standard
reference curve (R.P. Sharma et al, 1983a) especially
since sample matrix effects are known to be important
parameters in interference with the atomic absorption peak
and aging of the carbon tube furnace was also experienced
(A.J. Repta et al , 1980 ). The signal was more reliably
measured by peak height than by the integrated peak area
due to negative tails to the peak, probably caused by the
deuterium arc background correction. Pyrolytic coated
graphite tubes gave improved sensitivity. Some
precipitation was observed in the digested sample
solutions which could be dissolved by addition of hydrogen
peroxide but later reappeared. It could be redissolved on
simply heating the solutions to 50°C. Attempts to
evaporate off the nitric acid (at 125°C) and redissolve
the residue in 0. 1M HC1 still left some precipitate and
this procedure was not subsequently used. More elaborate
digestions, for example, by heating with perchloric acid
were beyond the facilities of this laboratory and the
digestion with concentrated nitric acid was thought to be
sufficient for the purpose.
The methodology of atomic absorption spectroscopy for
platinum has been the subject of considerable debate in
Ill
the literature in regard to sample preparation including
digestion and possible derivatization of products, the
presence of sample matrix effects, interference by various
ions and acids like nitric acid, and carbon furnace
conditions and instrument parameters (A.F. LeRoy et al,
1977; M.F. Pera et al, 1977; S.J. Bannister et al, 1979;
J. Smeyers-Verbeke et al , 1981; D. Priesner et al, 1981;
R.P. Sharma et al, 1983a). Various authors have reported
different sensitivities from 0 .055ng to 3 . 8ng platinum
without it being clear why there should be so much
variation (J. Haron, 1982; and references above).
4.1.2. Methods - [195mpt] cisplatinum uptake
[195mpt] cisplatinum in 0.9% saline (1.152mg/ml
cisplatinum, 0.58mCi/ml [l^Smpp] platinum) was obtained
from Dr. P. Bedford and Dr. B.T. Hill at the I.C.R.F.
laboratories in London. This was part of a batch prepared
by Dr. H. Sharma, Department of Medical Biophysics,
University of Manchester Medical School and I am grateful
for the gift of this compound. [195mpp] platinum is a )(-
ray emitting radionuclide with half life of 4.1 days which
limits its use.
Cells from the PE/01 family of cell lines were harvested
from log phase cultures and 5 x 10^ cells taken up in 5mls
RPMI-1640 without serum and incubated in suspension with
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[195mpt] cisplatinum for 1 to 4 hours at room temperature.
The cells were then spun down, washed twice with PBS and
resuspended in 2mls PBS and counted for 1 minute on a
^-counter with windows set at 15-150 KeV. This washing
procedure should leave at most lng/ml cisplatinum from the
medium. All procedures were done with appropriate lead-
brick shielding and monitoring in the Radioisotope Section
of the Department of Medical Physics, Western General
Hospital and I acknowledge the advice of Dr. J. Hannan of
that Department. The cellular platinum concentration
achieved was calculated from the counts obtained by
reference to a standard curve of [195mpt] cisplatinum from
the same stock and counted at the same time.
4.2.1 Results - Atomic Absorption Spectroscopy
Results from 3 experiments are reported here. Two
experiments show the increase in the amount of cellular
platinum in PE/01 and PE/04 cells over a 24 hour time
course with 5uM cisplatinum in the medium (Figure 38).
One flask of cells from each cell line was harvested for
each time point. In the first experiment the platinum
analysis included only one standard addition at lOOng/ml
cisplatinum and the second drying stage in the instrument
procedure was not used. Hence the second experiment is
more reliable but wide variation between the two
experiments can be seen. This is most probably due to
Figure 38 Time course of Cisplatinum uptake into
PE/01 and PE/04
1st experiment PE/01 K- X
PE/04 • •
2nd experiment PE/01 X1
PE/04 • •
Cells in monolayer culture were exposed to 5uM cisplatinum
in normal medium and harvested at various times up to 24
hours later and processed for measurement of total cellular
platinum by atomic absorption spectroscopy.
Each point represents treatment on one flask of cells.
The standard error bars for points in the 2nd experiment
are calculated from linear regression analysis on the
sample and three standard additions of cisplatinum.
 
113
working near the limits of sensitivity of the technique
and particularly in the early time points absorbance
readings were low, equivalent to approximately 20ng
platinum/ml, and the peaks sometimes complex rather than
singlets. However this concentration of platinum could be
detected and quantitated in the use of the lowest standard
addition of 40ng/ml (diluted 1 in 2 in the autosampler
cup) .
To assess whether there was a real difference in the
platinum taken up into PE/01 and PE/04 cells a third
experiment was done at the 24 hour time point where the
platinum concentration was highest and possible background
effects least. Duplicate flasks from both cell lines were
incubated with 1, 5 and lOuM cisplatinum and the cells
harvested and analysed as above. The flasks incubated
with luM cisplatinum showed barely detectable platinum
levels, the signal being within the background noise for 1
flask of PE/01. At 5uM and lOuM cisplatinum a platinum
signal was readily detected. The results are shown in
Table 12. Two flasks of cells not incubated with
cisplatinum were harvested and the cell sample in RPMI-
1640 spiked with cisplatinum (at 60 or lOOng platinum
equivalent) before being dried down and processed with the
other samples. The level of platinum detected was 94.7
jf37.6ng (94.7%) in the lOOng sample and 122.1 j^20.8ng
(122%) when reanalysed one week later, when the 60ng
TABLE 12
UPTAKE INTO CELLS OF PLATINUM FROM CISPLATINUM
AFTER 24 HOUR INCUBATION
Dose of Cisplatinum PE/01 PE/C4
l.OuM 0,3.9 4.6,4.9
(but AAS readings near background)
5. OuM 7.2, 7.3 16.5, 21.6
(a) 21.4, 10.2 8.4, 22.4
10.OuM 55.8, 37.2 33.6, 41.9
(a) from the two time course experiments shown in
figure 38.
114
sample showed 72.0 +9.9ng (120%) platinum detectable.
These standards show the technique was reasonably accurate
and serve to illustrate the variability observed.
In this third experiment PE/01 showed less cellular
platinum than PE/04 after 24 hour incubation with 5uM
cisplatinum but a similar level with lOuM cisplatinum
incubation. However combining the results for 24 hour 5uM
cisplatinum incubations from the 3 experiments gives 11.5
+ 3.4 (S.E.) fgm platinum/cell for PE/01 and 17.2 +3.2
(S.E.) fgm platinum/cell for PE/04 and these figures are
not significantly different.
4.2.2 Results - [195mpt] cisplatinum uptake
In the first experiment cells from the cell lines PE/01,
PE/04, PE/01 CisPtR, PE/06 derived in 20% 02 , and PE/06
derived in 5% 02 were incubated with 0.6, 2, 5 and lOug/ml
[195mpt] cisplatinum (2, 6.7, 16.7 and 33uM) for 70
minutes before the cells were spun down, washed and
counted. [195mpt] cisplatinum standards at 0.5, 2.5, 5,
10 and 25ng/ml cisplatinum in PBS were counted at the same
time. The results are shown in Figure 39. The amount of
cellular platinum observed increased linearly with
cisplatinum concentration in the incubation. By linear
regression analysis the only significant difference in the
slopes of the lines was for PE/06 (5% 02) which had a
significantly greater slope than PE/01 (p = 0.02), PE/01
Figure 39 0-95mp^ Cisplatinum Uptake after 1 hour
PE/01 x , PE/04 % , PE/01 CisPtR O
PE/06(20%02) ♦ , PE/06(5%02) O
Cells were harvested from monolayer culture and incubated
in suspension in RPMI-1640 with various concentrations of
t_195mpt3 cisplatinum for 70 minutes and the cellular
uptake of the radionuclide ^Pt then determined.
Linear regression lines are shown for each cell line





















CisPtR (p = 0.02) and PE/04 (P = 0.05). For the 4 lines
grown in 5% C02/air there was no significant difference in
the slopes implying no significant difference in uptake of
cisplatinum into the cells after approximately 1 hour
incubation with the drug. Even the difference between the
PE/01 CisPtR and PE/06 (5% C>2) lines at lOug/ml
cisplatinum is only 1.8 fold.
A second experiment was possible before the radionuclide
had decayed too far. Cells of the PE/01, PE/04 and PE/01
CisPtR lines were incubated with lOug/ml [195mpt]
cisplatinum (33uM) for 1, 2 and 4 hours before being spun
down, washed and counted. Counts from uptake into 3 x 10^
cells in 1 sample for each cell line at 1 hour instead of
5 x 10^ cells showed similar values when converted to
counts per cell. A recount after a third washing in PBS
showed a small decrease in the counts and results as fgm
cisplatinum/cel1 derived from these counts are shown in
Figure 40. The uptake at 1 hour was slightly higher than
in the previous experiment for PE/01 (3.2 versus 1.7 fgm
cisplatinum/cel1 after minus background in controls) but
gave similar values for the other two cell lines (PE/04
1.7 versus 1.8 fgm/cell; PE/01 CisPtR 1.7 versus 1.2
fgm/cell). Uptake at 2 and 4 hours was higher in PE/01
than the other two resistant cell lines PE/04 and PE/01
CisPtR.
Figure 40 Time Course of P^mPtl cisplatinum uptake
PE/01 x , PE/04 • , PE/01 CisPtR
Background o
Cells were harvested from monolayer culture and incubated
in suspension inRPMI-1640 for 1, 2, or 4 hours with 10 ug/ml
[195mpt3 cisplatinum before the amount of cellular 195mpt
radionuclide was determined.
Multiple values at one time point represent duplicates.
Background points at each time are shown and were for PE/01
cells incubated without radionuclide except for the higher




All the above readings are on a per cell basis. The cell
volumes of PE/01 and PE/01 CisPtR are the same and PE/04
had a mean volume 77% of the volume of PE/01 but with the
spread of cell volumes in each cell population, PE/04 was
not significantly different to PE/01 in this respect (data
in chapter 2). Thus the calculations here have not been
adjusted for cell volume.
4 . 3 Discussion
In this chapter I report experiments attempting to measure
platinum taken up into cells following cisplatinum
exposure at doses as near as practicable to the
biologically effective doses. However due to the
relatively poor sensitivity of the available techniques
the concentrations necessary to examine uptake of
cisplatinum into cells (2-33uM) are still higher than the
LD50s seen in chapter 3 (0.23uM and 3.3uM for continuous
or 1 hour dose of cisplatinum on PE/04).
Some of the data presented here suggests a difference in
the amount of cisplatinum taken up into PE/01 and PE/04
cells, the most convincing of which is the data in figure
40 when more cisplatinum was observed in PE/01 cells.
However the rest of the data, particularly the 24 hour
atomic absorption spectroscopy data and the 1 hour
radionuclide data (figure 39) suggest no difference in
cisplatinum uptake while the time course using atomic
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absorption spectroscopy is rather inconclusive. There was
little evidence for decreased uptake in PE/01 CisPtR
compared with the more sensitive PE/04 line. If the
calculated values for PE/04 are adjusted to take account
of the smaller mean cell volume the data in figure 40
might indicate a decrease in uptake from PE/01 to PE/04 to
PE/01 CisPtR as might be expected for resistance due to an
uptake difference. However a similar adjustment in figure
39 would suggest increased platinum uptake in PE/04
compared with PE/01 (and also in the 24 hour atomic
absorption data at 5uM cisplatinum). Given the range of
cell sizes in the population of PE/01 or PE/04 (data in
chapter 2, no significant difference between the cell
lines) any adjustment for cell volume in the uptake
figures would not improve the significance of any of the
differences observed.
Although the two techniques are not directly comparable,
since one was done on a growing cell monolayer at 37°C and
the other on trypsinised cells in suspension at room
temperature and probably only measuring bound platinum,
the amounts of cellular platinum observed were of the same
order of magnitude. IOuM cisplatinum for 24 hours gave
approximately 40 fgm platinum equivalent/cell by atomic
absorption spectroscopy or 0.2 fmoles/cell. lOug/ml
cisplatinum ( 3 3 uM ) for 4 hours gave 5-10 fgm
cisplatinum/cel1 by radionuclide analysis or approximately
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0.02-0.03 fmoles/cell.
The most detailed work on cisplatinum uptake has been down
by Scanlon and co-workers (K.J. Scanlon et al, 1983; R.B.
Gross et al, 1986; S. Shionaya et al, 1986) using the
[195mPt] piat inum isotope and they have emphasised the
effect of cisplatinum on amino acid transport. In their
initial study cisplatinum uptake was measured in L1210
cells after 1 hour at concentrations between 10 and 250uM
cisplatinum in a Cross and Taggart buffer at 37°C, with
drug removed at the end by dilution and washing in ice-
cold saline solution. Uptake was approximately 0.4, 2.4
and 4.9 fmoles/cell (values estimated from graph) at 10,
25 and 50uM cisplatinum in the incubation. The later more
detailed work using L1210 and a subline resistant to
cisplatinum (R.B. Gross et al, 1986) showed identical
uptake over 10 minutes at 2 and lOuM cisplatinum, and
similar uptake in the 2 lines over 75 minutes at 25uM
cisplatinum in Earls salt solution (0.022 and 0.015
fmole/cell respectively) although they noted 44% less
initial (background) binding of cisplatinum in the
resistant cells after 10 seconds. They also observed
virtually immediate efflux of approximately 50% of the
platinum when the cells were diluted into drug free medium
after 15, 30 or 60 minutes, although the absolute amounts
of platinum uptake and that which remained bound had
increased with time. Similar results were also observed
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for K562 human chronic myelogenous leukemia cells and a
subline resistant to cisplatinum (S. Shionaya et al,
1986). Incubation with 25uM cisplatinum for 75 minutes
gave 0.022 and 0.019 fmole platinum/cell. Experiments
done at 24°C instead of 37°C showed decreased uptake at
about 0.010 fmole/cell although almost 50% could still
efflux from the cell at this temperature. Thus my values
using the radionuclide probably more nearly represent
bound platinum (since the cells were washed at room
temperature) and the values from the atomic absorption
spectroscopy total cellular platinum. This question
remains somewhat equivocal in any study where potential
efflux during sample processing is not monitored.
Subcellular localization studies on homogenized rat
tissues (D.D. Choie et al , 1980; R.P. Sharma et al, 1983)
show some 40% of the platinum as low molecular weight
species in the final supernatant, designated cytosol ,
after separation of the cellular organelles.
Other workers using atomic absorption spectroscopy have
shown similar values to those above for amount of platinum
per cell but usually only bound platinum is represented.
Uozumi reported approximately 0.018 up to 0.064 fmole
platinum/cell in FM3A mouse tumour cells after a 30 minute
incubation with from 40 to 160uM cisplatinum (J. Uozumi et
al, 1984 ) and Ciccarelli reported approximately 0.003 ,
0.014 and 0.025 fmole/cell for CV-1 African green monkey
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kidney cells after a 48 hour incubation with 1, 5 and 1OuM
cisplatinum (R.B. Ciccarelli et al, 1985).
However variations between different cell types have been
noted. Eichho11z-Wirth , using proton induced
characteristic x-ray emission analysis, observed HeLa
cells to show 1.3 fold more cellular platinum than Chinese
hamster lung fibroblast cells and 4.4 fold more than
Syrian hamster kidney cells (H. Eichholtz-Wirth et al,
1986) which correlated well with their sensitivity to
cisplatinum. Another recent study using two human
prostate carcinoma cell lines also showed a difference in
uptake of cisplatinum (using the 191pt radioisotope)
correlated with differential sensitivity to the drug and
further correlated this with the amount of platinum bound
to DNA and protein (S.A. Metcalfe et al, 1986). Other
preliminary reports, reviewed recently by Fry, mainly
using L1210 cells and resistant sublines, also suggest
some changes in cisplatinum uptake or amount of cellular
bound platinum (D.W. Fry et al, 1986) correlated with drug
resistance.
One problem with all these studies has been the large
numbers of cells and high cisplatinum concentrations which
need to be used given the sensitivity of the techniques to
measure platinum (and in my study here I noticed an
increased matrix interference on the atomic absorption
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signal from the platinum with increased cell number) and
the poor suitability and availability of platinum
radioisotopes . Too high a dose of cisplatinum can give
results of doubtful biological relevance. This accounts
for the small amount of uptake data for cisplatinum
relative to may other drugs. One recent preliminary
/V
report has used the close cisplatinum analogue
ethylenediamine dichloro platinum (II) labelled with
in the stable ethylenediamine ligand (W.R. Waud et al ,
1985) and this may be an easier and more sensitive method
of examining uptake and bound drug provided the cell
sensitivity to this analogue parallels that of
cisplatinum. Nevertheless the above reports indicate that
uptake of cisplatinum or other membrane effects may be
important for resistance to the drug in some systems. My
data reported here are not strong enough to conclude that
there is an uptake difference in the PE/01 family of
ovarian carcinoma cell lines which would be significant to
explain the resistance observed.
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5. Mechanisms of resistance to cisplatinum
- Glutathione studies
Since the early 1960s thiols, compounds with free SH
groups, have been implicated in resistance to alkylating
agents (I- Hirono, 1961; T.A. Connors, 1966). Glutathione
is the principal non-protein thiol in cells and its
metabolism has been recently reviewed (A. Meister et al,
1983). Its importance in protecting cells against
oxidative stress and radiation has received wide attention
(J.E. Biaglow et al, 1983; J.D. Chapman et al, 1984) but
it is thought to play a role in the detoxification of a
variety of drugs, not just alkylating agents (B.A. Arrick
et al, 1984). The group of enzymes associated with
glutathione metabolism is obviously important and the
selective modification of their activity has been recently
reported (A. Meister, 1983). Amongst these enzymes the
importance of glutathione transferases in reacting
glutathione with electrophi1ic drugs has been recognised
(L.F. Chasseaud, 1979). The depletion of intracellular
glutathione can be achieved by inhibiting the enzyme }(-
glutamylcysteine synthetase, the penultimate step in
glutathione synthesis, with the specific inhibitor
buthionine-S, R-sulfoximine (BSO) (C.W. Griffith et al,
1979) and this has proved much more selective than using
thiol reactive agents like diethyl maleate to deplete
glutathione levels. Since the work of Griffith a number
of authors have reported the use of BSO to demonstrate
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various glutathione effects. In L1210 cells resistant to
melphalan where detoxification by glutathione had been
emphasised as the important mechanism of resistance (K.
Suzukake et al, 1983), sensitivity to melphalan could be
restored by reduction in cellular glutathione by
buthionine sulfoximine (S. Somfai-Relle et al, 1984). A
similar potentiation of melphalan toxicity by glutathione
depletion has also been observed in 3 human ovarian
carcinoma cell lines and a sub-line made resistant to
melphalan in vitro (J.A. Green et al, 1984).
Thiol compounds also protect against cisplatinum toxicity
and have been used to reduce its nephrotoxicity. In rats
sodium diethyldithiocarbamate could be administered to
protect the kidney but to have minimal effects on the
toxicity of cisplatinum against a subcutaneous tumour
(R.F. Borch et al, 1980). It can also reduce bone marrow
toxicity (R.G. Evans et al , 1984) and has been shown to
inhibit and reverse the reaction of cisplatinum with
proteins in vitro (S.L. Gonias et al, 1984). In a similar
way sodium thiosulphate reduces nephrotoxicity in mice
(S.B. Howell et al , 1980) and can thus improve the
therapeutic ratio of cisplatinum (Y. Iwamoto et al, 1984).
Recently I.V. thiosulphate has been used to protect
against the systemic toxicity of i.p. cisplatinum in
humans (S.B. Howell et al, 1983). Thiosulphate appears to
bind to cisplatinum and thus prevent its uptake into cells
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in vitro (J. Uozumi et al, 1984)- Treatment with
glutathione itself has also shown protective effects in
vivo (F. Zunino et al, 1983). Litterst and his colleagues
have shown changes in glutathione and glutathione-S-
transferase levels in rat liver and kidney after
cisplatinum treatment and suggested an association of
cisplatinum with glutathione in the tissue cytosols (C.L.
Litterst et al, 1982).
In this laboratory preliminary data by Dr. Adams had shown
differences in glutathione content and levels of
glutathione-S-tr ansf erases between the PE/01 and PE/04
cell lines (C.R. Wolf et al , 1984 abstract) with
glutathione concentrations of 0.8 and 5.9 nmol/10^ cells
and transferase activities 35 and 159 nmol CDNB
conjugate/min/10^ cells for PE/01 and PE/04 cells
respectively in logarithmic phase cultures. Further work
by Lewis (ICRF Laboratory of Molecular Pharmacology and
Drug Metabolism, Edinburgh) has confirmed this difference
at about 2-fold for both glutathione and glutathione-S-
transferase activity. To see whether this difference is
important to cisplatinum resistance I have measured
glutathione levels in the cell lines and the resistant
subline PE/01 CisPtR, and attempted to restore sensitivity
to cisplatinum using the glutathione synthesis inhibitor




BSO toxicity on PE/01 and PE/04 and the effect of
cisplatinum plus BSO on PE/04 was assessed at low cell
density by the same clonogenic assay on plastic used in
chapter 3. Two days after being plated out the cells were
treated with 50 or lOOuM BSO for 19 hours and then treated
with cisplatinum on the 3rd day for 2-2^/2 hours with BSO
still present before the medium was changed to fresh
medium without drugs. Alternatively cultures in 25cm2 or
75cm2 flasks (Nunc Gibco Ltd) at higher cell density but
in logarithmic phase were treated with up to ImM BSO or
cisplatinum plus ImM BSO, harvested immediately by
trypsinisation and plated out at low cell density into
35mm wells of 6-well plates in triplicate in the
clonogenic assay on plastic as above. All incubations
were at 37°C in a 5% C02/air high humidity incubator.
Measurement of reduced glutatione (GSH) levels was by the
fluorometric assay of Mokrasch (L.C. Mokrasch et al, 1984)
with some modifications. 5% trichloroacetic acid was used
as a protein precipitant instead of formic acid since
formic acid did not remove all the protein from the cell
supernatant (no visible precipitate versus considerable
precipitate from 5% TCA). In my attempts to use the assay
to quantitate lower levels of glutathione I found a
standard additions method gave more accurate results than
reading values from a standard curve since although a good
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linear increase in glutathione measured with increasing
cell number was observed the line did not extrapolate
through zero as shown in figure 41.
Between 1.5 and 8 x 10^ cells growing in 25cm2 or 75cm2
flasks were harvested by trypsinisation into cold
phosphate buffered saline. A small portion was removed
for later cell counting and the rest were spun down,
resuspended in 1ml cold PBS and transfered to a microfuge
tube and then repelletted and resuspended in either 500ul
or 1ml of cold 5% TCA. Reduced glutathione (GSH) in
solution is stable for a reasonable length of time when
kept cold and especially so in acidic conditions to
prevent its oxidation so that this initial part of the
procedure was done as quickly as possible. The cells in
cold 5% TCA were then sonicated (3X5 second pulses with
10 second intervals in iced water to prevent the solution
warming up) and the precipitate spun down in a microfuge
(20, 000g for 20 minutes at 4°C). A sample of the
supernatant was taken for glutathione determination.
A lOul sample of the supernatant was mixed with lOul of
buffered formaldehyde (1:4 (v/v) 37% formalin : 0.1M
Na2HP04). After 1 to 2 minutes lOuls of a reduced
glutathione standard solution in buffer (0.1M Na2HPC>4, 5mM
EDTA, pH 8.0) was added followed by 2mls of this buffer
and then lOOuls of o-phthalaldehyde (1 mg/ml in methanol).
Figure 41 Fluorometric assay for Glutathione -
with increasing cell number
PE/01 cells X
Glutathione standards •
PE/01 cells were harvested and various cell numbers
resuspended in 1ml of 5% TCA. A lOOul aliquot of the
cell supernatant was used to measure reduced glutathione
levels.
A standard curve of various concentrations of reduced
glutathione in 5% TCA is shown for reference.
Figure 41
Cell number (x 10 or Glutathione standard (uM)
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This final assay mix was left in the dark at room
temperature for 35-60 minutes before reading the
fluorescence on a Baird Nova s pectrof 1 uor imet er
(excitation wavelength 345nm and emission wavelength
425nm). Reduced glutathione standards and o-
phthalaIdehyde solutions were made up fresh daily. Three
glutathione standards between 2uM and 5OuM final
concentration were usually used.
In some assays lOOul samples of the supernatant plus
glutathione standard in 5% TCA were used with lOOul of
buffered formaldehyde and 1ml of buffer (solution volumes
as in the assay of Mokrasch) in an attempt to assay
relatively low cell numbers. Although similar results to
the above method were obtained, drifting and variation of
the fluorescence reading were observed. This was due to
the low pH (approximately pH7.1) in the final reaction
volume due to using trichloroacetic acid instead of formic
acid. Hissin had previously reported the importance of
the pH for the reaction with o-phthalaldehyde with the
fluorescence intensity decreasing below pH 8.0 (P.J.
Hissin et al , 1976). With a lOul sample of TCA and 2mls
of buffer a pH of 8.0 was maintained. In this study
oxidized glutathione (GSSG) was not measured and it
represents only a minor proportion of the total





PE/01 and PE/04 cells were incubated with BSO for
approximately 22 hours in the clonogenic assay to
ascertain a minimally toxic dose to use in the BSO +
cisplatinum experiments. The results are shown in figure
42, combined from experiments with incubations between 18
and 25 hours with BSO. A preliminary experiment with a 47
hour incubation showed a similar result but with toxicity
at lower concentrations of BSO. PE/01 was much more
sensitive than PE/04 and also showed sensitivity at levels
of BSO (35% survival at 20uM BSO for 22 hours, 8% survival
at lOuM BSO for 47 hours) less than those used for
melphalan potentiation by Green (J.A. Green et al, 1984)
or doses used in later work from the same group at the NCI
(K.G. Louie et al, 1985). Thus further work with BSO was
confined to PE/04.
In 3 separate later experiments with logarithmic phase
PE/04 cells growing in 25cm^ or 75cm2 flasks no toxicity
was observed with concentrations up to ImM BSO for 22
hours. Clearly the change in the condition of the cells,
perhaps the higher cell density, helped them maintain
viability at concentrations which were toxic in the usual
assay.
Figure 42 BSO Toxicity on cells at low cell density
PE/01 X X
PE/04 • •
BSO dose(a) % Survival
(uM) PE/01 PE/04
10 63.6 + 10.1(2)(b)
(61.0)(c)
20 35.6 t 11.8(3) 146.7 (1)
(32.8) (105.7)
50 24.1 + 1.7 (3) 82.7 ± 17.0(5)
(24.0) (75.6)
100 28.5 (1) 62.3 * 24.4(5)
(32.2) (46.9)
200 - 25.3 + 2.2 (3)
(43.0)
(a) exposure for 18-25 hours in different experiments.
(b) BSO toxicity assessed by the clonogenic assay on
plastic reported in chapter 3. Results using the
[%^-thymidine method for calculating clonogenic
survival after drug exposure are shown.
The number of experiments from which the mean and
standard error were calculated is shown in brackets.
(c) Mean survival calculated from visual colony count
of 1 well per triplicate is shown in brackets.
BSO conc. (uM)
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Cisplatinum + BSO toxicity
In the first experiment PE/04 cells (at low density in 6
well plates) were pretreated with 50uM BSO before a range
of cisplatinum doses as shown in Figure 43. BSO alone
reduced survival to 76% of the control and the Cisplatinum
plus BSO line has been adjusted to 100% to see if there
was any potentiation of cisplatinum toxicity. Some
difference is apparent in the lines using the [^H]-
thymidine pulse method of colony number assessment at the
end of the experiment although the slopes of the lines are
similar. However the visual colony count of 1 well per
triplicate, which showed reduced survival to 82% of
control by BSO alone, after adjustment for this effect
showed no potentiation of cisplatinum toxicity except at
the highest dose.
In a second experiment repeated in the same manner the
dose of BSO was increased to lOOuM and the results are
shown in Figure 44. Here the BSO alone wells were 112% of
control. After adjustment to 100% there was some small
decrease in survival with cisplatinum plus BSO but the
slope of the drug survival curves were again very similar
suggesting BSO had little potentiating effect.
After BSO at concentrations up to ImM had been shown to be
non-toxic to PE/04 in bulk culture, logarithmic phase
PE/04 cells in 75cm2 culture flasks were treated with ImM
Figure 43 PE/04 - Cisplatinum toxicity
t BSO (50uM)
Cisplatinum alone % •
Cisplatinum with BSO pretreatment 6 O
Cells were treated in the clonogenic assay on plastic
with 50 uM BSO for 19 hours before exposure to cisplatinum
for 2 hours with BSO still present.
Mean and standard error from triplicates in one
experiment using the [%F)-thymidine method to calculate
clonogenic survival.
BSO alone reduced survival to 76% - adjusted to 100%
in the graph for comparison with the cisplatinum toxicity
without BSO treatment.
The clonogenic survival calculated from a visual colony
count of 1 well per triplicate is also shown.
BSO alone reduced survival to 82% - adjusted to 100%
in the graph for comparison.
Cisplatinum alone • •
Cisplatinum with BSO pretreatment 0 O
 
Figure 44 PE/04 - Cisplatinum toxicity
t BSO (lOOuM)
Cisplatinum alone % •
Cisplatinum with BSO pretreatment o o
Cells were treated in the clonogenic assay on plastic
with 100 uM BSO for 19 hours before exposure to
cisplatinum for 2^/2 hours with BSO still present.
Mean and standard error from triplicates in one
experiment using the \[pH}-thymidine method to calculate
clonogenic survival.
BSO alone gave 112% survival - adjusted to 100% in




B SO for 22 hours and then treated with various
concentrations of cisplatinum for 2 hours in the presence
of BSO. After plating out to low cell density for the
clonogenic assay, no difference in the cisplatinum
survival curves with or without BSO was observed as shown
in Figure 45. It could also be seen that the cisplatinum
toxicity was the same in this bulk culture as it was at
low cell density in Figure 43 and 44.
Glutathione concentrations
The mean reduced glutathione concentration for PE/04 cells
in logarithmic phase in 3 experiments was 5.40 +_ 2.38
(SEM) nmoles GSH/10^ cells. Different BSO concentrations
from 50uM to ImM depleted the cellular glutathione to
similar levels (12.7% for 50uM BSO and 6.8% for ImM BSO in
one experiment and less than 10% of control for all BSO
concentrations from 50uM to ImM in a second experiment)
which suggested that 50uM BSO should be sufficient to
deplete the glutathione for the potentiation studies
above. Glutathione concentrations for PE/01 and PE/01
CisPtR in logarithmic cultures were 1.24 and 1.95 nmoles
GSH/10^ cells (in 1 experiment where PE/04 gave a value of
3.20 nmoles/10^ cells).
Assays using lOOul of cell supernatant leading to a lower
pH in the final fluorescence reaction solution gave
similar values for the glutathione concentrations. Mean
Figure 45 PE/04 - Cisplatinum toxicity
+ BSO (ImM)
Cisplatinum alone • •
Cisplatinum with BSO pretreatment o -o
PE/04 cells in logarithmic phase of growth (2 days
after trypsinisation of 2.5 x 10^ cells into 75 cm^
flasks) were treated with ImM BSO for 22 hours
followed by cisplatinum for 2 hours with BSO still
present.
Cells were harvested immediately and plated out at
low cell density in fresh medium in the clonogenic
assay on plastic.
Mean and standard error are from triplicates in the
one experiment using the L Hl-thymidine method to
calculate clonogenic survival.
BSO alone gave 99% survival - adjusted to 100% in
the graph for comparison with the cisplatinum




values including these experiments are shown in Table 13
for PE/01, PE/04 and PE/01 CisPtR. PE/06 ( 20%02) and
PE/06(5%02) gave values of 4.7 and 9.6nmoles GSH/10^ cells
in one experiment. A confluent culture of PE/01 gave a
value of 0.3nmoles GSH/IO^ cells in one experiment.
The GSH concentrations obtained here for PE/01 and PE/04
are similar to those obtained using an HPLC assay (paper
shown in appendix, C.R. Wolf et al, submitted for
publication 1986) and decreased glutathione levels in
confluent versus logarithmic cultures have also been shown
(A. D . Lewis et al, 1986). In this work I tried to use
only cells in logarithmic culture 2 to 3 days after
passaging. Glutathione content has been calculated as
nmol/10^ cells as reported by others and not adjusted for
cell volume differences between the cells which were
minimal (reported in Chapter 2 - as a percentage of the
PE/01 mean cell volume, the cell volume of the PE/04 and
PE/01 CisPtR lines was 77% and 97% respectively but all
three cell lines showed a range of cell size with no
significant difference in cell volume between them).
5.3 Discussion
This work has confirmed the difference in reduced
glutathione levels between PE/01 and PE/04 and in addition
shown that PE/01 CisPtR has slightly elevated GSH levels
compared with its parent PE/01 although not greater than
TABLE 13




PE/01 CisPtR 3.11 + 0.64(c)
(a) values are mean (and standard error) Qf
data from 4, 7 and 3 experiments for
PE/01, PE/04 and PE/01 CisPtR in
logarithmic phase cultures.
(b) significantly different from PE/01
(P<0.01).
(c) significantly different from PE/01 but
not from PE/04 (at p = 0.05).
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PE/04. Changes in glutathione levels with tissue culture
conditions, time since passaging and position in the cell
cycle (J.K. Dethmers et al, 1981; G.B. Post et .al, 1983;
L. Roizin-Towle, 1985) have been reported by others so
some variability might be expected in different
experiments but I attempted to minimise this by only using
good growing cultures in logarithmic phase.
Minimal potentiation of cisplatinum toxicity was observed
with BSO treatment where glutathione concentrations were
reduced to less than 10% in PE/04 cells. Other workers
have used higher levels of BSO than initially used in this
project (ImM BSO, J.K. Dethmers et al, 1981; 2mM BSO, B.A.
Arrick et al, 1982 ; 0.5mM BSO with ovarian carcinoma cell
lines, P.A. Andrews et al, 1985) for a similar length of
time without toxicity and levels up to lOmM BSO have been
used for shorter times (A. Russo et al, 1984). However the
glutathione level and extent of depletion by BSO reported
here is similar to that reported in the literature (see
references below). The residual 5-10% glutathione is
reported to resist depletion (E.C. Gaetjens et al, 1984)
or its loss be associated with marked BSO toxicity (J.K.
Dethmers et al, 1981). The greater sensitivity to BSO
toxicity at low cell density would suggest even greater
glutathione depletion under these conditions as has been
shown with glutathione depletion by spermine (A. Russo et
al, 1985). Even at this low cell density little
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potentiation was evident.
These results confirm those of Andrews with ovarian cell
lines and sublines who could potentiate melphalan and
chlorambucil (and interestingly trans-platinum) but not
cisplatinum toxicity (P.A. Andrews et al, 1985) and a
preliminary report by Holden using a head and neck
squamous cell carcinoma cell line made resistant to
cisplatinum (S.A. Holden et al, 1985). Andrews also found
no increase in glutathione levels in the sublines with
resistance acquired in vitro to cisplatinum although
glutathione levels could be increased 2-3 fold in sublines
made resistant to melphalan. However a recent preliminary
report by Andrews with more highly resistant sublines (9-
13 fold resistant instead of 2-3 fold resistant) showed
increased glutathione levels and the resistance could be
partially reversed (to about 4-fold) by BSO treatment
(P.A. Andrews et al, 1986). In my work here the PE/01
CisPtR subline has 25-fold resistance with only a 1.6-fold
increase in glutathione level with less glutathione than
the PE/04 cell line. Further work from the NCI group
using cisplatinum as well as melphalan did show
potentiation of cisplatinum toxicity by BSO treatment but
always to a lesser extent than for melphalan (dose
modification factors approximately half, T.C. Hamilton et
al, 1985). The different results obtained may be related
to the extent of cross-resistance between cisplatinum and
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melphalan in the different studies, with higher cross-
resistance in the cell lines of the NCI group.
BSO has been thought to be a relatively non-toxic agent
(S. Sonifai-Relle et al, 1984 ) depleting glutathione with
little effect on the rate of cell division (E.C. Gaetjens
et al, 1984) and other cellular metabolism (B.A. Arrick et
al , 1982 ) although others have regarded it as a cytostatic
agent (R.F. Cordeiro et al, 1986). Gaetjens has adapted
L1210 cells to proliferate continuously, with reduced
glutathione content, in BSO concentrations as high as lOmM
(E.C. Gaetjens et al, 1984).
The amount of glutathione depletion by BSO or enhancement
in various cell lines is not linearly related to the
expected toxicity of a drug like melphalan (T.C. Hamilton
et al, 1985). A 2-fold increase in glutathione content
does not necessarily indicate a 2-fold increase in
melphalan resistance and observations vary widely in
different systems. To further assess the importance of
glutathione in drug metabolism it is also possible to
increase intracellular glutathione levels with 2-
oxothiazolidine-4-carboxylate (OTZ) which is converted
intracellularly to cysteine by the enzyme 5-oxo-L-
prolinase and thus stimulates glutathione synthesis (A.
Meister, 1983). Glutathione levels 135-170% of controls
led to modest protection against melphalan and cisplatinum
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(1.2 and 1.4 fold) in human lung fibroblasts (A. Russo et
al, 1986).
The precise mechanism of the protective effect of
glutathione against these drugs is unknown. Although
glutathione will covalently conjugate to many
electrophilic agents often via a glutathione-S-transferase
(L.F. Chasseaud, 1979) evidence for direct conjugation to
melphalan or cisplatinum is equivocal (J. Levi et al,
1980; D.F. Long et al, 1981; C.L. Litterst et al, 1982).
However the conversion of melphalan to its non-toxic
derivative dihydroxy-melphalan has been related to the
intracellular concentration of glutathione (K. Suzukake et
al, 1983). A methionine substitution product of
cisplatinum has been tentatively described (P.T. Daley-
Yates et al, 1984). Since intracellular glutathione
concentrations are in the millimolar range (data here;
Meister et al, 1983), well in excess of drug
concentrations, its depletion presumably affects the
activity of some enzyme system, perhaps by being in the
range of the Km of a glutathione transferase as discussed
by Jakoby (W.B. Jakoby, 1978). Others have also suggested
that glutathione may play just as critical a role in
repair of drug induced damage (L. Roizin-Towle et al,
1984).
Significant changes in the levels of glutathione dependent
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enzymes can also occur. Tew and his colleagues have shown
an increase in glutathione-S-transferase activity and a
decrease in glutathione reductase activity in a Walker 256
rat carcinoma cell line resistant to bifunctional nitrogen
mustards and collaterally sensitive to nitrosoureas (A.L.
Wang et al, 1985; K.D. Tew et al, 1985). PE/04 had
increased glutathione-S-transferase activity over that of
PE/01 (C.R. Wolf et al, 1984 abstract). More recent work
has also shown increased activity of glutathione
peroxidase, glutathione reductase and ^{-glutamyl
transpeptidase in PE/04 compared with PE/01 (A. Lewis et
al, 1986 abstract). All these enzymes are potentially
involved in drug detoxification.
Attempts to translate these results in vitro to in vivo
systems have so far not met with much success. In one
recent study, L1210 cells metastatic to the liver had a 2-
fold increase in their glutathione content over that in
cells in ascitic fluid of the peritoneal cavity (S. Ahmed
et al, 1986). This effect, apparently due to the hepatic
microenvironment, was accompanied by increased resistance
to melphalan which negated the sensitization achieved by
BSO treatment in the peritoneal cavity. In our laboratory
others have shown altered glutathione levels in the bone
marrow induced by a priming dose of cyclophosphamide where
the time course of glutathione overshoot to increased
levels paralleled the reduced toxicity of a subsequent
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duse of cyclophosphamide (D.J. Adams et al, 1985). To
improve the therapeutic index of treatment differential
effects on host and tumour tissue will be necessary.
These may be effected by differences in the timing of
glutathione modulation in host and tumour.
The conclusion from the present work is that glutathione
appeared to be of little importance to the drug resistance
observed despite the differences in glutathione and GSH-
related enzymes. A survey of the literature also
indicates that glutathione is probably less important for
protection against cisplatinum than against the
bifunctional nitrogen mustards melphalan and chlorambucil.
However since glutathione levels can change in different
environments (S. Ahmed et al, 1986) and cisplatinum at
high concentrations in vitro is known to inhibit ){ -
glutamyl transpeptidase (D.L. Bodenner et al, 1986) and
other enzymes containing sulphydryl groups (J.L.- Aull et
al, 1979), some influence of metabolism at this level can
not be entirely discounted. Obvious further experiments
would involve attempted potentiation with BSO of melphalan
and chlorambucil toxicity in these cell lines to see if
there was a different effect to that with cisplatinum.
Modulation of glutathione metabolism at low oxygen tension
would also be worthwhile particularly in the light cf the
changed chlorambucil toxicity at low oxygen tension shown
in Chapter 3 and the well studied role of glutathione in
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hypoxic and aerobic cell responses to radiation (J.D.
Chapman et al, 1984). It is also possible that the
sulphydryl rich metallothionein protein may play a role in
resistance to cisplatinum as shown in cell lines induced
with cadmium (A. Bakka et al, 1981), although
metallothionein is not thought to be induced by
cisplatinum (A. Kraker et al, 1985 ; S. Kinsler et al,
1985) even though it is a normal component of many cells.
Obviously further investigations of drug resistance will
need to be aware of variations in glutathione metabolism
since it is an important general route of detoxification
of electrophiles and at least monitor non-protein thiol
levels and perhaps protein thiols as well, for example in
the other ovarian cell lines described in chapter 2.
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6. Mechanisms of resistance to Cisplatinum - DNA studies
The major target for cisplatinum toxicity is DNA (J.J.
Roberts et al, 1979) and early studies established that
DNA synthesis is inhibited before and at lower
concentrations of drug than RNA or protein synthesis (H.C.
Harder et al, 1970). As discussed in the introduction
(Chapter 1), it remains uncertain as to which DNA lesicns
are critical to toxicity but most attention has
concentrated on interstrand crosslinks and more recently
intrastrand crosslinks. A number of recent reviews have
considered the likely important DNA adducts (S.J. Lippard,
1982; B. Rosenberg 1985; A.L. Pinto et al, 1985; J.
Reedijk et al, 1985). Altered DNA repair of these lesicns
has been postulated to account for cellular resistance tc
cisplatinum (M. Fcx 1984).
Efforts to understand the toxicity of cisplatinum at the
DNA level have basically prcceeded in three directions.
Firstly a number of authors have shown increased toxicity
of cisplatinum towards cells deficient in DNA repair
pathways in well characterised bacterial mutants (R.
Alazard et al , 1982 ; M. Germanier et al, 1984 ; R.J. Fram
et al, 1985; I. Husain et al, 1985; D.J. Beck et al, 1985)
and yeast cells (M. A. Hannan et al , 198 4), but also in
human xeroderma pigmentosum and Fanconi anaemia mutants
(H.N.A. Fraval et al, 1978 ; E.H.A. Poll et al, 198 4).
Secondly attention has focussed on what DNA adducts are
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produced and in what frequencies by cisplat inum and its
analogues (A. Eastman, 1985; A.M.J. Fichtinger-Schepman et
al, 1985). It has recently become apparent that the most
abundant adduct is an intrastrand crosslink between
neighbouring guanine bases. This adduct . has been
quantitated immunochemically by two grcups (S.J. Lippard
et al, 1983; A.M.J. Fichtinger-Schepman et al, 1985) and
accounts for 35-45% of all adducts in Chinese hamster
ovary cells (A.C.M. Plooy et al , 1985). Thirdly, effort
has concentrated around the technique of alkaline elution
which has allowed sensitive analysis of DNA interstrand
crosslinks and DNA-protein crosslinks by measuring the
reduction in the elution in alkali of single stranded DNA
from membrane filters by the linking of DNA strands or DNA
and protein by the bifunctional reaction of cisplatinum
with DNA and protein in the cell. This emphasis stemmed
from early work showing superior interstrand crosslinking
by cisplatinum over that by transplatinum (J.M. Pascoe et
al, 1974) and also the correlation of interstrand
crosslinking with cisplatinum toxicity (L.A. Zwelling et
al, 1979a) although these crosslinks represent only
approximately 1% of DNA adducts (J.J. Roberts et al,
1982) .
Work by Zwelling and his colleagues mainly with L1210
cells has shown correlations between resistance (as well
as toxicity) and DNA interstrand crosslinks by alkaline
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elution (L.A. Zwelling et al, 1981; L.C. Erickson et al,
1981). In addition thiourea could inhibit toxicity and
crosslinking (L.A. Zwelling et al, 1979b). However others
have suggested that the crcsslinking is simply related to
dose of platinum (M.C. Strandberg et al, 1982). In L1210
sublines 20, 30 and 50-fold resistant to cisplatinum, the
same degree of crosslinking was found at a particular drug
dose for all three lines. Although the L1210 parent line
showed equivalent crosslinking at a 5-fold lower dose, in
agreement with the work of Zwelling, at equitoxic doses
the resistant sublines had more crosslinks than the
sensitive parent line. In both studies crosslinks
increased to a maximum at 6 to 12 hours after drug
exposure and then declined presumably due to DNA repair.
Other workers have suggested that the persistence of these
interstrand crosslinks for a considerable time could be
important for differential toxicity in different cells
(A.C.M. Plooy et al, 1984, 1985a).
The number of interstrand crosslinks appears to vary in
proportion to the total DNA-adduct formation (A.C.M. Plooy
et al , 1985b; R.J. Knox et al, 1986) and so their
measurement appeared to be a good first step in assessing
differential cisplatinum toxicity or resistance in the
cell lines in this project. In addition, inhibition of
DNA synthesis gives a broad indication of DNA damage.
That inhibition and possible subsequent replication on a
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damaged template may ultimately be the cytotoxic event
(J.J. Roberts et al, 1980; R. Alazard et al, 1982). Thus
these 2 assays were used here to initiate studies on
resistance at the DNA level.
An entirely different line of experimentation was taken to
explore possible gene amplification as a mechanism of
resistance. Gene amplification has been implicated in
resistance to a number of anticancer drugs although not so
far to cisplatinum (R.T. Schimke, 1984). Together with
Mr. Arthur Mitchell (of the MRC Clinical and Population
Cytogenetics Unit) I decided to investigate this
possibility using the technique of Roninson to detect new
highly repeated DNA sequences in a drug resistant cell
line (I.B. Roninson et al, 1984). For this purpose the
most highly resistant line PE/01 CisPtR was used since it
might be expected to have the highest degree of
amplification, if any had occurred.
6.1 Methods
Inhibitions of DNA synthesis by cisplatinum
Inhibition of DNA synthesis was measured by a pulse with
[]-thymidine at various times after cisplatinum
treatment essentially as described previously for melanoma
cells (P.G. Parsons et al , 1982 ). PE/01 and PE/04 cells
were plated in 0.4mls medium at 8 x 10^ and 5 x 10^
cells/well respectively in 16mm wells of a 24 well plate
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(Nunc, Gibco Ltd) and after 2 days another 0.3mls of
medium added. This procedure produced even spread of
cells across the well which were growing well by the third
day when fresh medium was added and the cells treated with
5uM cisplatinum. At various times thereafter duplicate
cultures were pulsed for 25 minutes with 15ul of lOOuCi/ml
[^H-methy1]-thymidine (52 Ci/mmol, Amersham UK) before
being harvested by trypsinisation and filtered onto GF/A
glass fibre discs (Whatman) with water and 5%
trichloroacetic acid. The filters were dried and counted
in a liquid scintillation counter (Packard model 4430).
Counts were expressed as percentage of control untreated
wells pulsed and harvested at the same time.
DNA-interstrand crosslinks induced by cisplatinum
The alkaline elution technique developed by Kohn was used
(K.W. Kohn et al, 1981). Some preliminary experiments
used Polyvinyl Chloride filters (BSWP 02500, Millipore
Corp.) with cell lysis by Sarkosyl (N-lauroyl sarcosine
sodium salt, Sigma) but most experiments used
polycarbonate membrane filters (2.0um pore size, Nuclepore
Corp.) with lysis by SDS (sodium dodecyl sulphate, BDH
Chemicals Ltd.) and using a proteinase K (Boehringer
Mannheim) treatment step. The 25mm diameter filters were
mounted in opaque Swinnex type filter holders (Millipore
Corp).
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Cells of PE/01, PE/04 or PE/01 CisPtR cell lines were
plated out in 25cm2 tissue culture flasks (Nunc, Gibco
Ltd) at 2 x 1C)6 cells/flask in 4mls medium. Late the next
day the cells were prelabelled with either 0.2uCi/ml [^H-
methyl]thymidine (52 Ci/mmol, Amersham) or 0.05uCi/ml
[ 14C -methyl]thymidine [54mCi/mmol, Amersham] in the medium
overnight. The following day, after a change to fresh
unlabelled medium for 1/2 hour, the cells were treated
with cisplatinum for 2 hours and then incubated in medium
without drug until being harvested at various later
timepoints. Cells were harvested by trypsinisation and
suspended in cold phosphate buffered saline (PBS). A cell
pellet was spun down, resuspended in 1ml PBS and
transferred to microfuge tubes (Eppendorf) which were kept
cold on ice and shielded from light. Cells in these tubes
were irradiated where necessary with 450 rads x-rays from
a Cobalt-60 source at approximately 150 rads/minute.
Control []-label led cells not treated with cisplatinum
were irradiated with x-rays and then added to cisplatinum
treated [44C]-labelled cells of the same cell line to act
as an internal control in each elution.
Polycarbonate filters in Swinnex filter holders were
washed with PBS, cells loaded on and washed through with
more PBS under gravity or by suction from a multi-channel
pump (Ismatec Instruments) at 0.4ml/minute (P. Bedford et
al, 1984). Lysis buffer (2% SDS, 0.025M Na2EDTA, pH 10.0)
145
was then added to drip through followed by lysis buffer
containing 0.5mg/ml proteinase K. The outlet tubes were
then clamped, more proteinase K lysis buffer added to fill
the filter holders and protein degraded for approximately
50 minutes. This solution was then allowed to drip
through before the alkaline elution buffer (approximately
0.1M tetrapropylammonium hydroxide, 0.02M EDTA (acid
form), 0.1% SDS, pH 12.3) was added. Elution was carried
out at a flow rate of approximately 0.03mls/minute,
although there was some variation between pump channels,
and 1 hour fractions collected in scintillation mini-vials
in a Gilson model 202 fraction collector adapted to take 8
channels at a time. After the elution the filters were
placed in scintillation vials, heated to 70° for 1 hour
with 0.5mls IN HC1 , cooled and neutralized with 1.25mls
0.4N NaOH. The filter holders and line tubing were washed
through with 0. 4N NaOH and the washings collected and
neutralized with IN HC1 . The fractions collected (1.5-
2mls volume) were neutralized with 75ul IN HC1 . The
filter, washings and fractions were counted on a liquid
scintillation counter (Packard) after addition of Unisolve
1 (Koch-Light Ltd), a scintillant which can accommodate up
to an equal volume of aqueous solution. All the samples
were neutralized as above to improve counting efficiency.
A sample of the lysis solution which had previously
dripped through the filter was also counted to check for
any loss of DNA before the elution but this never reached
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more than 5% and usually less than 3% of the total counts.
The data is presented graphically as log % DNA retained on
the filter versus time, using the elution of the [^H]-
labelled and irradiated control DNA as a modified time
scale to compensate for any differences between filters
and pump channels. I wrote a computer programme to assist
in converting the data to this form. The apparent cross¬
link frequency expressed in rad-equivalents was calculated
by the formula of Kohn.
Pc = < iLlL*0 " 1) PBR
V/ 1 " R1
where Pc is the cross-link frequency, Pgg the single
strand break frequency from the radiation, R0 the amount
of DNA retained on the filter after irradiation and R]_ the
DNA retained after drug treatment and irradiation. The
cross-link frequency was calculated at 20% of the control
irradiated DNA retained on the filter.
Repeated Sequence DNA Analysis
This work was done in collaboration with Mr. Arthur
Mitchell of the MRC Clinical and Population Cytogenetics
Unit who had an established interest in repeated DNA
sequences in the human genome. Therefore this work done
jointly with him would not have been possible without his
knowledge and technical expertise and the use of
restriction enzymes and DNA probes which he had available.
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Knowledge on repeated sequence DNA has been recently
reviewed (M.F. Singer, 1982).
DNA was prepared from confluent flasks of PE/01 (passage
81) and PE/01 CisPtR (passage 111) cells by the method of
Porteous (D.J. Porteous, 1985) with minor modifications.
This follows the standard procedures of cell lysis, RNAase
and pronase digestions, extractions with phenol and
chloroform and spooling out DNA after ethanol
precipitation. Two cycles of enzyme treatment, extraction
and DNA precipitation were used and the DNA redissolved in
5mls of lOmM Tris buffer pH 7.5. The expected UV spectrum
for purified DNA was observed and showed that the DNA
obtained was at 760ug/ml for PE/01 DNA and 522ug/ml for
PE/01 CisPtR DNA. Normal human DNA, designated M5, was
already available (A.R. Mitchell et al, 1985).
lOug samples of each of the three DNAs were digested with
various restriction endonucleases in 30uls total volume
for 6 hours and then run out on 1% agarose gels together
with lambda Hindlll markers (A.R. Mitchell et al, 1979)
and transferred to nitrocellulose filters by the method of
Southern (E.M. Southern, 1975). Restriction endonucleases
used were Haelll, BamHI, Hindlll, EcoRI, HinfI, Mbol,
Kpnl, Mspl, Hpall, Alul and Bglll. The DNAs on the
nitrocellulose filters were hybridized using the p82H
probe for repeated sequences in centromeric regions of
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human chromosomes (A.R. Mitchell et al, 1985) and also the
probe (D.J. Porteous, 1985) for the dispersed human
repeated sequence Kpnl (J.W. Adams et al, 1980; B. Shafit-
Zagardo et al, 1982) and the filters exposed to X-ray film
to visualise bands of hybridized DNA.
The technique of Roninson to detect repeated and amplified
DNA fragments, where the genome being tested in effect
provides the probe for any sufficiently repeated sequence,
was also tried (I.B. Roninson, 1983 ; I.B. Roninson et al,
1984 ). In a first experiment 60ug of each of the 3 DNAs
was digested with BamHI (60 units of enzyme in 180uls
final volume for 6 hours). 1.5ug DNA from these digests
was labelled as tracer DNA using T4 DNA polymerase for 30
minutes in the exonuclease reaction before addition to
200uCi [-32p]dCTP and the other deoxynucleotide
triphosphates for resynthesis. The tracer DNA of each
sort (M5, PE/01, PE/01 CisPt^) was then co-electrophoresed
with unlabelled "driver" DNA (15ug) of each sort from the
above digests. The gel was subjected to 2 cycles of in-
gel renaturation and Si nuclease digestion with
hybridization for 15 hours and then 2 hours in the 2
cycles respectively and was then dried down and
autoradiographed. A second experiment was done in similar
fashion except the T4 DNA polymerase exonuclease reaction
was continued for only 6 minutes to try to reduce the
background on the gel.
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6 . 2 Results
Inhibition of DNA synthesis by cisplatinum
PE/01 and PE/04 cells in log culture were treated with 5uM
cisplatinum and pulsed for 25 minutes with []-thymidine
at various times thereafter as a measure of DNA synthesis.
Cisplatinum exposure was continued for the duration of the
experiment. The results are shown in Figure 46.
Inhibition gradually increased with time. PE/01 showed a
small but consistently increased inhibition of DNA
synthesis compared with PE/04 over all of the 24 hour time
course.
DNA-interstrand crosslinks induced by cisplatinum
These experiments used the alkaline elution technique
developed by Kohn and his colleagues (K.W. Kohn et al,
1981). An initial experiment demonstrated equal elution
of DNA from PE/01 and PE/04 cells after irradiation with
500 rads of x-rays as shown in Figure 47. Since
variations in the elution rate between different channels
of the multichannel pump were apparent, the volume of the
eluant was used as an adjusted time scale to compare the
elution rate from different filters. In later experiments
with cisplatinum treatment, an internal control of
irradiated but otherwise untreated cells labelled with
[ ]-thymidine was used in each elution and its elution
rate served as an adjusted time scale to compare DNA
elution from different filters.
Figure 46 Cisplatinum Inhibition of DNA Synthesis
PE/01 x
PE/04 •
Cells were treated with 5uM cisplatinum and DNA
synthesis estimated by -thymidine incorporation
at various times thereafter.





Figure 47 Alkaline elution of X-irradiated cells
PE/01 control untreated cells O
treated with 200 rads X-rays ^
treated with 500 rads X-rays D
PE/04 control untreated cells •
treated with 500 rads X-rays •
Cells were harvested into cold PBS, irradiated from
a Cobalt 60 source, and eluted through polyvinyl
chloride filters with tetramethyl ammonium hydroxide
+ 0.02M EDTA pH 12.3 after cell lysis on the filter
with 0.2% sarkosyl, 2M NaCl, 0.02M Na2EDTA pH 10.0.
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Preliminary experiments showed a decrease in the elution
rate of DNA from PE/01 and PE/04 cells treated with 2uM
cisplatinum for 6 hours indicative of DNA-protein cross¬
links and/or DNA interstrand crosslinks. Therefore in
time course experiments a concentration of 5uM cisplatinum
was chosen with drug exposure being for 2 hours with
subsequent incubation without drug. Interstrand cross-
linking expressed in rad-equivalents, over a 24 hour
period is shown in Figure 48 for the cell lines PE/01 and
PE/04 with results from 3 experiments shown. Approx¬
imately 10% of DNA from unirradiated cells with or without
drug exposure eluted from the filter at the retention time
used to calculate crosslinking frequency. No evidence for
DNA single strand breaks caused by cisplatinum was seen.
Since only 8 filters could be eluted at one time it wasn't
possible to do an extensive timecourse with both cell
lines in the one experiment and the variation between
experiments was larger than expected. In only one of the
three experiments were PE/01 and PE/04 treated together
with cisplatinum and eluted on the same day. In light of
this variation, little difference between the two cell
lines at 5uM cisplatinum concentration was observed,
either in the development, extent or repair of interstrand
crosslinks. Maximum crosslinking appeared to occur at 6
to 12 hours as reported by others (L.A. Zwelling et al,
1979a; A.C.M. Plooy et al, 1984) but little repair of
these crosslinks was evident.
Figure 48 Time course of Development of DNA
Iriterstrand Crosslinks induced by
Cisplatinum
Experiment 1. PE/01 O
Experiment 2. PE/04 •
Experiment 3. PE/01 a , PE/04 m
(line drawn between mean values PE/01
PE/04 )
Cells were treated with 5 uM cisplatinum for the first
2 hours of the time course and then harvested at various
times later for assessment of DNA interstrand crosslinking
by alkaline elution.
Crosslinking is expressed in rad-equivalents by the




It was then decided to check the dose response of each
cell line in forming interstrand crosslinks to increasing
doses of cisplatinum. Cells were exposed to cisplatinum
for 2 hours and incubated for a further 4 hours without
drug (i.e. 6 hours total incubation as above) before being
harvested for the alkaline elution assay. The elution
curves for 3 different experiments are reported in Figures
49, 50 and 51 with each figure drawn on the same scale.
Again some variation between experiments can be observed.
However, a clear dose response of crosslinking with
increasing dose of cisplatinum above 5uM is apparent in
each experiment and at the higher doses of 20uM and 50uM
cisplatinum PE/01 showed greater interstrand crosslinking
than PE/04. In addition in the experiment shown in Figure
51 the interstrand crosslinking at these doses in the
resistant subline PE/01 CisPtR is considerably less than
either PE/01 or PE/04. Apparent crosslink frequencies
calculated in rad-equivalents from Figures 48-51 are shown
in Table 14. With the low doses of cisplatinum (luM and
5uM) it was more difficult to take accurate data from the
graphs. Mean values were 12, 67 and 158 rad-equivalents
for PE/01 and 19, 38 and 98 rad-equivalents for PE/04 at
doses of 5, 20 and 50uM cisplatinum respectively. These
values are of the same order of magnitude as reported by
others (L.A. Zwelling et al, 1981; L.C. Erickson et al,
1981). As also previously reported a linear increase in
crosslinking with cisplatinum dose was also apparent. The
Figure 49 Alkaline elution - PE/01 and PE/04
1, 5, 20 uM cisplatinum
1 uM cisplatinum PE/01 0 PE/04 •
5 urn cisplatinum PE/01 a PE/04 ■
20 um cisplatinum PE/01 <> PE/04 ♦
control unirradiated PE/01 PE/04 +
All cells irradiated with 450 rads X-rays (except
control cells) and treated with proteinase K after
cell lysis on the filter.
Elution is plotted against the elution of %-labelled
control cells of the same cell line irradiated with
450 rads X-rays and added with the ^C-labelled
cisplatinum treated cells on each filter. The
irradiation introduces DNA single strand breaks and
DNA interstrand crosslinks are evidenced by a reduction













Log(% %-control DNA) retained on filter
Figure 50 Alkaline elution - PE/01 and PE/04
5, 20, 50 uM cisplatinum
5 uM cisplatinum PE/01 u PE/04 ■
20 uM cisplatinum PE/01 O PE/04 ♦
50 uM cisplatinum PE/01 © PE/04 *
50 uM cisplatinum but
unirradiated PE/01 X
Control unirradiated PE/04 +
Elution after 450 rads X-rays and proteinase K treatment,
as detailed in Methods section and legend to figure 49.
 
Figure 51 Alkaline elution - PE/01, PE/04 and PE/01 CisPtR
20, 50 uM cisplatinum
20 uM cisplatinura
50 uM cisplatinura
50 uM cisplatinum but
unirradiated
Control unirradiated
PE/01 PE/04 ♦ PE/01 CisPtR $
PE/01 O PE/04 * PE/01 CisPtR §
PE/01 CisPtR +
PE/01 X
Elution after 450 rads X-rays and proteinase





Log(% %-control DNA) retained on filter
TABLE 14
DNA Interstrand-Crosslinking
































CisPtR (51) 15 64
* Numbers refer to the figure in the text which shows
the experiment from which the crosslink frequency has
been calculated.
(a) Crosslinking frequency 4 hours after a 2 hour
exposure to cisplatinum.
(c) Second reading shown here calculated from the same
experiment for PE/01 and PE/04 of the 3 experiments
shown in figure 40.
(d) Calculated at 48% instead of 20% of [^H] DNA retained
on the filter since fractions eluted more slowly in
this experiment.
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slope of a linear regression line of crosslinking versus
drug dose was some 1. 9x higher in PE/01 than PE/04,
indicative of more interstrand crosslinks being formed per
increment of cisplatinum dose increase in that cell line.
Repeated Sequence DNA Analysis
Two probes for specific repeated sequence DNA were
available, one for sequences shown to be located in
centromeric regions of all human chromosones (p82H, A.R.
Mitchell et al, 1985) and one for the dispersed Kpn
repeated sequence (D.J. Porteous, 1985; B. Shafit-Zagardo
et al, 1982). Both were used since it is possible that
new or rearranged amplified sequences could be found with
other repeated sequence DNA (as shown for methotrexate
resistance with amplified sequences associated with
satellite DNA (C.J. Bostock et al, 1980)) and thus shift
the position of DNA restriction fragments seen on agarose
gels. The DNA from the PE/01 and PE/01 CisPtR cell lines
was compared together with normal human DNA (A.R. Mitchell
et al, 1985). DNA digested with Haelll, BamHI, Hindlll,
EcoRI, Hinfl, Mbol, Kpnl, Mspl, Hpall, or Alul restriction
endonucleases was analysed with the p82H probe. A number
of differences were observed between the M5 normal human
DNA and the DNA from the 2 tumour cell lines. New DNA
bands and missing or very faint bands were seen in the
tumour lines with most of the restriction endonucleases
used except Kpnl which simply gave a smear of DNA and Mspl
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where most of the DNA hybridized on the gel was in the
high molecular weight region. On the other hand little
DNA hybridized in the high molecular weight region of the
gel with Hinfl with the normal DNA but there was a
considerable smear of DNA for PE/01 and PE/01 CisPtR.
Some possible differences between PE/01 and PE/01 CisPtR
appeared to be simply due to variation in intensity of
bands possible due to loading differences and were not
seen in a repeat experiment. Thus no new p82H hybridizing
bands were observed in PE/01 CisPtR compared with PE/01.
With the Kpn probe enzyme digests with Kpnl, Hindlll and
Bglll only were examined. Again some marked differences
between the M5 normal human DNA and the DNA of the 2 cell
lines were observed but no differences seen between the 2
cell lines.
The technique developed by Roninson (I.B. Roninson et al,
1984) was thought more, likely to show any differences
between the cell lines. It relies on in situ denaturation
and renaturation of DNA restriction fragments separated on
an agarose gel and displays amplified sequences as novel
bands which are missing from the control DNA. In this way
it can confirm the presence of DNA sequence amplification
without any prior knowledge of the nature of the amplified
sequence itself. However, a first experiment using this
technique gave a high background smear of DNA down the gel
which could not be removed. This made detection of bands
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of repeated sequence DNA difficult and was probably due to
labelling of the short interspersed Alu repetitive
sequences present in human DNA (C.M. Houck et al, 1979).
As discussed by Roninson (I.B. Roninson, 1983) labelling
may need to be limited to the terminal portion of the
restriction fragment' to avoid this problem and
consequently the T4 DNA polymerase exonuclease reaction
was reduced from 30 minutes to 6 minutes in a second
experiment. In addition in the first experiment
radioactivity in the M5 normal human DNA tracer was 10-
fold less than in the other DNA tracers and hence these
lanes on the gel could not be visualised effectively. A
diffuse band at low molecular weight appeared to show some
difference between PE/01 CisPtR and PE/01 in some lanes
but not in others. In the second experiment the band to
background ratio was much improved. However, here the
PE/01 CisPtR tracer had much reduced radioactivity and
these lanes could not be visualised so no comparison of
the 2 cell lines was possible. No significant differences
were observed between the M5 and PE/01 DNA although there
was some difference in the density of bands at low
molecular weight.
6.3 Discussion
In this study the measurement of DNA interstrand
crosslinking by cisplatinum correlated with resistance to
drug toxicity in the 3 cell lines PE/01, PE/04 and PE/01
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CisPtR. Reduced crosslinking at a particular dose of
cisplatinum correlated with increased resistance, in
agreement with the data of Zwelling (L.A. Zwelling et al,
1981) and more recent data in a preliminary report with
unrelated ovarian cancer cell lines (B.G. Ward et al,
1985). However, the difference in the amount of
crosslinking between the cell lines, particularly for
PE/01 CisPtR may not be enough to completely explain the
degree of resistance observed. Other factors would appear
to be important as well, such as mono-adduct quenching,
other lesions, or effects before the drug reaches the
nucleus, as suggested by others in similar studies based
on the alkaline elution technique (M.C. Strandberg et al ,
1982; K. Micetich et al, 1983) although crosslinking may
not necessarily need to show a linear correlation with the
extent of resistance to explain that resistance. Others
have emphasised that the extent of total platinum bound to
DNA is correlated with drug toxicity (J.J. Roberts et al,
1980; R.J. Knox et al, 1986 ) and interstrand crosslinks
may simply correlate with Pt-DNA binding (as in the study
of A.C.M. Plooy et al, 1985b) or some other toxic DNA
1esion.
Some variation in the estimate of crosslinks at a range of
elution end points was observed, at variance with the
reports of Kohn's group (R.A.G. Ewig et al, 1978) but seen
by others (M.C. Strandberg et al, 1982), although the
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relation between different crosslink estimates within an
experiment remained very similar at different retention
times. The crosslink frequency was also calculated
according to the method of Plooy which mathematically
should give a better estimate since crosslinks are assumed
to slow rather than stop elution of DNA from the filter at
the retention time chosen (A.C.M. Plooy et al, 1984).
This method calculates DNA retention at 50% control
irradiated DNA retained on the filter. Since both methods
need to estimate the retention of treated DNA graphically,
it can be seen in my experiments that differences between
different cell lines or treatments appear small and thus
difficult to estimate at 50% control DNA retained compared
with 20% control DNA retained. Also since the lines
graphed are slightly curved rather than straight, almost
no difference at 50% control DNA retained can change to a
clear difference when more DNA has eluted (as also
discussed by M.C. Strandberg et al, 1982). For these
reasons the method of Kohn was preferred, since the two
methods also gave qualitatively similar results although
as reported by Plooy his method gives crosslink
frequencies approximately 2-fold higher than the Kohn
method. Thus the frequencies obtained can only be
regarded as relative values and so no attempt was made to
compute absolute values of crosslinks/10^ daltons DNA or
cross-links/cell as quoted by some authors (M.F. Pera et
al, 1981; A.C.M. Plooy et al, 1984). Only the estimated
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crosslink frequencies according to the Kohn method have
been reported here. At low cisplatinum doses interstrand
crosslinking was difficult to measure (figures 49 and 50
have one curve below the irradiation only curve which
mathematically would lead to minus crosslinking values as
also shown by L.C. Erickson et al, 1981). However the
crosslinking frequencies shown in Table 14 are of the same
order of magnitude as reported by others (L.A. Zwelling et
al, 1981; L.C. Erickson et al, 1981) and show a linear
increase with cisplatinum dose as also previously
reported.
Although interstrand crosslinks are a minor DNA lesion
caused by cisplatinum (J.J. Roberts et al , 1982; A.
Eastman, 1985) they may nevertheless have a biological
role if DNA replication cannot proceed past a lesion
involving both DNA strands particularly if the lesion is
difficult to repair and thus persists in the DNA (A.C.M.
Plooy et al, 1 985a). In addition inhibition of
interstrand crosslink formation by thiourea (L.A. Zwelling
et al, 1979b) or diethyldithiocarbamate (D.L. Bodenner et
al, 1986) was correlated with reduced cytotoxicity of
cisplatinum and when these thio compounds were added after
crosslinks had formed no reduction in crosslinks or
toxicity was observed. The kinetics of the formation and
repair of interstrand crosslinks has been extensively
studied (K. Micetich et al, 1983; A.C.M. Plooy et al,
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1985a). Murray has investigated their persistence in vivo
and shown variations amongst normal mouse tissues and in 2
different tumours (D. Murray et al, 1985). A recent
preliminary report showed a correlation of interstrand
crosslinks with drug sensitivity in 2 bladder carcinoma
cell lines but less crosslinks in a more sensitive
testicular tumour cell line at an equitoxic dose
indicating differences between tissues which may be
important (P. Bedford et al, 1986). The mechanism of the
slow formation of interstrand crosslinks is uncertain but
it can occur even in DNA preparations in buffer (A.
Eastman, 1985; R.J. Knox et al, 1986) and is presumably
due to the appropriate conformational changes in the
secondary structure of the DNA after a mono-adduct is
formed (A. Eastman, 1985). Since DNA-protein crosslinks
and intrastrand crosslinks are formed rapidly (K. Micetich
et al, 1983 ; A.C.M. Plooy et al, 1985) other mono-adducts
must be either repaired or be in positions where no other
reactions are possible to form stable products in the
meantime. It is possible that these mono-adducts are
stabilised temporarily by other ligands such as phosphates
(E. Segal et al, 1985) or the exocyclic ring oxygen at the
6 position of guanine (S.J. Lippard, 1982). A recent
preliminary report has suggested that a late step in the
repair of a rare DNA lesion, such as an interstrand
crosslink, may be important in sensitive versus resistant
Walker 256 carcinoma cells (J.J. Roberts et al, 1986).
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Interstrand crosslinking is known to be important for
other agents like the bifunctional alkylating agent
melphalan (P.G. Parsons, 1984). Quantitatively minor
lesions have also been shown to be important for other
agents, particularly in the well characterised case of
monofunctional alkylating agents and the 0^-alkylguanine
lesion (D.B. Yarosh, 1985).
Since cis-bifunctionality is important to cisplatinum
toxicity, intrastrand crosslinks which can be formed by
cis- but not trans- platinum have received increasing
recent attention (A.C.M. Plooy et al , 1985; E. Reed et al,
1986). Reed and his colleagues have suggested a positive
correlation between formation of DNA intrastrand cross¬
links in DNA of buffy coat cells from peripheral blood of
testicular and ovarian cancer patients and response to
therapy. Although the intrastrand crosslink is the major
DNA lesion caused by cisplatinum (A. Eastman, 1985; A.C.M.
Plooy et al, 1985) its true biological significance is yet
to be assessed. Filipski has suggested it is the important
toxic lesion for\phage inactivation by cisplatinum (J.
Filipski et al, 1980 ). Chemically 2 neighbouring guanines
in a DNA strand is the preferred site for cisplatinum
binding (A. Eastman, 1983). It may inhibit DNA replication
(A.L. Pinto et al, 1985a) or it may be a difficult lesion
to repair (A.C.M. Plooy et al, 1985; R.B. Cicarell et al,
1985) and its role awaits further elucidation.
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The importance of the various DNA repair pathways in
repairing cisplatinum-DNA damage is unclear, partly due to
the complexity and the lack of knowledge in detail in
mammalian cells (M. Fox, 1984). Cisplatinum mono-adducts
are repaired most efficiently (A.C.M. Plooy et al, 1985)
and their repair or "quenching" before more toxic (or
difficult to repair) lesions are formed may be important
in cellular resistance to cisplatinum (K. Micetich et al,
1983). Excision repair and postreplication repair
pathways have both been implicated (J.J. Roberts et al,
1979). Some authors have emphasised the role of excision
repair (I. Husain et al, 1985 ) and its possible role in
removing intrastrand crosslinks (D.J. Beck et al, 1985).
Others have recognised differences in responses to UV or
cisplatinum damage indicative of differences in their
"excision" repair (H.N.A. Fravel et al, 1978; M. Germanier
et al, 1984). More than one pathway may be involved.
Excision and. recombinationa1 repair together were
emphasised by Hannan, possibly necessary to repair
interstrand crosslinks (M.A. Hannan et al, 1984).
Postreplication repair has been implicated through the
potentiation of cisplatinum toxicity by caffeine (J.J.
Roberts et al , 1979 , 1986a). Based on this work Roberts
has suggested that the important final genotoxic lesion is
a double strand break formed upon attempted DNA repair or
replication on a damaged template (J.J. Roberts et al,
1986a). Recovery from the cytotoxic effects of
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cisplatinum has been observed in normal human fibroblasts
after confluent holding (E.H.A. Poll et al, 1985) also
suggesting the importance of repair before DNA
replication. The DNA damage probably causes the
inhibition of DNA synthesis observed after cisplatinum
treatment. In this project a small increase in inhibition
of DNA synthesis was observed in the sensitive cell line
which supports the evidence of increased DNA damage seen
in the alkaline elution assay. A similar correlation of
low resistance (2-fold) and increased interstrand
crosslinking and inhibition of DNA synthesis (2-fold for
both) has been observed in 2 unrelated bladder
transitional cell carcinomas (P. Bedford et al, 1986a).
Further experiments with the alkaline elution assay could
define the kinetics and repair of interstrand crosslinks.
DNA-protein crosslinks could be investigated particularly
at short times as an indicator of the amount of active
platinum species reaching the nucleus (as suggested by
J.M. Ducore, 1986). The importance of these lesions needs
to be investigated in other cell lines and with the other
platinum analogues cross-resistant and not cross-resistant
to cisplatinum. The recognition of intrastrand crosslinks
would also be important but this would rely on obtaining
the appropriate antibodies (A.M.J. Fichtinger-Schepman et
al , 1985a). Total platinum binding to DNA can be assessed
using atomic absorption spectroscopy as in Chapter 4 and
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as described for ovarian cancer cells by Knox (R.J. Knox
et al, 1986).
In the repeated sequence DNA analysis no evidence for gene
amplification was obtained. It is not surprising that
some differences between the normal human DNA and the 2
cell lines were obtained since it involved DNA from
different individuals and the 2 cell lines represent
tumour DNA. The technique of Roninson needs gene
amplification to approximately 15-30 copies before it
would be detected (I.B. Roninson et al, 1984 ) and it is
possible that the PE/01 CisPtR sub-line which is 25-fold
resistant might not have enough amplified copies if gene
amplification had in fact occurred. Others have also
since used this technique (A.T. Fojo et al , 1985 ; P.
Meltzer et al, 1986) and its particular advantage is in
detecting amplification when the nature of the amplified
sequence in question is unknown so it may therefore be a
very useful technique for further work. As reviewed by
Stark (G.R. Stark, 1986) there is no data as yet to
implicate gene amplification (so far identified with
methotrexate and the pleiotropic drug resistant
phenotypes) as a mechanism of resistance to cisplatinum
but this possibility will need to await further
investigation.
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7 . General Discussion
7 .1 Deve lopment_of_an ovarian tuirour model for drug
JT®stance studies
This project has used 2 human ovarian carcinoma cell lines
derived from ascites at different times frcm the one
patient as a basis for a model of drug resistance in
ovarian cancer. As the project progressed the model has
been characterised in detail and extended with resistant
sublines derived in vitro and other cell lines derived
from further tumour, particularly ascites, samples which
were collected from patients referred to the Department of
Clinical Oncology. Cross-resistance to a variety of drugs
has been investigated and emphasis has been placed on
mechanisms of resistance to cis-platinum which has become
the leading drug in the chemotherapy of ovarian cancer.
The specific results have been discussed in the light of
the current literature at the end of the relevant
chapters.
The philosophy of the project has been to build up a model
which was as close to the clinical situation as possible.
Therefore only human ovarian cancer cells have been used
and further ascites samples continue to be collected and
frozen in liquid nitrogen when net used immediately. This
bank of ascites cells will be useful for drug sensitivity
testing or biochemical tests suggested by the work on the
derived cell lines. I have also attempted to avoid
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possible variability in results due to continued passaging
of cell lines (discussed in Chapter 3) and again different
passages, froir the earliest passages where there were
enough cells, have been frozen in liquid nitrogen for
future reference as needed. While I was keen to take the
work back from the cell lines to the original ascites the
project did not get this far in the time available. Large
numbers of cells and repeat experiments are often
necessary in investigating mechanisms of resistance and
this limited this work to the cell lines. Since the
stored ascites cells represent a precious and, for any one
patient with particular characteristics of tumour,
treatment and response, limited resource they have been
kept until now for further work envisaged in this
laboratory. One area for future study would be the
possibility of using the alkaline elution assay (with a
fluorescent dye to measure the DNA, P. Bedford et al ,
1984) to measure cisplatinum induced DNA crosslinking in
ascites samples either in vitro or after patient treatment
in vivo.
Obviously the postulate of resistance to cisplatinum
acquired in the patient from which the PE/01, PE/04 and
PE/06 cell lines were derived would be greatly
strengthened if differences in drug sensitivity in the
ascites samples (from which the cell lines were derived)
could be shown. The work of Trent and his colleagues has
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demonstrated cytogenetic variation between ovarian ascites
samples and derived cell lines (J.M. Trent et al, 1985).
Two ascites 9 months apart from 1 patient showed a very
similar karyotype. A cell line derived from the first
ascites showed a different karyotype (at passage 3 and
which remained stable in culture) and a cell line derived
from the second ascites represented a minor population in
the ascites (and its karyotype changed in culture).
However most of the karyotypic alterations of the tumour
were conserved in the cell lines. (R.N. Buick et al,
1985). Rather more karyotypic changes between primary
tumours and cell lines have been observed for human
gliomas and these occurred in the first weeks of culture
(J.R. Shapiro et al, 1985). Variations in
chemosensitivity between different clones were also
observed. Near diploid clones appeared to be more stable
karyotypically but could be rapidly overgrown by faster
growing hyperdiploid cells which were also more sensitive
to BCNU treatment. Greater variation in karyotype was
observed in explant cultures than in immediate clonal
cultures (J.R. Shapiro et al, 1981). Clearly culture of
human tumour cells in vitro places them under a different
selective environment which may change features
representative of the tumour. In any case the PE/01,
PE/04 and PE/06 cell lines represent a useful in vitrc
model for investigating mechanisms of lew level
resistance. The similar resistance of PE/04 and PE/06
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over PE/01 supports the idea of a change or selection
induced by the patient's chemotherapy.
While collection of ascites continued I was particularly
interested to obtain ascites from patients previously
untreated with chemotherapy or radiotherapy and to follow
their progress where this was possible. Cells from the
first ascites or tumour sample provide a reference point
of the tumour population before selection or alteration by
drug treatment. Serial sets of samples from the same
patient patient would help to analyse drug resistance
acquired in vivo as distinct from the many studies of drug
resistance where cell lines have been treated in vitro to
give resistant sub-lines (T.C. Hamilton et al, 1984a).
Four interesting multiple sets of ascites have been
collected here (Chapter 2), of which time only permitted
the PE/01 family of cell lines to be studied in detail as
yet. One study by Buick and his colleagues has reported a
series of 7 ascites from 1 patient (W.J. Mackillop et al,
1983) with cell lines reported from the first and last
ascites (R.N. Buick et al , 1985) but drug sensitivity data
has been reported only from the second cell line and not
from any of the ascites. Another study with 2 ascites
samples from 1 patient showed an increase in the P-
glycoprotein, which has been associated with the
pleiotropic drug resistance phenotype, in the second
sample after treatment with cyclophosphamide, doxorubicin
167
and cisplatinum (D.R. Bell et al, 1985). Wilson has also
reported 2 ascites samples from 1 patient but with
chemosensitivity data only from the primary culture of the
first sample and a cell line derived from the second
sample (A.P. Wilson, 1984) and sensitivity in the cell
line also varied with passaging. Evidence for increased
resistance of post-treatment samples (not all ovarian) has
been provided in a study of 12 patients where multiple
samples were available in the Hamburger/Salmon assay (S.E.
Salmon et al, 1980). With ovarian adenocarcinoma it was
feasible to collect a series of samples of the metastatic
disease in the form of ascites fluid over the course of a
patient's progress.
A second emphasis of this project was in concentrating on
low levels of resistance since these are most probably of
particular clinical relevance (as also emphasised by A.
Rosowsky et al, 1985 ). The variation in drug sensitivity
regarded as important is discussed at the end of Chapter 3
with my drug sensitivity results. Since patients are
usually exposed to doses of antineoplastic drugs which
approach the maximally tolerated dose which is limited by
toxicity to normal tissues, a 3-fold increase in
resistance of the tumour could not normally be matched by
a 3-fold increase in dose of drug. This is consistent
with the often seen initial response with later relapse
and non-response to the same drug regimen. Thus the PE/01
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and PE/04 resistant sublines were derived in cisplatinum
concentrations up to luM which would normally be highly
toxic to the parent cells, but no attempt was made to
generate even more highly resistant sublines. Tumour
heterogeneity with a range of drug sensitivity less than
10-fold (T. Tsuruo et al, 1981), for example a 5-fold
range as observed by Yung in clonal glioma cell lines from
a single tumour (W-K. A. Yung et al, 1982), would be very
significant for therapy as discussed recently (A.J. Dembo,
1984; R.C.F. Leonard et al, 1985). These variations may
be due to different microenvironments, especially for
metastases (H. Rubin, 1985; S. Ahmad et al, 1986), as well
as genetic differences (J.H. Goldie et al, 1984).
In looking at mechanisms of resistance an attempt was also
made to stay at drug doses comparable with the
biologically toxic dose (e.g. the LD50) since too high
doses of drug can lead to biochemical events irrelevant to
the biological phenomenon of interest (F.N. Ghadially et
al, 1981). This emphasis on low level resistance and
biologically relevant doses created its own experimental
problems. Many clues as to the possible biochemical
mechanisms responsible for resistance have been obtained
from highly resistant cells and the main possibilities for
cisplatinum resistance have been investigated in Chapters
4,5 and 6. However as can be seen from the data, often a
higher drug dose than that originally chosen needed to be
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used, due to the sensitivity of the assays or to looking
for differences between PE/01 and PE/04 which might be
near to the variability seen in an assay. These problems
were reason in part for deriving the PE/01 CisPtR and
PE/04 CisPtR sublines with resistance to cisplatinum at
somewhat higher levels so that possible differences
between these lines could be observed. Nevertheless I
believe these principles mentioned here are important if
observations in tumour models are to have significance for
clinical therapy. Our knowledge of mechanisms of drug
action in various experimental systems now needs to be
translated to these more relevant models.
Until now the only clearly defined differences between
PE/01 and PE/04 which may be relevant to drug resistance
are the different interstrand crosslinking at the same
dose of cisplatinum and the different level of glutathione
and glutathione dependent enzymes, although reducing
glutathione levels with BSO had little effect on
cisplatinum toxicity. In PE/01 CisPtR a further decrease
in interstrand crosslinking was observed but no further
increase in glutathione levels. The PE/04 CisPtR subline
was more difficult to derive than PE/01 CisPtR and it is
possible that a different mechanism of resistance was
acquired. Certainly further investigations of the
mechanisms of resistance are required in these 2 resistant
sublines together with the 2 resistant lines (PE/04 and
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PE/06) derived directly from ascites, particularly to see
if there is a common mechanism of resistance or not.
These experiments then need to be expanded to include cell
lines (and ascites) from other patients in order to
determine if general conclusions on cellular mechanisms
important to resistance to cisplatinum can be made.
Equally similar experiments with cross-resistant and non-
cross-resistant platinum analogues would be useful.
During the course of this project efforts by others in
this laboratory have focused on attempts to establish
xenografts in neonatally thymectomised mice from the
ovarian carcinoma cell lines and ascites. Early attempts
using 10^ cells injected subcutaneously appeared to give
some tumours but these then regressed. Later efforts by
Dr. Langdon in our laboratory has succeeded in
establishing a subcutaneous xenograft from 10® injected
cells of the PE/04 cell line which has progressed although
growth is still slow. Some islets of tumour cells could
also be seen from an intramuscular injection of 10® cells
but no tumours grew from an intraperitoneal injection.
Some work with PE/01, although with smaller numbers of
cells, showed some subcutaneous growth although the
tumours appeared to only grow to a certain extent and then
stop. Clearly a very large tumour cell injection which is
almost a solid tumour mass (10® cells in 0.1ml saline) is
necessary to establish a xenograft. However it would
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appear that both cell lines are tumorigenic. This
experience is similar to that of others who found
difficulty in establishing xenografts from ascites or cell
suspensions (S. Kullander et al, 1978; P.J. Selby et al,
1980; G.G. Steel et al, 1983). Friedlander established
xenografts from ascites or cell lines using a relatively
high cell number (5 x 10^ cells, M.L. Friedlander et al ,
1985) and an intraperitoneal xenograft has also been
reported (T.C. Hamilton et al, 1984). Clearly this sort
of work is necessary to complement the work reported in my
project and improve the overall model system used in this
laboratory. An in vivo system is particularly useful in
assessing drug combinations or modifiers of drug action.
No attempt has been made to test drug combinations in
vitro in this project since it is much more difficult to
assess the significance of such in vitro results. Recent
work at the I.C.R.F. in London has also established
intraperitoneal ovarian tumours in nude mice from cell
lines and ascites material with a good success rate (Dr.
Bruce Ward, personal communication; I.C.R.F. Annual report
1985 , section 26.10) and this may be a very appropriate
model.
Other future studies of relevance for drug resistance
include the phenotypic characterisation of cells (e.g. by
a range of antibodies) to enable cells of different
phenotype to be cultured together (but be still
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identifiable) and their response to antineoplastic drugs
then assessed, since subpopulation interactions may be
very important for drug resistance (P.J. Tofilon et al,
1984). Another useful extension of the model in this
regard would also be the development of spheroid cultures
for looking at cell-cell interactions, relative hypoxia
and drug penetration (T. Nederman, 1984; C. Erlichman et
al, 1985) especially in those cell lines like PE/014 which
naturally form domes and rounded cysts of cells in
culture. Others have grown ovarian tumour cells on
extracellular matrix instead of plastic (K. Crickard et
al, 1986) and different drug sensitivity data have been
reported for mouse mammary tumour lines in collagen gel
cultures versus normal clonogenic assays (B.E. Miller et
al, 1985).
The model presented here is now being broadened to test
the other ovarian cancer samples and cell lines so that
the observations made here can be generalised where
possible. While in vitro sensitivity data, especially
with cell lines, needs to compare a range of cell lines to
attempt to reflect the clinical response of the tumour of
origin (J.R.W. Masters et al, 1986), they can also suggest
patterns of cross-resistanee and possible common
mechanisms of resistance. With related ascites cells or
cell lines like the PE/01 family of lines the biochemical
differences between them may be specifically related to
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their different exposure to particular antineoplastic
drugs without the addition of interpatient variability.
In addition it is possible to make correlations between
the drug sensitivity of cell lines (M. Albrecht et al,
1985) as well as primary samples (S.E. Salmon, 1984) with
the clinical sensitivity of the tumour (ovarian carcinoma)
from which they were derived.
7.2 Treatment of ovarian cancer - platinum drugs
Several recently published clinical studies have confirmed
and extended the data on various combination chemotherapy
regimens discussed in Chapter 1. The chemotherapy of
ovarian cancer has been summarised in a number of recent
reviews (C.J. Rodenburg et al, 1984; R.F. Ozols et al,
1984 ; M.H.N. Tattersall, 1985 ; G.S. Richardson et al ,
1985; F.M. Muggia et al, 1985). Despite some recently
reported reservations to the contrary (C.J. Williams et
al, 1985; M.H.N. Tattersall et al, 1986) the consensus
would appear to be that cisplatinum based combination
regimens are at present the best choice for treatment of
advanced ovarian cancer after primary surgery (R.F. Ozols,
1985; J.G. McVie, 1986). The CHAP-5 cisplatinum-
containing regimen has been shown to be superior to the
Hexa-CAF regimen (J.P. Neijt et al, 1984). In some
instances cisplatinum also appears to be useful in second
line treatment even in relapses after first line
combination treatment including cisplatinum (V. Seltzer et
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al , 1985 ; M. Bruzzone et al, 1986). High dose cisplatinum
therapy (>100mg/m2) has also received continued interest
and shown responses even in patients resistant to standard
doses (R.F. Ozols et al, 1985) The use of intraperitoneal
therapy to administer a higher dose to the tumour has also
been investigated further by a number of groups and has
been recently reviewed (Gastrointestinal tumor study group
intraperitoneal therapy workshop, 1985). Interest in
other drugs (J.T. Thigpen et al, 1984) has continued to
centre round the platinum analogues, particularly CBDCA
(reviewed recently, S.K. Carter et al, 1985) but a number
of analogues have received phase I and phase II trials
(see Chapter 3 Discussion).
This clinical picture serves to confirm the emphasis of
this project in focussing on cisplatinum as the drug of
choice in ovarian cancer. Resistance to this drug is
therefore critical . This appears to be most convincingly
related to the amount of DNA lesions which are formed.
The relative lack of cross resistance of CHIP and CBDCA to
cisplatinum observed here (Chapter 3) is thus potentially
very useful and the mechanisms of their action on ovarian
carcinoma cells needs to be studied further. Clinically
only an approximately 20-25% response rate has been
observed for CBDCA in cisplatinum pretreated patients (R.
Canetta et al , 1985; E. Wiltshaw, 1985) while preliminary
data for CHIP suggest a similar picture (C. Sessa et al,
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1986). Knox has suggested that cisplatinum and CBDCA are
equally toxic if bound to the cell's DNA to the same
extent (R.J. Knox et al, 1986) but CBDCA appears to be
less reactive on a molar basis in forming DNA lesions like
interstrand crosslinks (K.C.'Micetich et al, 1985). In
L1210 cells lack of cross-resistance to cisplatinum has
also been reported for platinum complexes based on 1,2-
diaminocyclohexane as the stable amine ligand (M.P. Hacker
et al, 1985) as well as for some other analogues (W.C.
Rose et al, 1984).
7 . 3 Drug resistance studies
Acquisition of drug resistance during the progression of
many clinical tumours has been increasingly recognised as
a critical problem to the continued improvement of cancer
therapy and has been the subject of a number of recent
reviews (G.A. Curt et al, 1984) extending to issues of
journals (Cancer Treatment Reviews, llrSuppl A, 1984;
Cancer Surveys, 5(1), 1986) and books (B.W. Fox et al,
1984). Carter (S.K. Carter, 1984) and McGuire (W.L.
McGuire et al , 1985) have discussed the present trends in
the direction of research on the subject. Other reviews
have emphasised drug disposition (J.G. McVie, 1984), the
genetic nature of resistance (J.H. Goldie et al, 1984),
the pleiotropic resistance phenotype and multidrug
resistance (Cancer Treatment Reports, 67(10), 1983; J.H.
Gerlach et al, 1986) gene amplification (R.T. Schimke,
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1984; G.R. Stark, 1986) membrane alterations (D.W. Fry et
al, 1986), DNA repair (M. Fox, 1984; A.L. Harris, 1985)
collateral sensitivity (B.T. Hill, 1984) and tumour
heterogeneity (D.L. Dexter et al, 1986). One recent new
approach has been to isolate more sensitive mutants,
rather than generate more resistant cells by exposing them
to drug in vitro, with the idea that, tumour resistance can
almost by definition be equated with normal tissue
sensitivity and therefore the nature of more sensitive
cells is of most interest (C.N. Robson et al, 1985).
Resistance to cisplatinum at the cellular level has only
recently become the subject of detailed attention (as
discussed in Chapters 4,5 and 6) with most studies still
seeking mainly to understand its mechanism of action (C.L.
Litterst, 1984; J. Reedijk et al, 1985). However the
number of papers presented at the recent meeting of the
American Association for Cancer Research (Proc. Am. Assoc.
Cancer Res., 27,1986) on this topic, with papers dealing
with cisplatinum uptake (Nos. 1033,1038,1044,1069,1134 and
1155), cisplatinum and glutathione metabolism especially
using BSO depletion of glutathione both in vitro and in
vivo (Nos. 1139,1148,1155,1562 and 1665), intracellular
metabolites (No. 1069), DNA adducts (Nos. 1033, 1046, 1132
and 1154), cross-resistance of analogues (Nos. 1133, 1134,
1138 and 1562) and rate of acquired resistance in vitro
(No. 1549), illustrates the increased interest engendered
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over the duration of this project and the subject has been
recently reviewed (A. Eastman et al, 1986). One group at
the NCI, Bethesda (T.C. Hamilton et al, 1984; T.C.
Hamilton et al, 1985; Proc. Am. Assoc. Cancer Res. 27,
1986 Abstract Nos. 1046,1132 and 1562) and another at the
University of California, San Diego (P.A. Andrews et al,
1985; Proc. Am. Assoc. Cancer Res. 27, 1986 Abstract Nos.
1069 and 1148) have used ovarian cell lines to study the
mechanisms of resistance to cisplatinum. It is becoming
apparent that as with other drugs resistance can be
acquired in various ways and at the level of membrane,
cytoplasm and nucleus with the possibility that different
factors can be involved together in the resistance of a
particular cell. In this project it seems clear that the
amount of DNA lesions formed by cisplatinum is important
but whether resistance is due to decreased formation of
DNA adducts (affected by cytoplasmic or nuclear events)
or increased DNA repair is uncertain. Reduction of
transport of drug into the cell or effects of glutathione
metabolism did not seem to play a major role. While some
workers have concentrated on one aspect of the drug's
mechanism of action, usually through the availability of a
particular assay, this can often lead to uncertainty as to
the overall picture. I attempted to study as many
different factors as possible in a new and unusual model,
although more work leading on from the results presented
here is obviously necessary before definite conclusions
178
can be drawn. It will also then be important to determine
which factors turn out to be most commonly involved in
vivo in the resistance of the majority of patients '
tumours. Multiple factors may be particularly important
for low level resistance although this is disputed by some
(E.P. Clark, 1986). In addition different factors may be
important for different analogues.
7.4 The future - overcoming drug resistance?
Apart from the importance of drug disposition and the
responses of the tumour at a cellular level discussed
above, other factors may be important. Cell-cell
interactions have been shown to affect the sensitivity of
cells to BCNU in mixtures of sensitive and resistant
subpopulations (P.J. Tofilon et al, 1984). Another study
using subpopulations of a mouse mammary tumour has shown
one subpopulation to affect the chemosensitivity (to
cyclophosphamide or methotrexate) of another subpopulation
even when the subpopulations were injected on opposite
flanks of the mouse, or in vitro when grown on separate
coverslips in one Petri dish (B.E. Miller et al, 1981).
An extracellular factor which transmits the cell response
of UV-irradiated cells to non-irradiated cells has also
been reported (M. Schorpp et al, 1984). Poste has
suggested (in relation to the metastatic phenotype) that
in polyclonal populations the various clonal
subpopulations interact with one another to stabilize
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their relative proportions and cloning results in rapid
emergence of variant subclones (G. Poste et al, 1981).
This might suggest that caution should be exercised in
cloning cell lines in vitro to show heterogeneity of drug
sensitivity since one may simply be introducing new
variability on top of the selection presence of growth in
vitro in the first instance. While tumour heterogeneity
(within a primary tumour or between it and metastases, T.
Tsuruo et al , 1981) is recognised as an important
component in the resistance of tumours to chemotherapy
(reviewed in Sem. Oncol. 12 ( 3), 1985) the interactions
between clones or subpopulations as well as their
individual characteristics will need to be considered in
attempting to overcome the resistance. For example in the
experiments of Miller mentioned above a resistant
subpopulation was more sensitive in the presence of the
sensitive subpopulation. Thus once the sensitive
population is eliminated the resistant subpopulation may
emerge causing increased difficulty in treating the
tumour. This might then be analogous to the problem of
latent metastases (M.F.A. Woodruff, 1975).
Many studies have reported the increased efficacy of drug
combinations and the experimental use of agents such as
BSO (discussed in Chapter 5) to modify drug response. The
effect of modification of glutathione and thiol metabolism
on responses to radiation and chemotherapy has been the
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subject of intensive study as discussed recently and is
clearly more complicated than originally thought with
possible membrane effects and compartments of glutathione
in the cell (J.M. Brown (ed), 1986). An obvious extension
of this project would be to test various combinations
particularly as the in vivo counterpart of the model is
developed. Experimentally cisplatinum has been combined
with a number of other antitumour drugs (J-P. Bergerat et
al , 1979a) with synergism particularly observed with
cytosine arabinoside (AraC) (J-P. Bergerat et al, 1981; H.
Vadi et al, 1986). Sequence dependent synergism has also
been reported with dichloromethotrexate (A.F. Sobrero et
al , 1985), and Etoposide (VP-16) (G. Zupi et al, 1985).
Interactions of platinum complexes with x-irradiation have
been observed (E.B. Douple et al , 1980 ) including
experiments in organotypic cultures (R. Beaupain et al,
1985). In addition the effects of a number of modifiers
of cell metabolism on cisplatinum toxicity have been
reported including natural nucleosides (B. Drewinko et al,
1985a), polyamine depleters- (S.M. Oredsson et al, 1982),
inhibitors of ribonucleoside diphosphate reductase like
hydroxyurea (G.R. Gale et al, 1979), calmodulin
antagonists (Y. Kikuchi et al, 1984), interferon (J.
Carmichael et al, 1986) and caffeine an inhibitor of post-
replication repair (J.J. Roberts et al, 1986a). All these
modifications may allow greater or more effective doses of
drugs to be administered either by protection of host
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cells or greater tumour cell kill. Some combinations can
have increased effectiveness apparently just due to
pharmacokinetic changes as with the effect of misonidazole
on nitrogen mustards ' action in vivo (F.Y.F. Lee et al,
1986) and the amount of drug reaching tumour cells needs
analysis in assessing the biological response (P. Workman,
1986 ) .
One recent attempt to transpose these experimental results
into the clinical situation has been that of Markman who
treated patients mostly with ovarian cancer with
intraperitoneal cisplatinum and AraC concomitantly with
intravenous sodium thiosulphate (M. Markman et al, 1985).
The intraperitoneal route allows high doses of cisplatinum
and AraC to be administered to the tumour while also
potentially exploiting the synergism between the two
drugs, and the intravenous sodium thiosulphate helps to
prevent systemic toxicity due to cisplatinum. Responses
in previously refractory patients were observed. Conte
has attempted to induce (with iphosphamide) , and monitor,
recruitment of ovarian ascites cells into S phase so as to
schedule antimetabolite treatment at the appropriate time
although without observing tumour responses as yet in
refractory patients (P.F. Conte et al, 1984). There are
also some reports of sequential or alternating therapy in
ovarian cancer based on the Goldie-Coldman hypothesis
(A.J. Dembo, 1984) but not so far with results improved
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over standard therapy (M.W. Pasmantier et al, 1985 ; F.
Lawton et al, 1985).
Obviously new drugs are needed to improve present therapy
and, while better use of present drugs and introduction of
new analogues will be helpful, entirely new types of drugs
and therapy can be envisaged. The search for agents to
induce cell differentiation (A. Bloch, 1984) has recently
become an active area of research. Where the cancer has
reached an advanced stage with perhaps a highly
heterogenous population with multiple resistance the goal
must be to use different therapeutic approaches together,
as DeVita ( 1983 ) has said, "to give the cancer cell a
series of impossible choices".
This project has developed a model for investigating drug
resistance in ovarian cancer in vitro and examined
resistance and mechanisms of resistance to cisplatinum
together with cross-resistance to analogues of clinical
interest. It is hoped that this research and the ideas
put forward as a result of it may contribute in the future
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ABSTRACT
Two ovarian cell lines have been derived from
the ascites of a patient before and after the
onset of resistance to chemotherapy involving
cis-platinum, chlorambucil and 5-fluorouracil.
Characterization of these lines shows them to have
various features in common and some significant
differences. Cytologically the lines cannot be
distinguished and they both contain high concent¬
rations of oestrogen receptor. However they do
differ with respect to their growth character¬
istics, karyotype, glutathione content and
sensitivity to cis-platinum. The karyotypes of
the two lines show several marker chromosomes in
common but the resistant line contained a chromo¬
some 8 and 17 absent in the earlier sensitive
line. This suggests a clonal origin with subse¬
quent divergence to a heterogeneous population.
INTRODUCTION
Ovarian adenocarcinoma is a disease respon¬
sive to a variety of chemotherapeutic agents
(Rodenberg & Cleton, 1984). However the remissions
which result from treatment are often short, and
following relapse the patients are usually
resistant to subsequent chemotherapy (Rodenberg &
Cleton, 1984). There are numerous possible
explanations why tumours are refractory to treat¬
ment (Hill, 1982). Firstly, there may be altera¬
tions in drug disposition not related to the tumour
cells themselves. Secondly, there is the possib¬
ility that the tumour cells when exposed to
cytotoxic compounds acquire resistance to them.
The phenomenon of acquired resistance has been
extensively studied and is well characterized for
many cell culture model systems (Schimke, 1984;
Louie et al. 1985). In the majority of reports,
resistant cells have been produced in vitro by
selection, i.e. by growing the cell lines in the
presence of the drug under investigation (Fojo et
al. 1985). In view of the relative difficulty in
obtaining tissue samples and transferring them
successfully into culture (Bertoncello et al.
1982), there are still only a few reports which
unequivocally indicate that acquired drug resis¬
tance is an important factor in the failure of
chemotherapy (Bell et al. 1985). A third explana¬
tion for resistance is the presence of minor cell
populations within the original tumour which are
intrinsically more resistant to chemotherapy and
that following initial treatment these cells
become the major population within the tumour.
This represents the basis of the Goldie-Coldman
model (Goldie & Coldman, 1979) and is supported by
many reports of tumour cell heterogeneity (Heppner,
1984).
In order to investigate these possibilities,
we have obtained ascites samples from a patient
before and after the onset of clinical drug
resistance. Two cell lines have been established
from these samples, characterized, and tested for
drug sensitivity.
MATERIALS & METHODS
Source of Ascites Samples and Cell Lines
The patient who was diagnosed as having
ovarian adenocarcinoma in April 1980 was treated
with seven courses of 5-fluorouracil (500 mg/m2
I.V.), cis-platinum (30 mg/m2 I.V.) and
chlorambucil (0.1 mg/kg oral) over a period of 7
months. A complete response - determined by
second-look laparotomy - was obtained and no
further treatment was given until relapse 14
months later. A sample of ascitic fluid was
obtained at this time and the cells were isolated
and put into tissue culture (cell line PE01). The
patient then received a further six courses of
treatment (February-August 1982) as described
above and responded well initially but relapsed
in November 1982. The patient was then treated
with a higher dose of cis-platinum (100 mg/m2) but
did not respond. A cell line was derived from a
second ascites sample (PE04) taken in December
1982. The patient died in February 1983.
The cell lines were derived in the following
manner. The freshly obtained ascites samples were
mixed with 100 units of preservative-free heparin
and the cells sedimented by centrifugation. After
the cells had been washed twice with phosphate-
buffered saline (PBS), red cells were removed
using a Ficoll Hypaque gradient. Tumour cells at
the interface were aspirated off, washed twice
with PBS and checked for viability by nigrosin
staining. Aliquots of 105 cells per ml were then
cultured at 37°, 100? humidity and 5? CO2 in RPMI
1640 + 10? foetal calf serum (v/v) with added
insulin (2.5 yg/ml), streptomycin (100 yg/ml),
penicillin (100 IU/ml) and 3~[N-morpholino]pro-
panesulphonic acid (12.5 mM). PE01 and PE04 were
subcultured after 21 and 4 weeks respectively.
Confluent cultures were passaged by 1:5 or 1:10
splits. Periodic assays for mycoplasma were
negative.
Cytology
Cells at passage 1 and 79 of PE01 and 2
and 48 of PE04 were harvested and grown on sterile
22 x 22 mm coverslips in 35 mm wells (6 well
plates, Sterilin, UK). When good, even growth was
obtained the cells were fixed and stained with PAP
to reveal gross morphology or with PAS-diastase to
stain for mucin.
Karyotyping
Chromosome preparations were made from the
patient's peripheral blood as well as the cell
lines PE01 and PE04 at various passages in
culture. These preparations were stained with
spermidine bis-acridine by the Q-band technique of
Van de Sande et al (1979).
Drug Sensitivity Assay
Drug sensitivity assays were carried out at
the same time for the 2 cell lines. Cells were
at passages 77 to 82 and 46 to 51 for PE01 and
PE04 respectively,
a) Clonogenic Assay in Soft Agar
The in vitro soft agar assay of Courtenay
et al (1978) was used. A single cell preparation
was obtained by vigorous aspiration and passage
through a 19 gauge needle. Viability was checked
with nigrosin stain. 5 x 103 and 1 x 103 cells/ml
in a test tube for PEC1 and PE04 respectively were
incubated with drug in the agar for 21 days with
1 ml of fresh medium added on days 7 and 14.
8
Colonies of greater than 50 cells were scored
visually.
b) Clonogenic Assay on Plastic
Assay conditions were modified from those
described by Parsons & Brown (1979) to suit these
ovarian cell lines. Cells were plated out in
35 mm wells (6 well Linbro plates, Flow
Laboratories, UK) at 2 x 103 and 103 cells/well
for PE01 and PE04 respectively in medium contain¬
ing 1mM pyruvate to give 100 to 200 colonies in
control wells. After 2 days, when cells had
firmly attached but had not yet divided, drugs
were added to wells in triplicate and left on for
3 days. Medium was changed every 2 to 3 days.
After 12 to 14 days colonies were counted
visually.
Colony Forming Efficiency and Doubling Time
The colony forming efficiency of the lines in
agar and on plastic was determined in the
Courtenay assay and the assay on plastic as
described. Doubling time was determined by
plating at 5 x 103 cells per well in a 24 well
plate (NUNC, Gibco Ltd) and harvesting rows of 4
wells at the same time each day for 12 days.
Harvested cells were counted by Coulter Counter.
Glutathione & Glutathione Transferase Assays
Glutathione levels were determined by HPLC
following derivitization with monobromobimane
(Gaetjens, 1984). Glutathione transferase
activity using 1-chloro-2,4-dinitrobenzene as
substrate was determined by the method of Habig et
al (1974). Cells used were in log phase and the
values were expressed per 10& viable cells.
Hormone Receptor Assays
Oestrogen and progestogen receptor assays
were carried out on confluent cell cultures
maintained for 6 to 10 days in steroid stripped
medium (Hawkins et al. 1981; Hamilton et al.
1983).
DNA Content
DMA content was measured on a fluorescent-
activated cell sorter using human lymphocytes as





Examination of the ascites samples and the
cell lines derived from them is shown in Figure 1.
In contrast to the original ascites sample taken
in April 1980, the two later samples from which
cell lines PE01 and PE04 were derived were largely
devoid of both macrophages and lymphocytes. The
ascitic fluids contained groups of cells as well
as single cells of adenocarcinomatous type,
characterized by large nuclei eccentrically
situated in the cytoplasm and occasional signet
ring cells due to the presence of a large vacuole
containing mucopolysaccharide. The latter
property is consistent with ovarian metastases.
Cytological examination of the cell lines showed
them to be very similar to the cells of the
ascitic fluid (Figures 1d & 1e). Soth cell lines
had large oval nuclei and prominent, sometimes
multiple, nucleoli, contained signet ring cells
and were mucin secreting. No cytological
difference between the cell lines or between
different passages of the cell lines was apparent
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even at the ultrastructural level by electron
microscopy (results not shown),
ii. Drug Sensitivity
The sensitivity of PE01 and PEO^'to the
cytotoxic drugs used clinically, i.e. cis-
platinum, chlorambucil and 5-fluorouracil, tested
using clonogenic assays in agar and on plastic is
shown in Charts 1, 2 & 3. Two different assays
were used to give us greater confidence in the
significance of the drug sensitivity differences
between the 2 cell lines. A 3"fold difference in
the sensitivities of the lines to cis-platinum was
measured using either assay. Both assays gave
similar results, the LD50 values being 8.0 x lO'^M
and 2.7 x 10~7m in the agar assay and 6.4 x 10"^M
and 2.0 x 10~?M in the assay on plastic for PE01
and PE04 respectively. For chlorambucil the
sensitivity difference was 3-fold in the plastic
assay and only 1.3-fold in the assay on agar. In
the case of 5-fluorouracil, no differences between
the cell lines were measured by either assay.
Although there was more variation between experi¬
ments in measuring sensitivity to 5-fluorouracil,
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probably due to variation in the nucleosides in
serum batches, no differences between the cell
lines within an experiment were observed. Both
cell lines appeared more sensitive to 5-fluorour-
acil in the agar assay.
iii. Cell Line Characteristics
A summary of the general properties of the
two cell lines are shown in Table 1 and Figure 2.
PE04 had a higher colony efficiency. Both
glutathione and glutathione transferase activity,
components central to the deactivation of alkyl¬
ating agents (Mitchell et al. 1982), were approxi¬
mately 2-fold higher in PE04 than in PE01. Both
cell lines had high levels of oestrogen receptor,
the value for PE04 being slightly higher than that
of PE01, and undetectable levels of progestogen
receptors after 10 days culture in steroid
stripped medium (Hamilton et al. 1983).
iv. Karyotype
Karyotypes of the cell lines and peripheral
blood are shown in Figure 3.
The cells from the peripheral blood showed a
normal 46,XX karyotype even after the chemo-
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therapy, whereas the cell lines from the ascites
were hypodiploici. However their DNA content was
slightly greater than that of normal diploid human
lymphocytes. The modal chromosome numbers from
different spreads varied between 39 and 42.
Examples of the chromosome complement of PE01 and
PE04 with 41 chromosomes are illustrated (Figures
3b & 3c). Figure 3a is a Q-banded karyotype made
from a normal peripheral blood cell taken from the
patient 4 weeks before she died. The cultured
ascites cells, in addition to being hypodiploid,
contained many abnormal chromosomes. The chromo¬
somes that are considered to be normal are marked
with a white square. PE01 has only 20 such
chromosomes. None of the cells analysed contained
a normal 8 or 17 chromosome or any material that
could be considered as coming from either of these
chromosomes although this cannot be excluded
because there are so many rearranged chromosomes.
PE01 had 12 consistent abnormalities which were:
both 3s inv(3)(p-q+), 5p-, 9p+, 11p+, both 13s
13q~ and 13q+» 22q+ and 4 chromosomes of unknown
origin. The number and appearance of the other
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abnormal chromosomes varied. Of the 4 chromosomes
of unknown origin 2 marker chromosomes had a
similar appearance - two prominent bands on the
distal long arm but the pericentric chromatin was
very pale, uniformly staining and reminiscent of
homogeneous staining regions (HSR). These regions
were not C-band positive. The other two chromo¬
somes appeared to be isochromosomes being
metacentric with a very similar banding pattern
each side of the centromere, one being half the
size of the other.
In contrast, PE04 had an apparently normal
member of each chromosome pair including a
chromosome 8 and 17 but excepting an X and 13
chromosome. However, the 13q— chromosome now has
material translocated to the brilliant pi 1 which
could make this chromosome complete although
rearranged. Of the consistent abnormalities seen
in PE01, the following are seen in PE04:
inv(3)(p-q+) with the brilliant Q-band, 5p-, 9p+,
11p+, 13q+» 22q+, one of the marker chromosomes
with the possible HSR and in many cells the
smaller of the two isochromosomes was seen. PE04
15
had acquired a ring chromosome which was approxim¬
ately the size of a D group chromosome, and also
other rearranged chromosomes.
The 'normal' 22 in both PE01 and PE04 has
lost the intense satellites. Deletion of
satellites or the whole of an acrocentric short
arm is often found as a constitutional 'abnor¬
mality' in normal individuals.
DISCUSSION
Two ovarian adenocarcinoma cell lines have
been established from ascites obtained before and
after the onset of resistance to chemotherapy. A
marked difference was observed in the sensitivity
of these lines to cis-platinum, one of the
chemotherapeutic agents used for treating the
patient. Although the difference in sensitivity
of these lines to cis-platinum was only 3-fold, we
believe that changes in drug sensitivity of this
order of magnitude would be important clinically
(Ozols et al. 1984; Hamilton et al. 1984). No
change in drug sensitivity with passaging in vitro
was observed. Whilst not the only possible expla-
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nation, our in vitro data suggest that the tumour
cell population or subpopulations changed in the
patient during the drug treatment and the
difference in drug sensitivity could explain the
resistance of this patient to further treatment.
In support of such in vivo change is the fact that
the PE04 cell line was derived more rapidly and
with much less difficulty than the PE01 line. The
LD50 levels reported here are at the lower end of
the range for cis-platinum toxicity values (0.03~3
pM) reported in the literature for ovarian (Holzel
et al. 1985; Buick et al. 1985; Van Putten et al.
1986) and other human cell lines (B.T. Hill et al.
1984) and below that reported for normal human
bone marrow cells (0.9 pM) (Umbach et al. 1985).
Although the cell lines were cytologically
similar, there were significant differences in
their karyotypes. Chromosome abnormalities found
in the tumour cells of other patients with ovarian
carcinoma have also been bizarre, and inevitably
some of the rearranged chromosomes in these
tumours have involved the same chromosomes as in
the tumour cells from the present case (Hamilton
17
et al. 1983; Freedman et al. 1978; S.M. Hill et
al. 1984; Kakati et al. 1975; Van der Reit-Fox et
al. 1979; Woods et al. 1979). However, we did not
find the (6;14) translocation which it is
suggested may characterise this carcinoma (Trent &
Salmon, 1981), although we did observe a 3p~marker
similar to that observed by others (Panani .&
Ferti-Passantonopoulou, 1985; Mackillop et al.
1983).
No double minutes were found in these cells.
The appearance of two marker chromosomes in PE01
was consistent with them carrying homogeneous •
staining regions (HSRs). HSRs have been, but need
not necessarily be, associated with the acquis¬
ition of drug resistance (Schimke, 1984). It is
interesting that the number of HSRs was reduced in
PE04. PE04 appears to contain more 'normal'
chromosomes than the earlier PE01 culture. Since
both cell lines have several rearranged chromo¬
somes in common and were cytogenetically very
heterogeneous, it could be argued that the two
cell lines probably arose from a common ancestor,
both diverged and co-existed in the body, but that
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PE01 was more susceptible to the initial drug
treatment and was overgrown by PE04. It is very
unlikely that PE04 evolved from PE01 as it would
be almost impossible to regain a normal 8 and 17
having once lost them. The two cell lines there¬
fore represent a model for the study of human
tumour cell heterogeneity. There was no evidence
that the karyotype or properties of the cells
changed during passaging in vitro.
Variation in sensitivity to cis-platinum due
to tumour cell heterogeneity has been observed in
clonal human glioma lines isolated from a single
untreated tumour (Yung et al. 1982). This sort of
heterogeneity has been observed by others (Tsuruo
& Fidler, 1981) and has also been found in primary
ovarian cancer samples (Siracky, 1979). Our
results which suggest PEOM is not a lineal
descendent of PE01 would support the importance
and relevance of sub-population heterogeneity in
drug resistance.
PE01 and PEOH contained extremely high levels
of oestrogen receptor but undetectable levels of
progestogen receptors. Whether progestogen
19
receptors could be induced by oestrogen, specifi¬
cally excluded from the assay here, is as yet
unknown. Oestrogen and progestogen receptor
positive ovarian tumours and cell lines have been
reported (Hamilton et al. 1983; Lazo et al. 1984)
but the levels of oestrogen receptor detected here
are very high compared with most reports (eg mean
of 18 and maximum of 163 fmol receptor/mg cyto-
solic protein in 56 ovarian tumour samples reported
by Lazo et al, [1984]).
Two assays have been used in this study to
investigate drug sensitivity to increase our
confidence in differences in sensitivity measured.
These were a relatively simple assay involving
colony counting of attached colonies in 6-well
plates and the more complex assay involving colony
growth in soft agar. The comparative sensitivity
of the cell lines determined with these assays was
similar although some differences were apparent.
The reason why chlorambucil gave a larger sensi¬
tivity difference between PE01 and PE04 using the
assay on plastic is unclear but preliminary
experiments suggest it may be related to the
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increased oxygen tension (20$ O2 vs. 5$ O2). The
growth conditions in agar are clearly different to
those in monolayer on plastic. In particular
anchorage dependence (Stephens et al. 1980),
oxygen tension (Gupta & Krishnan, 1982) and the
addition of rat red blood cells in the Courtenay
assay (Endresen et al. 1985) have all been shown
to affect chemosensitivity measurements for some
cells. Also the metabolic state of the cells when
treated in suspension after trypsinisation, or
after attachment has been shown to be important
(Twentyman, 1979).
These conditions may also explain the
difference in sensitivity to 5-fluorouracil
between the 2 assays although other factors such
as the presence of thymidine (Engelbrecht et al.
1984) in the Hams F-12 medium (and not in RPMI-
1640) used in the Courtenay assay or the length of
time (3 days vs. 21 days) of drug exposure
(Sobrero & Bertino, 1983) may also influence the
results. The data here would suggest that great
care should be taken in relating in vitro assay
results back to a patient since different assays
21
can give different results, as here with chloram¬
bucil .
It is interesting to note the difference in
glutathione levels in our cell lines. The role of
glutathione in the protection of cells from
cis-platinum is not clear. However the role of
this peptide in the detoxification of alkylating
agents in general is well established (Mitchell et
al. 1982). There is also some evidence which
suggests that thiol-containing compounds can
increase the survivals of cis-platinum treated
mice as well as reduce both the kidney and gastro¬
intestinal tract toxicity of cis-platinum (Allan
et al. 1986; Borch & Pleasants, 1979). The
potential importance of intracellular thiols is
exemplified by a recent report by Green et al
(198*0 who demonstrated that an ovarian cell line
resistant to melphalan was made sensitive to this
compound by suppressing glutathione biosynthesis.
In our cell lines the glutathione levels are
similar to those of other ovarian cell lines as
reported by Louie et al (1985). Other workers
have suggested that glutathione metabolism may be
22
more important for melphalan and chlorambucil
toxicity than for cis-platinum (Andrews et al.
1985). However, the higher thiol level in PEt)M may
be a contributing factor to its increased resist¬
ance demonstrated in the present study.
The overall sensitivity or relative resis¬
tance of ovarian cancer to cis-platinum is
multifactorial. Differences in thiol levels are
just one of these factors. Tumour heterogeneity,
demonstrated here cytogenetically, is also clearly
important. Compared with the relative restriction
of working with fresh ascites we believe that the
cell lines described in this paper constitute an
appropriate and useful model for the further study
of mechanisms of drug resistance in this important
human tumour.
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Cytology of Ascites and Cell Lines Samples
Samples were prepared and stained with Papanicalaou stain as described
in the MATERIALS & METHODS.
a) Ascites cells April 1980
b) Ascites cells February 1982
c) Ascites cells December 1982
d) Cell line PE01 passage 79
e) Cell line PE04 passage 48
FIGURE 2:
Glutathione and Glutathione-S-transferase Activity in Cell Lines PE01
and PE04
Glutathione and glutathione-S-transferase activity was measured as
described in materials and methods. Hatched boxes represent
glutathione content and open boxes glutathione-S-transferase
activity. Values were means of three separate experiments carried out
in triplicate, bars represent the standard error.
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FIGURE 3:
Karyotypes of Peripheral Lymphocytes, and Cell Lines PE01 and PEOU
a) A Q-band karyotype of a normal cell from a peri¬
pheral blood culture, showing the Q-band polymorphisms.
b) Karyotype of a cell from PE01. The chromosomes
marked with a white square are considered to be normal.
The abnormal chromosomes which are arrowed are also
found in PE04.
c) Karyotype of a cell from PE04. Symbols are as
above for figure b. The chromosomes marked +
are either normal chromosomes or consistent chromosome
abnormalities not found in PE01 .
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CHART 1
Drug Sensitivity for Cell Lines PE01 and PE04 Using Cis-Platinum
a) Clonogenic assay in soft agar according to
Courtenay et al (1978). Points, means of 1-2 experi¬
ments PE01 and 2-6 experiments PE04, bars represent the
standard error.
b) Clonogenic assay on plastic. Assay conditions as
described in the MATERIALS AND METHODS section. Points,
means of 2-4 experiments, bars represent the standard
error.
CHART 2
Drug Sensitivity for Cell Lines PE01 and PEQ4 using Chlorambucil
Legend as in Chart 1. Points, means of 2-5
experiments, bars represent the standard error.
CHART 3
Drug Sensitivity for Cell Lines PE01 and PEQ4 Using 5-Fluorouracil
Legend as in Chart 1. A typical experiment is shown.
Points, means of 5 replicates (agar) or triplicates
(plastic), bars represent the standard error.
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